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A B S T R A C T
Background
Use of topical nonsteroidal anti-inflammatory drugs (NSAIDs) to treat chronic musculoskeletal conditions has become widely accepted
because they can provide pain relief without associated systemic adverse events. This review is an update of ’Topical NSAIDs for chronic
musculoskeletal pain in adults’, originally published in Issue 9, 2012.
Objectives
To review the evidence from randomised, double-blind, controlled trials on the efficacy and safety of topically applied NSAIDs for
chronic musculoskeletal pain in adults.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and our own in-house database;
the date of the last search was February 2016. We also searched the references lists of included studies and reviews, and sought
unpublished studies by asking personal contacts and searching online clinical trial registers and manufacturers’ web sites.
Selection criteria
We included randomised, double-blind, active or inert carrier (placebo) controlled trials in which treatments were administered to
adults with chronic musculoskeletal pain of moderate or severe intensity. Studies had to meet stringent quality criteria and there had
to be at least 10 participants in each treatment arm, with application of treatment at least once daily.
Data collection and analysis
Two review authors independently assessed studies for inclusion and extracted data. We used numbers of participants achieving each
outcome to calculate risk ratio and numbers needed to treat (NNT) or harm (NNH) compared to carrier or other active treatment.
We were particularly interested to compare different formulations (gel, cream, plaster) of individual NSAIDs. The primary outcome
was ’clinical success’, defined as at least a 50% reduction in pain, or an equivalent measure such as a ’very good’ or ’excellent’ global
assessment of treatment, or ’none’ or ’slight’ pain on rest or movement, measured on a categorical scale.
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Main results
We identified five new studies for this update, which now has information from 10,631 participants in 39 studies, a 38% increase
in participants from the earlier review; 33 studies compared a topical NSAID with carrier. All studies examined topical NSAIDs for
treatment of osteoarthritis, and for pooled analyses studies were generally of moderate or high methodological quality, although we
considered some at risk of bias from short duration and small size.
In studies lasting 6 to 12 weeks, topical diclofenac and topical ketoprofen were significantly more effective than carrier for reducing
pain; about 60% of participants had much reduced pain. With topical diclofenac, the NNT for clinical success in six trials (2343
participants) was 9.8 (95% confidence interval (CI) 7.1 to 16) (moderate quality evidence). With topical ketoprofen, the NNT for
clinical success in four trials (2573 participants) was 6.9 (5.4 to 9.3) (moderate quality evidence). There was too little information
for analysis of other individual topical NSAIDs compared with carrier. Few trials compared a topical NSAID to an oral NSAID, but
overall they showed similar efficacy (low quality evidence). These efficacy results were almost completely derived from people with knee
osteoarthritis.
There was an increase in local adverse events (mostly mild skin reactions) with topical diclofenac compared with carrier or oral NSAIDs,
but no increase with topical ketoprofen (moderate quality evidence). Reporting of systemic adverse events (such as gastrointestinal
upsets) was poor, but where reported there was no difference between topical NSAID and carrier (very low quality evidence). Serious
adverse events were infrequent and not different between topical NSAID and carrier (very low quality evidence).
Clinical success with carrier occurred commonly - in around half the participants in studies lasting 6 to 12 weeks. Both direct and
indirect comparison of clinical success with oral placebo indicates that response rates with carrier (topical placebo) are about twice those
seen with oral placebo.
A substantial amount of data from completed, unpublished studies was unavailable (up to 6000 participants). To the best of our
knowledge, much of this probably relates to formulations that have never been marketed.
Authors’ conclusions
Topical diclofenac and topical ketoprofen can provide good levels of pain relief beyond carrier in osteoarthritis for a minority of people,
but there is no evidence for other chronic painful conditions. There is emerging evidence that at least some of the substantial placebo
effects seen in longer duration studies derive from effects imparted by the NSAID carrier itself, and that NSAIDs add to that.
P L A I N L A N G U A G E S U M M A R Y
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Bottom line
Topical diclofenac and topical ketoprofen can provide good levels of pain relief in osteoarthritis, but only for about 10% more people
than get this result with topical placebo. There is no evidence for other chronic painful conditions.
Background
Chronic musculoskeletal pain occurs in conditions like osteoarthritis. Pain is typically moderate or severe in intensity, lasting for three
months or more.
Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are applied to unbroken skin where it hurts in the form of a gel, cream, spray,
or plaster. Topical NSAIDs penetrate the skin, enter tissues or joints, and reduce processes that cause pain in the tissue. Drug levels
in the blood with topical NSAIDs are very much lower than with the same drug taken by mouth. This minimises the risk of harmful
effects.
Study characteristics
This review is an update of ’Topical NSAIDs for chronic musculoskeletal pain in adults’, originally published in 2012. We found 39
generally high-quality studies with 10,631 participants where topical NSAIDwas used at least once a day. These studies tested a number
of different topical drugs, mostly against a topical placebo. We were interested in participants having good pain reduction (by about
half ), ideally 6 to 12 weeks after treatment started. Studies that last longer are more representative of the real world, because in these
chronic conditions the pain almost never goes away if untreated. We looked at individual NSAIDs to see how effective they were.
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Key results
Diclofenac and ketoprofen were the only two with good quality and longer duration studies, mostly in people aged over 40 years with
painful knee arthritis. The comparison was between topical diclofenac or ketoprofen in a solution or gel, and the solution or gel without
any drug in it (topical placebo). For diclofenac and ketoprofen, about 6 people out of 10 with osteoarthritis had much reduced pain
after 6 to 12 weeks, compared with 5 out of 10 with topical placebo (moderate quality evidence).
Skin reactions (mostly mild) were more common (20 in 100) with topical diclofenac than topical placebo (5 in 100); there was no
difference between topical ketoprofen and topical placebo (moderate quality evidence). Other adverse events, like stomach upsets, were
poorly reported in these studies, but were no different between topical diclofenac or ketoprofen and topical placebo (very low quality
evidence). Serious adverse events were uncommon.
Quality of the evidence
We rated the quality of the evidence for topical diclofenac and topical ketoprofen compared with placebo as moderate for efficacy, and
very low for harmful effects. Moderate quality evidence means that further research may change our estimate of the effect, and very
low quality evidence means that we are very uncertain about the accuracy of our estimate.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Topical NSAIDs compared with topical placebo for chronic musculoskeletal pain in adults
Patient or population: adults with chronic musculoskeletal pain (osteoarthritis)
Settings: community
Intervention: topical NSAID (topical diclofenac and ketoprofen only for efficacy outcomes); treatment duration 6 to 12 weeks
Comparison: topical placebo
Probable outcome with
intervention
Probable outcome with
intervention
Probable outcome with
comparator
RR, NNT, NNTp, or NNH
(95% CI)
No of studies, partici-
pants
Quality of the evidence
(GRADE)
Comments
Topical diclofenac gel
or solution
Clinical success (for
example 50% reduction
in pain)
600 in 1000 500 in 1000 RR 1.2 (1.1 to 1.3)
NNT 9.8 (7.1 to 16)
6 studies
2342 part icipants
Moderate Adequate numbers of
studies, part icipants,
and events, and consis-
tency of ef fect, but the
size of the ef fect was
modest and could be
overturned by null ef -
fect studies
Topical ketoprofen gel
Clinical success (for
example 50% reduction
in pain)
630 in 1000 480 in 1000 RR 1.1 (1.01 to 1.2)
NNT 6.9 (5.4 to 9.3)
4 studies
2573 part icipants
Moderate Adequate numbers of
studies, part icipants,
and events, but there
was inconsistency of
ef fect between studies
(I2 = 83%). The size
of the ef fect was mod-
est and could be over-
turned by null ef fect
studies
Topical diclofenac gel
or solution
Local adverse events
140 in 1000 78 in 1000 RR 1.8 (1.5 to 2.2)
NNH 16 (12 to 23)
15 studies
3658 part icipants
Moderate Adequate numbers of
studies, part icipants,
and events, but there
was inconsistency of
ef fect (I2 = 76%), pos-
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sibly due to dif fer-
ences in data collec-
t ion. The size of the ef -
fect was modest and
could be overturned by
addit ional studies
Topical ketoprofen gel
Local adverse events
150 in 1000 130 in 1000 RR 1.0 (0.85 to 1.3) 4 studies
2621 part icipants
Moderate Adequate numbers of
studies, part icipants,
and events, and consis-
tency of ef fect (no ef -
fect), but the size of the
ef fect was modest and
could be overturned by
addit ional studies
Systemic adverse
events
Poor report ing of systemic adverse events, but no dif ference between act ive and placebo, however
reported
Low quality Adequate numbers of
studies and part ici-
pants, and consistency
of ef fect (no ef fect), but
few events and poor,
inconsistent report ing.
Fewer than half of el-
igible studies reported
this event
Serious adverse events In topical NSAID versus placebo, 30 serious adverse events split equally between treatments Very low quality The majority of studies
did not report this out-
come, few events
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: We are very uncertain about the est imate.
CI: conf idence interval; RR: risk rat io; NNT: number needed to treat; NNTp: number needed to prevent an event happening;
NNH: number needed to harm; NSAID: nonsteroidal ant i-inf lammatory drug
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B A C K G R O U N D
This review is an update of a review of topical nonsteroidal anti-
inflammatory drugs (NSAIDs) for chronic musculoskeletal pain
in adults, originally published in Issue 9, 2012 (Derry 2012a).
The use of topical NSAIDs for pain relief has been a controversial
subject in analgesic practice. In some parts of the world (much of
Western Europe, for instance) they have been available for many
years, are widely available without prescription, widely advertised,
used extensively, and evidence for their use is considered adequate.
In other parts of the world they were regarded as little more than
placebo, with any apparent effect attributed to the process of rub-
bing at the site of the affected area. In some places (the United
States (US), for instance) their use was almost unknown until 5
to 10 years ago. In England 5.8 million prescriptions for topical
NSAIDs were dispensed in the community in 2014 (PCA 2015),
mainly for formulations of ibuprofen (3 million) and diclofenac
(1.5 million).
There is good evidence for the efficacy of topical NSAIDs in acute
and chronic musculoskeletal pain (Mason 2004a; Mason 2004b;
Moore 1998a). In the US the Food and Drug Administration li-
censed topical nonsteroidal products in 2007, and in England the
National Institute for Clinical Excellence (NICE) recommended
topical therapies as first line treatment in its guidelines for os-
teoarthritis in 2008 and updated guidance in 2014 (NICE 2008;
NICE 2014). Earlier reviews of topical analgesics cover not only
clinical trials, but also studies investigating the underlying science
to explain biological plausibility (Bandolier 2005; Moore 2008a).
This review is one of a series on topical analgesics, including top-
ical capsaicin at low and high doses (Derry 2012b; Derry 2013),
and topical NSAIDs in acute pain conditions (Derry 2015), and
salicylate-containing rubefacients (Derry 2014).
Description of the condition
We searched for studies treating any chronic pain condition with
a topical NSAID, but the only studies identified were in chronic
pain caused by osteoarthritis.
Osteoarthritis is the most common form of joint disease and a
leading cause of pain, physical disability, and reduced quality of
life throughout the world. It is a major part of musculoskeletal
disorders, and a major cause of disability in the community (Vos
2012). Osteoarthritis particularly affects older people. Symptoms
include pain, tenderness, and stiffness in the affected joint, all
which can affect function. If the pain level prevents movement,
the associated muscles may atrophy (waste) and ligaments become
lax. The most commonly affected joints are the knees, hands, and
hips (NICE 2014).
Osteoarthritis is characterised by localised areas of loss of articular
cartilage in the joint, accompanied by subchondral bone changes,
osteophyte formation at the joint margins, thickening of the joint
capsule, and mild synovitis. Trauma to the joint triggers a repair
process that can result in a joint that is temporarily symptom-free,
but structurally altered. When the repair process is not adequate
the joint becomes symptomatic (NICE 2014).
Description of the intervention
NSAIDs reversibly inhibit cyclooxygenase (prostaglandin en-
doperoxide synthase), the enzyme mediating production
of prostaglandins and thromboxane A2 (Fitzgerald 2001).
Prostaglandins mediate a variety of physiological functions such
as maintenance of the gastric mucosal barrier, regulation of renal
blood flow, and regulation of endothelial tone. They also play an
important role in inflammatory and nociceptive processes.
NSAIDs taken orally or intravenously are transported to all parts
of the body in the blood, and relatively high blood concentrations
are needed to achieve effective tissue concentrations at the site of
the pain and inflammation.These high concentrations throughout
the body can give rise to a number of adverse events that can
be unpleasant (for example, dyspepsia) or potentially serious (for
example, gastrointestinal bleeding or myocardial infarction).
A topical medication is one applied to body surfaces such as the
skin ormucousmembranes to treat ailments. A large range of types
of topical formulation may be used, including but not limited to
creams, foams, gels, lotions, ointments, and plasters. The exact
formulation of a topical medication is often determined by how
fast drug absorption is wanted. Plasters containing drug reservoirs
result in slow absorption rates, lower blood levels, and reduced
first pass effect in the liver. They have been used especially for
transdermal opioids or contraceptive steroids. Other formulations
add substances that improve skin penetration, in trying to achieve
higher levels in the tissue rather than the blood. This effect has
been sought with gels and plasters of NSAIDs.
Topical NSAIDs are formulated for direct application to the
painful site, and to produce a local pain-relieving effect while
avoiding body-wide distribution of the drug at physiologically ac-
tive levels (McPherson 2013). This method of application (dos-
ing) necessarily limits their use to more superficial painful con-
ditions such as osteoarthritis of the knee or hand. They would
not, for example, be indicated for deep visceral pain, deep-seated
joints such as the hip or the spine, or headaches. They are also not
appropriate for use on broken skin, so would not be used on open
wounds (accidental or surgical).
Topical placebo has frequently been used in studies in order to
demonstrate the benefits of topical NSAID. Topical placebo has
been thought to be inert, and without any analgesic effect of its
own. However, in recent studies that compared a ketoprofen gel
formulation (IDEA-033) with the gel carrier (TDT-064) the anal-
gesic effect was almost equivalent to that of the ketoprofen gel,
and with a significantly larger effect than oral placebo. It is sug-
gested that this is due to a ’biolubrication’ mechanism (Conaghan
2014). Whether this is true, and whether there is any special ben-
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efit of one carrier over another, is speculative. For the purposes of
this update, we have chosen to use the term ’carrier’ rather than
’placebo’ except for oral placebos.
How the intervention might work
For a topical formulation to be effective, it must first penetrate the
skin. Only when the drug has entered the lower layers of the skin
can it be absorbed by blood, or penetrate deeper into areas where
inflammation occurs. Individual drugs have different degrees of
penetration. A balance between lipid and aqueous solubility is
needed to optimise penetration, and use of prodrug esters has
been suggested as a way of enhancing permeability. Formulation
is also crucial to good skin penetration, and efficacy has to be
judged on formulation - including drug concentration - as well as
drug. Experiments with artificial membranes or human epidermis
suggest that creams are generally less effective than gels or sprays,
but newer formulations such as microemulsions may have greater
potential (Moore 2008a).
Once the drug has reached the site of action, it must be present at a
sufficiently high concentration to inhibit cyclooxygenase enzymes
and produce pain relief. It is probable that topical NSAIDs exert
their action both by local reduction of symptoms arising fromperi-
articular structures, and by systemic delivery to intracapsular struc-
tures. Tissue levels of NSAIDs applied topically certainly reach
levels high enough to inhibit cyclooxygenase-2 (Bandolier 2005;
Haroutiunian 2010; Moore 2008a). Plasma concentrations found
after topical administration, however, are only a fraction (usually
much less than 5%) of the levels found in plasma following oral
administration. Topical application can potentially limit systemic
adverse events by increasing local effects, and minimising systemic
concentrations of the drug. We know that upper gastrointestinal
bleeding is low with chronic use of topical NSAIDs (Evans 1995),
but have no certain knowledge of lower effects on heart failure, or
renal failure, both of which are associated with oral NSAID use.
Why it is important to do this review
Since the last review in 2012, a number of new studies have
beenpublished,mainly involving topical ketoprofen formulations.
These new studies are generally of higher quality than many of the
earlier ones in this review, and have the potential to substantially
influence the strength of its conclusions. Moreover, the additional
information allows for analysis based not only on a particular drug,
but also on the formulation of that drug. This can provide bet-
ter insight into whether formulation affects the efficacy of topical
NSAIDs in chronic musculoskeletal pain.
An updated review of evidence for topical NSAIDs is needed to
inform choices made by consumers, prescribers, and commission-
ers (purchasers of health care). This is one of a series of reviews
being conducted on topical analgesics, including NSAIDs in acute
pain (Derry 2015), topical salicylate-containing rubefacients for
acute and chronic musculoskeletal pain (Derry 2014), and topical
capsaicin for neuropathic pain (Derry 2012b; Derry 2013).
O B J E C T I V E S
To review the evidence from randomised, double-blind, controlled
trials on the efficacy and safety of topically applied NSAIDs for
chronic musculoskeletal pain in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised, controlled, double-blind trials compar-
ing topical NSAIDs with inert carrier (placebo) or other active
treatment for chronic musculoskeletal pain, with at least 10 par-
ticipants per treatment arm and duration of at least two weeks, al-
though we were particularly interested in outcomes at six weeks or
longer. We excluded studies published only as short (conference)
abstracts or studying experimentally induced pain. We considered
studies using a cross-over design only if data from the first treat-
ment period were reported separately.
Types of participants
Adult participants (16 years or more) with chronic musculoskele-
tal pain of at least three months’ duration and at least moderate
intensity. We excluded studies examining participants with neu-
ropathic pain or fibromyalgia.
Types of interventions
Included studies had at least one treatment arm using a topical
NSAID, and a comparator armusing inert carrier alone or an active
analgesic intervention such as an oral NSAID. Topical NSAIDs
had to be applied at least once daily. We did not include salicylates
because they are no longer classified as topical NSAIDs and are
covered in a separate review (Derry 2014).
Types of outcome measures
We sought information on participant characteristics: age, sex, and
condition to be treated.
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Primary outcomes
The primary outcome was ’clinical success’, defined as at least a
50% reduction in pain, or an equivalent measure such as a ’very
good’ or ’excellent’ global assessment of treatment, or ’none’ or
’slight’ pain on rest or movement, measured on a categorical scale
(Moore 1998a; Moore 2013). We used the following hierarchy of
outcomes, in order of preference, to extract data for the primary
outcome:
• Participant-reported reduction in pain of at least 50%.
• Participant-reported global assessment of treatment.
• Pain on movement.
• Pain at rest or spontaneous pain.
If none of these measures were available we used undefined ’im-
provement’ where it was reported. We used only participant-re-
ported outcomes of efficacy, and not physician or investigator-re-
ported outcomes.
Secondary outcomes
• Numbers of participants with adverse events: local and
systemic, and particularly serious gastrointestinal problems.
• Numbers of withdrawals: all cause, lack of efficacy, and
adverse events.
We anticipated that outcomes would be reported after different
durations of treatment, and extracted results for any treatment
duration of two weeks or more, with longer durations of treatment
preferred because of potential bias in short duration studies (PaPaS
2012). We also anticipated that reporting of adverse events would
vary between studies with regard to the terminology used, method
of ascertainment, and categories reported (occurring in at least 5%
of participants or where there is a statistically significant difference
between treatment groups). We took care to identify these details
where relevant.
Search methods for identification of studies
Electronic searches
We searched the following databases:
• Cochrane Central Register of Controlled Trials
(CENTRAL 2012, Issue 5) for the original review, and via the
Cochrane Register of Studies Online (CRSO) to 3 February
2016 for this update.
• MEDLINE (via Ovid) (from 2004 to 7 June 2012 for the
original review, and to 3 February 2016 for this update).
• EMBASE (via Ovid) (2004 to 7 June 2012 for the original
review, and to 3 February 2016 for this update).
• Oxford Pain Relief Database, Jadad 1996a, for the original
review. This resource is no longer being updated.
There was no language restriction.
See Appendix 1 for the CENTRAL search strategy, Appendix 2 for
the MEDLINE search strategy, and Appendix 3 for the EMBASE
search strategy.
Searching other resources
We searched the reference lists of review articles and included
studies. Manufacturers have previously been asked for details of
unpublished studies (Derry 2012a; Mason 2004b), and we did
not approach them again for this review.
We searched clinical trial registries (clinicaltrials.gov and theWorld
Health Organization International Clinical Trials Registry Plat-
form) and asked personal contacts for information about ongoing
and unpublished studies.
Data collection and analysis
We did not blind review authors to the authors’ names and insti-
tutions, journal of publication, or study results at any stage of the
review. We resolved disagreements through discussion.
Selection of studies
Two review authors independently screened the titles and abstracts
of each study identified by the search to eliminate those that clearly
did not satisfy the inclusion criteria, and obtained full copies of
the remaining studies. The same authors then independently read
these studies to determine eligibility.
Data extraction and management
Two review authors independently extracted information about
the participants, the intervention, and the study design using a
standard data extraction form. One review author entered data
suitable for meta-analysis into RevMan 5.3 (RevMan 2014), and
another checked it.
Assessment of risk of bias in included studies
We used the Oxford Quality Score as the basis for inclusion, lim-
iting inclusion to studies that were randomised and double-blind
as a minimum (Jadad 1996b).
Two authors independently assessed risk of bias for each study us-
ing the criteria outlined in the Cochrane Handbook for Systematic
Reviews of Interventions with any disagreements resolved by dis-
cussion (Chapter 8.5, Higgins 2011). We assessed the following
for each study.
1. Random sequence generation (checking for possible
selection bias). We assessed the method used to generate the
allocation sequence as: low risk of bias (any truly random
process, for example, random number table; computer random
number generator); unclear risk of bias (method used to generate
sequence was not clearly stated). We excluded studies using a
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non-random process, which were therefore at high risk of bias
(for example, odd or even date of birth; hospital or clinic record
number).
2. Allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
before assignment determines whether intervention allocation
could have been foreseen in advance of, or during recruitment,
or changed after assignment. We assessed the methods as: low
risk of bias (for example, telephone or central randomisation;
consecutively numbered, sealed, opaque envelopes); unclear risk
of bias (method was not clearly stated). We excluded studies that
did not conceal allocation and were therefore at high risk of bias
(for example, open list).
3. Blinding of outcome assessment (checking for possible
detection bias). We assessed the methods used to blind study
participants and outcome assessors from knowledge of which
intervention a participant received. We assessed the methods as:
low risk of bias (study stated that it was blinded and described
the method used to achieve blinding, for example, identical
tubes containing gel, or identical plasters; matched in appearance
and smell); unclear risk of bias (study stated that it was blinded
but did not provide an adequate description of how blinding was
achieved). We excluded studies that were not double-blind and
therefore at high risk of bias.
4. Incomplete outcome data (checking for possible attrition
bias due to the amount, nature, and handling of incomplete
outcome data). We assessed the methods used to deal with
incomplete data as: low risk of bias (less than 10% of
participants did not complete the study or used ’baseline
observation carried forward’ analysis, or both); unclear risk of
bias (used ’last observation carried forward’ (LOCF) analysis); or
high risk of bias (used ’completer’ analysis).
5. Size (checking for possible biases confounded by small size).
Small studies have been shown to overestimate treatment effects,
probably due to methodological weaknesses (Dechartres 2013;
Nüesch 2010). We assessed studies as at low risk of bias if they
had at least 200 participants per treatment arm, at unclear risk if
they had 50 to 200 participants per treatment arm, and at high
risk if they had fewer than 50 participants per treatment arm.
Measures of treatment effect
We used risk ratio (RR) to establish statistical difference and num-
bers needed to treat for an additional beneficial outcome (NNT)
and pooled percentages as absolute measures of benefit or harm.
We used the following terms to describe adverse outcomes in terms
of harm or prevention of harm.
• When significantly fewer adverse outcomes occurred with
treatment than with control (placebo or active), we used the term
the number needed to treat to prevent one additional outcome
(NNTp).
• When significantly more adverse outcomes occurred with
treatment compared with control (placebo or active), we used
the term the number needed to treat for an additional harmful
outcome (NNH).
We did not use continuous data because it is inappropriate where
there is an underlying skewed distribution, as is usually the case
with analgesic response (Moore 2010a).
Unit of analysis issues
Randomisation was to the individual participant.
Dealing with missing data
Wherever possible we used intention-to-treat (ITT) analysis where
the ITT population consists of participants who were randomised,
applied at least one dose of the assigned study medication, and
provided at least one post-baseline assessment. We assigned miss-
ing participants zero improvement.
We also looked for information about methods of imputation for
missing data.
Assessment of heterogeneity
We examined heterogeneity visually using L’Abbé plots (L’Abbé
1987), a visual method for assessing differences in results of indi-
vidual studies, and with the I2 statistic.
Assessment of reporting biases
The aim of this review was to use dichotomous data of known
utility (Moore 2013). The review did not depend on what the
authors of the original studies chose to report or not. Studies that
did not report dichotomous results, but only average pain data,
did not contribute to analyses (Moore 2010a).
We assessed publication bias using amethod designed to detect the
amount of unpublished data with a null effect required to make
any result clinically irrelevant (usually taken to mean a NNT of
10 or higher; Moore 2008b).
Data synthesis
We analysed data by the individual NSAID and comparator; for
example, we analysed topical diclofenac versus carrier (topical
placebo), and topical diclofenac versus active comparator, whether
that was an oral NSAID, a different topical NSAID, or a different
(non-NSAID) topical treatment. For topical NSAID versus car-
rier, we split the analyses according to the duration of the study
(2 to ≤ 6 weeks, and 6 to 12 weeks), and the particular topical
formulation used (plaster versus gel, cream, spray, or solution).
Where appropriate, we pooled data for each dichotomous out-
come and calculated RRwith 95% confidence intervals (CI) using
the fixed-effect model (Morris 1995). We assumed a statistically
significant benefit of active treatment over control when the lower
limit of the 95% CI of the relative benefit is greater than one, and
9Topical NSAIDs for chronic musculoskeletal pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
for control over active treatment when the upper limit of the 95%
CI is less than one. We calculated NNTs and NNHs with 95%
CIs by the method of Cook and Sackett (Cook 1995).
We did not carry out pooled analysis where there were fewer than
200 participants in the comparison (Moore 1998b).
We planned to test for statistically significant differences between
NNTs for different topical NSAIDs versus carrier using the z test
where there were sufficient data to do so, and where the clinical
trials were sufficiently similar in types of patient, outcome, and
duration to make such comparisons sensible (Tramer 1997).
Quality of the evidence
Two review authors independently rated the quality of each out-
come. We used the GRADE system to assess the quality of the
evidence related to the key outcomes listed in Types of outcome
measures, as appropriate (Appendix 4; Chapter 12.2, Higgins
2011).
Summary of findings table
We have included a ’Summary of findings’ table, as set out in the
author guide (PaPaS 2012), and recommended in the Cochrane
Handbook (Chapter 4.6.6, Higgins 2011) to present the main
findings in a transparent and simple tabular format. In particular,
we included key information concerning the quality of evidence,
the magnitude of effect of the interventions examined, and the
sum of available data on the outcomes of ’clinical success’ (for ex-
ample at least 50% pain intensity reduction), local adverse events,
systemic adverse events, and serious adverse events.
Subgroup analysis and investigation of heterogeneity
We carried out subgroup analyses for different NSAIDs, duration
of study, and topical formulation for the primary analysis (seeData
synthesis above).
Sensitivity analysis
We did not plan any sensitivity analyses because the amount of
data for individual NSAIDs was expected to be small.
It was anticipated that data for active comparators would be very
limited, and preclude any subgroup and sensitivity analyses.
R E S U L T S
Description of studies
Results of the search
For this update we identified 257 studies in CENTRAL, 121 stud-
ies in MEDLINE, and 397 studies in EMBASE. After deduplica-
tion and screening we obtained full copies of five published studies
to assess them for inclusion. We excluded one study after read-
ing the full reports (Verkleij 2015), and included four (Conaghan
2013; Kneer 2013; Rother 2013; Varadi 2013). We have re-
quested full copies of two further published studies (Bohlooli
2012; Niempoog 2012), which are awaiting classification.
New searches of clinical trial registries identified 17 additional
reports of studies. One study satisfied inclusion criteria, was not
published but had results posted, and is included in this re-
view (NCT01980940). The remaining studies were completed,
or have passed their estimated completion date, but have no
study results posted. Some studies identified in the earlier review
have now been published (NCT00670475; Bohlooli 2012 and
NCT01496326; Varadi 2013), and two are now removed because
they clearly did not satisfy our inclusion criteria; one was open-
label (NCT00372333) and the other treated neuropathic pain
(NCT01508676). One study has been reported as part of a pooled
analysis, and is already included in this review (NCT00426621,
in Baraf 2011). Some others have been presented as posters and
abstracts at conferences, but we have been unable to obtain suffi-
cient details from the manufacturers to allow us to include them
in this review.
We have assigned the status of ’ongoing study’ to three
studies that were scheduled to complete in October 2014 (
NCT02121002), January 2015 (NCT02068859), and Novem-
ber 2015 (NCT01377038). It is possible that these studies will
reach full publication.We judged that the remaining 12 completed
studies that remain unpublished and without results in the registry
report are unlikely to ever reach full publication, except possibly
as part of a post-hoc pooled analysis, and have put them into an
appendix (Appendix 5). These unpublished studies included al-
most 6000 participants.
For the earlier review we identified 47 potential studies (45 pub-
lications) from our searches and from the earlier published re-
views (Mason 2004b; Moore 1998a); we excluded 13 studies (13
publications) from that review, leaving 34 studies (32 publica-
tions) that satisfied our inclusion criteria. Two of the included
studies were available only as a synopsis from the manufacturer
(102-93-1; 108-97), and the remainder were journal publications.
Together this updated review has 39 included studies (37 publi-
cations) (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
Thirty-three studies (30 publications, one registry report) com-
pared a topical NSAID with carrier alone. Of these, five stud-
ies also included a treatment arm with oral NSAID (Conaghan
2013; Rother 2007; Sandelin 1997; Simon 2009; Tugwell 2004),
and one included a treatment arm with another non-NSAID top-
ical treatment (McCleane 2000). Two studies compared a topi-
cal NSAID with a different oral NSAID (Dickson 1991; Zacher
2001), and four compared one topical NSAID with another topi-
cal treatment (Balthazar-Letawe 1987; Burgos 2001; van Haselen
2000; Widrig 2007).
Three studies that are new in this update (Conaghan 2013; Kneer
2013; Rother 2013), and one from the earlier review (Rother
2007), compared a ketoprofen gel formulation (IDEA-033) with
the gel carrier (TDT-064). The carrier was probably thought to
be inert in terms of analgesic activity when the trials were planned
and carried out, but it demonstrated an analgesic effect almost
equivalent to that of the ketoprofen gel. It is suggested that this is
due to a ’biolubrication’ mechanism (Conaghan 2014).
In this update 5019 participants were treated with a topical
NSAID, 3779 with placebo or carrier, 1591 with an oral NSAID,
and 242 with another topical remedy (10,631 in total). In the
previous review, the total number of participants was 7688. The
update has almost 3000 more participants from large studies, a
38% increase on the previous review.
Topical NSAIDs used were diclofenac, eltenac, etoricoxib, fel-
binac, flufenamate, flurbiprofen, indomethacin, ibuprofen, ke-
toprofen, nimesulide, piketoprofen, and piroxicam. They were
applied as solutions, gels, or plasters (patches). Topical placebo
was the carrier without the active NSAID. Seven studies used a
dimethyl sulphoxide (DMSO)-based carrier (102-93-1; 108-97;
Baer 2005; Bookman 2004; Rother 2007; Roth 2004; Simon
2009), of which four undertook separate analyses of placebo with
or without DMSO (102-93-1; 108-97; Bookman 2004; Simon
2009).Where available we have used data for placebowithDMSO
as the comparator. Instructions for application of topical treat-
ments were generally clear; a set quantity of gel or solution was ap-
plied onto the affected area with gentle massage, topical solution
was applied around the circumference of the affected area without
massage, and patches were applied topically. Doses of drugs are not
normally calculated, and treatment is defined in terms of number
of treatments each day using a specified quantity of agent (such as
40 drops of diclofenac in DMSO solution). Although the quan-
tity of topical agent to be applied was generally well described,
particularly in more recent studies, the actual dose applied was not
always reported or easily calculated to allow comparison between
studies.
Oral NSAIDs used were diclofenac (Sandelin 1997; Simon 2009;
Tugwell 2004), celecoxib (Conaghan 2013; Roth 2004), and
ibuprofen (Dickson 1991; Zacher 2001), all in tablet form.
Studies recruited male and female adults, most with a diagnosis of
primary osteoarthritis of the knee or hand, with independent radi-
ological confirmation of osteoarthritis within three to six months
before trial commencement. Some studies included other types of
chronic pain and used less precise descriptions of diagnosis, such
as “soft tissue rheumatism” (Burgos 2001), “cervical and lumbar
back pain” (Hohmeister 1983), and “musculoskeletal pain of at
least 3 months duration” (McCleane 2000). The mean age in in-
dividual studies, where reported, ranged from 59 to 65 years, and
all studies included both men and women. Participants were gen-
erally excluded for pregnancy or lactation, sensitivity to NSAIDs,
concomitant skin disease or damage at the application site, sec-
ondary osteoarthritis, or systemic inflammatory disease.
Participants were treated for at least two weeks (an inclusion cri-
terion) and for different durations up to 12 weeks. Most studies
lasted two to three weeks, but the majority of participants were
in the longer duration (6 to 12 week) studies, which were more
recent, larger, and tended to be of higher reporting quality. Par-
ticipants were usually assessed in clinic at intervals during treat-
ment and sometimes also over the phone. Compliance to study
medication, where reported, was measured by weighing bottles at
the start of each clinic visit. Rescue medication in the form of oral
paracetamol was allowed by most trials, except during 24 hours, or
in some cases 48 hours, preceding the assessments. Some studies
specified limits on the total amount of paracetamol allowed with-
out being classified as a treatment failure; for example, 2 grams
daily on three consecutive days. Aspirin at low dose was permitted
for cardiovascular prophylaxis.
Nearly all studies reported group mean changes (pain, physical
function) as their primary outcomes but dichotomous outcomes
suitable for a “responder analysis” were available in most or sup-
plied by the manufacturer (Nuvo Research Inc for Pennsaid®).
The measurement tools for documenting pain and physical func-
tion were varied and included the Osteoarthritis Research Soci-
ety International Index (OARSI), Western Ontario and McMas-
ter Universities Arthritis Index (WOMAC: visual analogue scale
or Likert), Australian/Canadian HandOsteoarthritis Index (AUS-
CAN), Lequesne index, and patient global evaluation of treatment
(PGE).
Methods used to report adverse events included patient reports,
diary assessments, questionnaires, clinical observation, and blood
testing. Adverse events were frequently separated into application-
site (local) and systemic events.
Full details of included studies are in the ’Characteristics of
included studies’ table.
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Excluded studies
We excluded 15 studies after obtaining the full papers. Details are
in the ’Characteristics of excluded studies’ table. Most exclusions
were due to short duration and lack of blinding.
Risk of bias in included studies
All studies included were both randomised and double-blind.
Eighteen studies were given a quality score of 5/5, 15 a score of
4/5, five a score of 3/5, and one a score of 2/5 for methodologi-
cal quality using the Oxford Quality Scale. Four studies did not
report fully on withdrawals (102-93-1; Bolten 1991; Link 1996;
Rose 1991; Varadi 2013). A breakdown of the scores can be seen
in the ’Characteristics of included studies’ table.
We also completed a ’Risk of bias’ assessment. The main deficien-
cies were in study duration and trial size, particularly in the older
studies (Figure 2). Short study duration to test an intervention
for a chronic condition, and small study size, both tend to over-
estimate treatment effect. Newer studies tended to be of longer
duration (up to 12 weeks) and larger.
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Figure 2. ’Risk of bias’ summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
All studies were randomised, but 17 did not adequately describe
the methods used to generate the random number sequence, and
25 did not adequately describe the methods used to conceal the
allocation of the sequence.
Blinding
All studies were blinded to both personnel and participants. Eight
did not adequately describe the methods used to blind the in-
terventions, and we judged them to be at unknown risk for this
item (102-93-1; 108-97; Balthazar-Letawe 1987; Grace 1999;
Hohmeister 1983; Link 1996; Rose 1991; Rother 2013). We
judged the remaining studies to be at low risk of bias for this item.
Incomplete outcome data
We judged one study to be at high risk of bias for this item because
withdrawal rates exceeded 10% and missing data were analysed
using LOCF (Burgos 2001). We judged 27 studies at unknown
risk, in most cases because they did not report the method used
to deal with missing data or withdrawals, although five of these
studies did not contribute data to the primary outcome analy-
ses (102-93-1; 108-97; Balthazar-Letawe 1987; Ottillinger 2001;
Sandelin 1997). We judged the remaining nine studies to be at
low risk.
Other potential sources of bias
Only four of the included studies had sufficient numbers of par-
ticipants in each treatment arm (≥ 200) to be judged at low risk
of bias due to size (Baraf 2011; Conaghan 2013; Rother 2013;
Tugwell 2004). Twelve studies had fewer than 50 participants per
treatment armandwe judged themat high risk (102-93-1; 108-97;
Balthazar-Letawe 1987; Ergun 2007; Galeazzi 1993; Grace 1999;
Gui 1982; Hohmeister 1983; McCleane 2000; NCT01980940;
Rose 1991; Varadi 2013). The remaining 21 studies had between
50 and 200 participants per treatment arm.
Effects of interventions
See: Summary of findings for the main comparison
Results from individual studies are provided in Appendix 6 (effi-
cacy) and Appendix 7 (adverse events and withdrawals). A sum-
mary of the main results, together with a judgement on the qual-
ity of the evidence for each outcome, is presented in Summary of
findings for the main comparison.
1. Topical NSAID versus carrier (topical ’placebo’)
Participants with ’clinical success’
There were sufficient data for pooled analysis for diclofenac and
ketoprofen only, and the calculations below are based on the def-
inition of clinical success as at least a 50% reduction in pain, or
an equivalent measure such as a ’very good’ or ’excellent’ global
assessment of treatment, or ’none’ or ’slight’ pain on rest or move-
ment, measured on a categorical scale.
Diclofenac
Six studies (four publications; 2343 participants) of 6 to 12 weeks’
duration provided data for this outcome; four used a gel formula-
tion (Altman 2009; Baraf 2011), and two a solution (Baer 2005;
Roth 2004). All defined ’success’ as either at least a 50% reduc-
tion in pain intensity or an Osteoarthritis Research Society Inter-
national Index (OARSI) response that includes response to pain,
pain, function, and patient’s global assessment (Dougados 2000).
The condition studied was knee arthritis in all except one, which
examined hand arthritis (Altman 2009).
• The proportion of participants experiencing clinical success
with diclofenac was 60% (716/1185, range 44% to 66%).
• The proportion of participants experiencing clinical success
with carrier was 50% (582/1158, range 25% to 57%) (Analysis
1.1; Figure 3).
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Figure 3. Forest plot of comparison: 8 Diclofenac versus carrier, outcome: 8.1 Clinical success.
• The risk ratio (RR) of treatment compared with carrier was
1.2 (95% confidence interval (CI) 1.1 to 1.3), and the NNT was
9.8 (7.1 to 16).
Restricting the analysis to knee arthritis only (1958 participants)
made no difference to the results.
We judged the quality of this evidence as moderate; there were
adequate numbers of studies, participants, and events, and con-
sistency of effect, but the size of the effect was modest and could
be overturned by null effect studies.
Five studies (732 participants) of 2 to < 6weeks’ duration provided
data for this outcome; two used a plaster formulation (Bruhlmann
2003; Dreiser 1993), two used a gel (Grace 1999; Niethard 2005),
and one used a solution (Bookman 2004). Bookman 2004 de-
fined ’success’ as at least a 50% reduction in pain intensity, and
the remainder typically used patient global evaluation (PGE) cate-
gories of ’very good’ or ’excellent’. The condition studied was knee
arthritis in all studies.
• The proportion of participants experiencing clinical success
with diclofenac was 43% (159/368, range 31% to 71%).
• The proportion of participants experiencing clinical success
with carrier was 23% (84/364, range 7.7% to 33%).
• The RR of treatment compared with carrier was 1.9 (1.5 to
2.3), and the NNT was 5.0 (3.7 to 7.4) (Analysis 1.1; Figure 3).
We judged the quality of this evidence as moderate; there were
adequate numbers of studies, participants, and events, and consis-
tency of effect, but the size of the effect was modest and could be
overturned by null effect studies. The short duration of the studies
may also lead to an overestimation of effect.
• For the plaster alone (258 participants) the RR was 2.7 (1.8
to 3.9) and the NNT was 3.1 (2.3 to 4.6).
• For the gel and solution (474 participants), the RR was 1.5
(1.2 to 2.0) and the NNT was 7.5 (4.6 to 20).
Ketoprofen
Four studies (2573 participants) of 6 to 12 weeks’ duration pro-
vided data for this outcome; all used a gel formulation (IDEA-
033) and defined ’success’ as either at least a 50% reduction in pain
intensity or an OARSI response (Conaghan 2013; Kneer 2013;
Rother 2013). Conaghan 2013 tested two different doses (100 mg
and 200 mg daily) and Kneer 2013 tested three doses (50 mg,
100 mg, and 200 mg daily). There was no discernable difference
between doses, so we have combined all doses for analysis. The
condition studied was knee arthritis in all studies.
• The proportion of participants experiencing clinical success
with ketoprofen was 63% (944/1503, range 41% to 89%).
• The proportion of participants experiencing clinical success
with carrier was 48% (516/1070, range 28% to 78%).
• The RR of treatment compared with carrier was 1.1 (1.01 to
1.2), and the NNT was 6.9 (5.4 to 9.3) (Analysis 2.1; Figure 4).
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Figure 4. Forest plot of comparison: 9 Ketoprofen versus carrier, outcome: 9.1 Clinical success.
• For the 200 mg dose only (1685 participants), the RR was
1.1 (0.98 to 1.2); the NNT was not calculated.
We judged the quality of this evidence as moderate; there were
adequate numbers of studies, participants, and events, but there
was inconsistency of effect (I2 = 83%) with one study showing
a significantly worse result with ketoprofen than placebo (Rother
2013). Moreover, the size of the effect was modest and could be
overturned by null effect studies.
There were no studies of ketoprofen of less than six weeks’ dura-
tion.
Other topical NSAIDs
Single studies reported dichotomous data for ’clinical success’ for
etoricoxib, felbinac, nimesulide, and ibuprofen, and two reported
data for piroxicam. All were of shorter duration. There were in-
sufficient data to draw any conclusions about efficacy.
Bolten 1991: 34/142 participants experienced undefined ’im-
provement’ in pain at rest with felbinac gel 3% for two weeks,
compared with 15/139 with carrier.
Ergun 2007: 23/49 participants reported PGE of very good or
excellent with nimesulide gel 1% for 30 days, compared with 2/
21 with carrier.
Gui 1982: 14/18 participants experience undefined ’improve-
ment’ on movement with ibuprofen cream for three weeks, com-
pared with 7/19 with carrier.
McCleane 2000: 1/50 participants experienced at least a 50%
reduction inpain intensitywith piroxicamgel 2.5% for fourweeks,
compared with 4/50 with carrier.
NCT01980940: 13/24 participants reported a response to treat-
ment of well or very well with etoricoxib 50 mg gel for two weeks,
compared with 14/24 with carrier.
Rose 1991: 8/15 participants reported PGE of very good or excel-
lent with both piroxicam gel 0.5% and carrier for two weeks.
Participants with local adverse events
Local adverse events were irritation of the area to which the topical
NSAID was applied, including dry skin, redness or erythema, and
itch or pruritis. Twenty-nine studies (27 publications), with 7594
participants, reported information on participants in each treat-
ment arm with local adverse events. Events were usually described
as mild and transient.
There were wide variations in the incidence of events for both con-
trol (0% to 43%) and topical NSAID (0% to 51%), with a high
incidence in the control arm of a study generally accompanied by
a high incidence in the active arm. This may in part reflect differ-
ences in the way adverse event data were collected (spontaneous
reports, questioning, diary, checklist), and which symptoms were
recorded as adverse events. For example, one study reported that
21 participants receiving active treatment and six receiving con-
trol ’developed dry skin at the application site’, but only four and
one, respectively, were reported to have ’application site reactions’
(102-93-1). Others reported dry skin as the most common local
adverse event (Baer 2005; Bookman 2004).
Where data were available we have included dry skin as a local
adverse event. Some studies reported the number of participants
with specific local adverse events, and in these cases we have used
the number for the most common event (usually dry skin); this
assumes that all those who reported dry skin also had rash or ery-
thema or redness, and may slightly underestimate the total num-
ber of participants with any local adverse event. Further variation
in incidence may arise due to differing treatment periods, and for
active treatment arms variation is to be expected due to use of
different drugs and different strengths of the applied drug, or dif-
ferent total amounts applied.
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Diclofenac - all formulations
Fifteen studies (13 publications, 3658 participants) reported on
the number of participants experiencing local adverse events with
diclofenac (102-93-1; Altman 2009; Baer 2005; Baraf 2011;
Bookman 2004; Bruhlmann 2003; Dreiser 1993; Galeazzi 1993;
Grace 1999;Niethard2005;Roth 1995;Roth 2004; Simon2009).
There was no consistent difference in reported event rates for dif-
ferent formulations, so we have combined them for analysis.
• The proportion of participants experiencing local adverse
events with diclofenac was 261/1842 (14%, range 0% to 51%).
• The proportion of participants experiencing local adverse
events with carrier was 141/1816 (7.8%, range 0% to 43%).
• The RR of treatment compared with carrier was 1.8 (1.5 to
2.2), and the NNH was 16 (12 to 23) (Analysis 1.2).
We judged the quality of this evidence as moderate; there were
adequate numbers of studies, participants, and events, but there
was inconsistency of effect (I2 = 76%), possibly due to differences
in data collection, and the size of the effect was modest.
Ketoprofen
Four studies (2621 participants) reported on the number of par-
ticipants experiencing local adverse events with ketoprofen gel
(Conaghan 2013; Kneer 2013; Rother 2007; Rother 2013). All
used the same formulation (IDEA-033) and doses were 50 mg,
100 mg, and 200 mg daily.
• The proportion of participants experiencing local adverse
events with ketoprofen (all doses) was 236/1542 (15%, range
5.6% to 28%).
• The proportion of participants experiencing local adverse
events with carrier was 139/1079 (13%, range 5.9% to 20%).
• The RR of treatment compared with carrier was 1.0 (0.85
to 1.3); the NNH was not calculated (Analysis 2.2).
• No individual study showed a significant difference
between ketoprofen and carrier. For the 200 mg dose alone, the
RR was 1.1 (0.92 to 1.4); the NNH was not calculated.
We judged the quality of this evidence as moderate; there were
adequate numbers of studies, participants, and events, and con-
sistency of effect (no effect), but the size of the effect was modest.
Other NSAIDs
Ten studies reported on the number of participants experienc-
ing local adverse events with eltenac (Ottillinger 2001; Sandelin
1997), felbinac (Bolten 1991), flufenamate (Hohmeister 1983),
flurbiprofen (Poul 1993), ibuprofen (Gui 1982; Varadi 2013),
nimesulide (Ergun 2007), and piroxicam (Rose 1991; vanHaselen
2000), compared with carrier. There were insufficient data for
quantitative analysis for any of these interventions. Event rates
were generally below 10% in all treatment arms, and individ-
ual studies did not indicate any major difference between topical
NSAID and carrier alone.
There were too few studies, participants, and events to draw any
conclusions about local adverse events for any of these NSAIDs.
Participants with systemic adverse events
Fourteen studies, with 2237 participants in comparisons with car-
rier, reported information on participants with systemic adverse
events in each treatment arm. Events were wide ranging, includ-
ing headache, diarrhoea, drowsiness, and dyspepsia, and were usu-
ally described as mild. In most studies the incidence was below or
around 10%, and as with local adverse events, a higher incidence
in the control arm was generally accompanied by a higher inci-
dence in the active arm.
There was no difference between topical NSAID and carrier alone
in any individual study, or for topical diclofenac (1266 partici-
pants, RR 0.89 (0.59 to 1.3)) (Analysis 1.3) or for all other topical
NSAIDs combined (971 participants, RR 1.2 (0.77 to 1.8)).
Many studies did not report data for participants with any sys-
temic adverse event, but did report information either about spe-
cific adverse events (nausea) or events occurring within an organ
system (gastrointestinal). There were no significant differences in
the incidence of gastrointestinal adverse events between any top-
ical NSAID and carrier in any individual study, or for topical di-
clofenac (3240 participants, RR 1.1 (0.76 to 1.6)) (Analysis 1.4)
or topical ketoprofen (2621 participants, RR 0.96 (0.69 to 1.3))
(Analysis 2.3).
We judged the quality of this evidence for systemic adverse events
as very low; there were adequate numbers of studies and partici-
pants, and consistency of effect (no effect), but fewer than half of
eligible studies reported this outcome, reporting was inconsistent,
and there were small numbers of events.
Participants with serious adverse events
Ten studies (seven publications, one registry report, 4889 partici-
pants) reported the occurrence of serious adverse events.
Baraf 2011 (three studies, 1426 participants) reported 12 serious
adverse events with diclofenac and five with carrier, one of which
was considered to be related to the study drug. An 80-year-old
woman treated with diclofenac sodium gel, who had multiple
risk factors for peripheral vascular disease, experienced deep vein
thrombosis and pulmonary embolism, which was managed with
warfarin and heparin. One other participant (76-year-old male)
treatedwith diclofenac also had pre-existingmedical problems and
died of atrial fibrillation, but this was not considered related to
treatment.
Conaghan 2013 (1395 participants) reported no serious adverse
events with ketoprofen 100 mg daily and three with the carrier
alone, three serious events with ketoprofen 200 mg daily and four
with the carrier alone, and four with oral celecoxib 200 mg daily
18Topical NSAIDs for chronic musculoskeletal pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
and one with oral placebo. None were considered treatment re-
lated.
NCT01980940 (48 participants) reported no serious adverse
events for either etoricoxib 50 mg gel or carrier.
Niethard 2005 (238 participants) reported one participant in the
carrier group who had a brain tumour.
Roth 2004 (397 participants) reported no serious adverse events
in the topical ketoprofen arm, but one in the oral celecoxib arm
(myocardial infarction), and one in the carrier arm (angina).
Rother 2013 (555 participants) reported three serious adverse
events with ketoprofen 200 mg daily and four with carrier only.
One event with ketoprofen (headache) was possibly treatment re-
lated.
Simon 2009 (755 participants) reported no serious adverse events
in the topical diclofenac arm, but one in the dimethyl sulphoxide
(DMSO) vehicle control arm (acute enteritis), four in the carrier
withoutDMSOarm (anaemia, fracturedhip, dislocated prosthetic
hip, cerebrovascular event), and three in the oral diclofenac arm
(leg cellulitis, unstable angina, transient ischaemic attack).
Varadi 2013 (75 participants) reported no serious adverse events.
We judged the quality of this evidence for serious adverse events as
very low; only one in three eligible studies reported this outcome
and there were small numbers of events. There was no clear indi-
cation that serious adverse events were more common with topical
NSAID than with carrier.
Withdrawals due to adverse events
Twenty-five studies (22 publications, one clinical registry report),
with 7004 participants in comparisons with carrier, reported the
numbers of participants who withdrew due to an adverse event.
Event rates ranged from 0% to 17% with active treatment, and
from 0% to 16% with carrier, but were generally around 5%.
There was a statistically significant difference between topical di-
clofenac and carrier (3552 participants, RR 1.6 (1.1 to 2.1), NNH
51 (30 to 170) (Analysis 1.5), but not for ketoprofen and carrier
(2621 participants, RR 1.28 (0.92 to 1.8), the NNH was not cal-
culated) (Analysis 2.4).
We judged the quality of this evidence as moderate; there were
adequate numbers of studies, participants, and events, and con-
sistency of effect, but the size of the effect was very small for di-
clofenac (no effect for ketoprofen).
There were no significant differences between topical NSAID and
carrier in any of the individual studies using other NSAIDs.
Withdrawals due to lack of efficacy
Twenty studies, with 6702 participants in comparisons with car-
rier, reported on the numbers of participants who discontinued
treatment due to lack of efficacy. Event rates varied from 0% to
17% with active treatment, and from 0% to 26% with carrier,
with higher rates often, but not always, associated with studies of
longer duration.
Significantly fewer participants withdrew due to lack of efficacy
with topical diclofenac than with carrier; 3455 participants, RR
0.59 (0.47 to 0.75), NNTp 26 (18 to 47) (Analysis 1.6),
There was no significant difference between topical ketoprofen
and carrier; 2885 participants, RR 1.1 (0.80 to 1.6), the NNTp
was not calculated (Analysis 2.5).
We judged the quality of this evidence as moderate; there were
adequate numbers of studies, participants, and events, and con-
sistency of effect, but the size of the effect was very small for di-
clofenac (no effect for ketoprofen).
There were no significant differences between topical NSAID and
carrier in any of the individual studies using other NSAIDs.
2. Topical NSAID versus any oral NSAID
Participants with clinical success
Five studies contributed to this analysis, of which two also had a
placebo arm (Rother 2007; Simon 2009); 877 participants were
treated with a topical NSAID and 858 with an oral NSAID. All
studies used the double dummy method to maintain blinding.
• Dickson 1991 compared 1 g 0.5% piroxicam gel with oral
ibuprofen tablet 400 mg, administered three times a day for four
weeks. The response rate was 64% (75/117) with piroxicam gel
and 60% (71/118) with ibuprofen tablets (response: PGE).
• Rother 2007 compared 110 mg ketoprofen gel with oral
celecoxib tablet 100 mg, administered twice daily for six weeks.
The response rate was 46% (64/138) with ketoprofen gel and
39% (51/132) with celecoxib tablets (response: PGE).
• Simon 2009 compared 40 drops of 1.5% topical diclofenac
solution with DMSO (Pennsaid®) administered four times daily
with slow-release oral diclofenac tablet 100 mg taken once daily,
for 12 weeks. The response rate was 47% (73/154) with
diclofenac solution and 51% (77/151) with diclofenac tablets
(response: ≥ 50% pain relief ).
• Tugwell 2004 compared 50 drops of 1.5% topical
diclofenac solution with DMSO (Pennsaid®) with oral
diclofenac tablet 50 mg administered three times a day for 12
weeks. The response rate was 66% (201/303) with diclofenac
solution and 70% (210/301) with diclofenac tablets (response:
OMERACT-OARSI).
• Zacher 2001 compared diclofenac Emulgel applied four
times daily as a 10 cm ribbon of ointment with oral ibuprofen
tablet 300 mg taken three times daily for three weeks. The
response rate was 40% (66/165) with diclofenac Emulgel and
34% (53/156) with ibuprofen tablets (response: ≥ 40% pain
relief ).
Although there were differences between studies in topical NSAID
used, oral NSAID comparator, and duration of study, we pooled
these studies in an exploratory analysis because knowing whether
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there is any major difference in effect size between topical and oral
NSAID is important.
• The proportion of participants experiencing successful
treatment with a topical NSAID was 55% (479/877, range 40%
to 66%).
• The proportion of participants experiencing successful
treatment with oral NSAID was 54% (462/858, range 34% to
70%).
• The RR of topical treatment compared with oral was 1.03
(0.95 to 1.1).
• The NNT was not calculated (Analysis 3.1; Figure 5).
Figure 5. Forest plot of comparison: Topical NSAID versus oral NSAID, outcome: Clinical success.
We judged the quality of the evidence to be moderate. While the
studies were well designed and conducted, and the number of
participants and events adequate, and with a consistent lack of
effect (I2 = 34%), the analysis combined different topical and oral
preparations.
One included study was not strictly blinded between topical keto-
profen and oral celecoxib, and so those results were not included
in this analysis, although results were consistent with there being
no difference between them (Conaghan 2013).
Participants with local adverse events
Five studies contributed to this analysis (Dickson 1991; Roth
2004; Sandelin 1997; Simon 2009; Tugwell 2004). A total of 846
were treated with a topical NSAID and 805 with an oral NSAID.
• The proportion of participants experiencing a local adverse
event with a topical NSAID was 22% (182/846, range 3% to
28%).
• The proportion of participants experiencing a local adverse
event with an oral NSAID was 5.8% (47/805, range 1% to 7%).
• The RR for a topical NSAID compared with oral NSAID
was 3.7 (2.8 to 5.1) (Analysis 3.2).
• The NNH was 6.4 (5.3 to 8.0).
We judged the quality of the evidence as very low; there were ade-
quate numbers of studies, participants and events, but the validity
of combining these studies is questionable, and there was inconsis-
tency in the results (I2 = 90%). The finding of fewer local adverse
events with oral NSAID than with topical NSAID is plausible.
Participants with systemic adverse events
Studies comparing a topical NSAID with an oral NSAID did not
report the total number of participants experiencing any systemic
adverse event, but some did report the numbers in each treatment
arm who experienced gastrointestinal adverse events. Gastroin-
testinal events commonly limit the use of oral NSAIDs and have
been the driving force behind use of topical agents, so they are
considered here. Six studies contributed to this analysis (Dickson
1991; Roth 2004; Sandelin 1997; Simon 2009; Tugwell 2004;
Zacher 2001). A total of 1011 participants were treated with a
topical NSAID and 950 with an oral NSAID.
• The proportion of participants experiencing a
gastrointestinal adverse event with a topical NSAID was 17%
(167/1011, range 5% to 35%).
• The proportion of participants experiencing a
gastrointestinal adverse event with an oral NSAID was 26%
(248/950, range 9% to 48%).
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• The RR for a topical NSAID compared with oral NSAID
was 0.66 (0.56 to 0.77) (Analysis 3.3).
• The NNTp was 10 (7.6 to 17).
We judged the quality of the evidence as very low; there were ade-
quate numbers of studies, participants and events, but the validity
of combining these studies is questionable, and there was some
inconsistency in the results (I2 = 62%). The finding of fewer sys-
temic adverse events with topical NSAID than with oral NSAID
is plausible.
Participants with serious adverse events
Rother 2007 (397 participants) reported no serious adverse events
in the topical ketoprofen arm, but one in the oral celecoxib arm
(myocardial infarction), and one in the carrier arm (angina).
Simon 2009 (755 participants) reported no serious adverse events
in the topical diclofenac arm, but one in the DMSO carrier con-
trol arm (acute enteritis), four in the carrier without DMSO arm
(anaemia, fractured hip, dislocated prosthetic hip, cerebrovascular
event), and three in the oral diclofenac arm (leg cellulitis, unstable
angina, transient ischaemic attack).
Zacher 2001 (321 participants) reported ileus in one participant
who took oral ibuprofen. The event was judged to be unrelated to
the study medication.
There were too few events to draw any conclusions about serious
adverse events.
Withdrawals due to adverse events
Six studies provided information about withdrawals due to adverse
events (Dickson 1991; Rother 2007; Sandelin 1997; Simon 2009;
Tugwell 2004; Zacher 2001); 1011 participants were treated with
topical NSAID and 950 with oral NSAID.
• The proportion of participants withdrawing due to an
adverse event with a topical NSAID was 12% (121/1011, range
3% to 21%).
• The proportion of participants withdrawing due to an
adverse event with oral NSAID was 15% (140/950, range 1% to
25%).
• The RR for topical NSAID compared with oral NSAID
was 0.85 (0.68 to 1.1) (Analysis 3.4).
• The NNTp was not calculated.
We judged the quality of the evidence as very low; there were
adequate numbers of studies, participants and modest numbers of
events, but the validity of combining these studies is questionable.
Withdrawals due to lack of efficacy
Only three studies provided information specifically about with-
drawals due to lack of efficacy (Rother 2007; Simon 2009; Tugwell
2004); 603 participants were treated with topical NSAID and 594
with oral NSAID.
• The proportion of participants withdrawing due to lack of
efficacy with a topical NSAID was 7% (45/603, range 1% to
10%).
• The proportion of participants withdrawing due to lack of
efficacy with oral NSAID was 3% (18/594, range 2% to 3%).
• The RR for topical NSAID compared with oral NSAID
was 2.5 (1.5 to 4.2) (Analysis 3.5).
• The NNTp was 23 (14 to 52).
We judged the quality of the evidence as very low; there were
adequate numbers of studies, participants and modest numbers of
events, but the validity of combining these studies is questionable.
3. Topical NSAID versus different topical NSAID
Participants with clinical success
Burgos 2001 compared flurbiprofen LAT patch 40 mg applied
twice daily with piketoprofen cream 1.8% applied three times
daily. There was a response rate of 79% (46/58) with flurbiprofen
and 65% (39/60) with piketoprofen. This study used an undefined
outcome of “any relief ” as a measure of clinical success.
Participants with local adverse events
Burgos 2001 reported that 3% (2/61) had experienced a local
adverse event with flurbiprofen LAT patch 40 mg compared to
2% (1/60) with piketoprofen cream 1.8%.
Participants with systemic adverse events
There were no data for systemic adverse events in the study com-
paring one topical NSAID with another.
Participants with serious adverse events
There were no reported serious adverse events in the study com-
paring one topical NSAID with another.
Withdrawals due to adverse events
Burgos 2001 reported that 2/64 participants withdrew due to an
adverse event with flurbiprofen LAT patch 40 mg compared with
1/65 with piketoprofen cream 1.8%.
Withdrawals due to lack of efficacy
Burgos 2001 reported that 2/64 participants withdrew due to lack
of efficacy with flurbiprofen LAT patch 40 mg compared with 3/
65 with piketoprofen cream 1.8%.
Therewere too fewdata to drawany conclusions fromcomparisons
of one topical NSAID with another.
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4. Topical NSAID versus different topical treatment
Participants with clinical success
Three studies compared a topical NSAID with a different topical
treatment.
• McCleane 2000 compared 2.5% piroxicam gel to 1%
glyceryl trinitrate (GTN) and a mixture containing 2.5%
piroxicam gel with 1% GTN, applied three times daily for four
weeks. There was a response rate of 3% (1/40) with piroxicam
alone, 11% (4/36) with GTN, and 19% (7/37) with piroxicam/
GTN mixture (response: ≥ 50% pain relief ).
• van Haselen 2000 compared 1 g 0.5% piroxicam gel to 1 g
SLR® homeopathic gel, containing Symphytum officinale
(comfrey), Rhus toxicodendron (poison ivy), and Ledum palustre
(marsh-tea), applied three times daily for four weeks. There was a
response rate of 22% (20/91) with piroxicam and 43% (38/89)
with SLR® homeopathic gel (response: PGE).
• Widrig 2007 compared ibuprofen 5% gel with topical
arnica 50% gel applied as a 4 cm strip three times daily for three
weeks. There was a response rate of 59% (50/85) with ibuprofen
and 64% (57/89) with topical arnica, but this was a completer
analysis (response: PGE).
There were insufficient data for meta-analysis for any of these
comparisons.
Participants with local adverse events
• McCleane 2000 reported no local adverse events with any
of the three topical treatments.
• van Haselen 2000 reported 12% (11/91) had experienced a
local adverse reaction with 0.5% piroxicam gel, compared to 9%
(7/89) with SLR® homeopathic gel.
• Widrig 2007 reported only 7% (7/99) had experienced a
local adverse reaction with both ibuprofen 5% gel and topical
arnica 50% gel.
There were insufficient data to comment on differences between
topical treatments for local adverse events.
Participants with systemic adverse events
• McCleane 2000 reported that one participant in each arm
treated with piroxicam experienced a gastrointestinal event
(nausea, dyspepsia), and one in the placebo arm (nausea).
Seventeen participants treated with topical glyceryl trinitrate
experienced nitrate headaches.
• van Haselen 2000 reported that 5.5% (5/89 and 5/91)
participants had experienced a systemic adverse reaction with
0.5% piroxicam gel and SLR® homeopathic gel.
• Widrig 2007 reported 8% (8/99) had experienced a
systemic adverse reaction with ibuprofen 5% gel and 14% (14/
100) with topical arnica 50% gel.
There were insufficient data to comment on differences between
topical treatments for systemic adverse events.
Participants with serious adverse events
Widrig 2007 (198 participants) reported back trauma due to a fall
in one participant in the arnica treatment arm.
Withdrawals due to adverse events
• McCleane 2000 reported that 1/50 participants withdrew
due to an adverse event with 2.5% piroxicam cream, and none
with 1% GTN cream.
• van Haselen 2000 reported that 1/89 participants withdrew
due to an adverse event with 0.5% piroxicam gel, compared to 1/
91 with SLR® homeopathic gel.
• Widrig 2007 reported that 1/98 participants withdrew due
to an adverse event ibuprofen 5% gel, compared with 3/100 with
topical arnica 50% gel.
There were too few events to comment on differences between
topical treatments for adverse event withdrawals.
Withdrawals due to lack of efficacy
There were no reports specifically for withdrawals due to lack of
efficacy in the three studies comparing a topical NSAID with a
non-NSAID topical treatment.
D I S C U S S I O N
This update added data from only five studies, but increased the
total number of participants by 38%, from 7688 to 10,631. The
additional data came mainly from large studies of high reporting
quality using ketoprofen gel.
Summary of main results
The results of this updated review are that diclofenac gel or solu-
tion has a modest benefit in longer-term studies of 6 to 12 weeks’
duration. The NNT of 9.8 (95% confidence interval (CI) 7.1 to
16) barely reached statistical significance (moderate quality evi-
dence); shorter duration studies had a slightly lower, better, NNT
of 7.5. For ketoprofen gel, with all ketoprofen doses combined,
the NNTwas 6.9 (5.4 to 9.3) (moderate quality evidence). Again,
this comparison only just reached statistical significance, and for
just the 200 mg dose no significant benefit was found over carrier.
It is worth mentioning that, for ketoprofen, one study produced
an opposite result, where carrier was better than carrier plus keto-
profen (Figure 4).
It is also worth noting that the proportion of participants report-
ing significant pain relief with carrier (topical placebo) in both
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these analyses was about 50% over 6 to 12 weeks, thus limiting
the potential to demonstrate efficacy (Figure 6). It is also worth
noting that there were no robust data for any other topical non-
steroidal anti-inflammatory drugs (NSAIDs) in any formulation,
and that, in a limited number of comparisons, topical NSAID
was not differentiated from oral NSAID. The frequency of local
adverse events did not differ between topical NSAID and topical
placebo carrier (moderate quality evidence), and although report-
ing of systemic adverse events was poor they also did not differ
(very low quality evidence). This benign adverse event profile is
why topical NSAIDs are recommended as first-line treatment for
musculoskeletal conditions (Gaskell 2014; NICE 2014).
Figure 6. Placebo responses in topical NSAID studies for at least 50% pain intensity reduction after 12
weeks, compared with oral placebo from a pooled analysis and a single study with direct comparison with
topical placebo.
The efficacy results in this update are not unlike those found for
longer duration studies of diclofenac in the previous version of
this review, where the measured NNT then was 10 (7.3 to 17),
based on largely the same data. In the previous version, as here,
shorter duration studies produced lower, better, NNT values. The
results for ketoprofen are new, and show that in the formulation
used there was no additional benefit for the topical NSAID over
the topical carrier. Suggestions that in these studies the topical
carrier had some analgesic effect of its own has to be judged by the
almost identical topical carrier (placebo) rates found in the topical
diclofenac and topical ketoprofen studies. What is interesting is
that the topical placebo carrier response rate in 6 to 12-week studies
of around 50% is almost double that found for oral placebo in 12-
week studies, where it was 22% to 27% for the outcome of at least
50% pain intensity reduction over baseline (Figure 6), and 31%
to 41% for the outcome of at least 30% pain intensity reduction
(Moore 2010b). This at least raises the possibility that topical
carriers confer some analgesic effect themselves, as suggested by
direct comparison (Conaghan 2013).
Overall completeness and applicability of
evidence
There is a tension between pooling studies to produce analyses
with larger numbers and the subsequent large increases in clini-
cal and statistical heterogeneity on the one hand, and using the
approach of clinical homogeneity with subsequent smaller num-
bers of participants on the other. In this review, as in the previous
version, we have attempted as much as possible to analyse data by
topical NSAID in a particular formulation. This should facilitate
decisions regarding choice of topical NSAID, since there is no in-
herent reason why different NSAIDs and different formulations
should perform equally.
While 11 different NSAIDs were investigated in our included
studies, there were sufficient data to make any judgement of clin-
ical utility for formulations of diclofenac and ketoprofen only.
The most likely chronic musculoskeletal condition for which top-
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ical NSAIDs are likely to be used is osteoarthritis, and the vast
majority of participants in these studies had this condition (all
participants in more recent studies). Relevant age groups were well
represented, with mean age in individual studies ranging from 59
to 65 years, and inclusion of individuals aged 90 years or more in
some studies.
Quality of the evidence
The quality of evidence on efficacy for longer duration studies (8
to 12 weeks) was good, with studies fulfilling all the criteria for
good evidence in chronic pain trials (Moore 2010a; Moore 2012).
Shorter duration studies tended to be small, have less well defined
outcomes, and lack clarity on imputation methods. Shorter dura-
tion studies tended to have lower (better)NNTvalues, whether for
all topical NSAIDs or topical diclofenac alone. This differential
effect of study duration on efficacy estimate may reflect a number
of variables, particularly the likelihood of larger biases in shorter
duration studies, but it also emphasises the need to concentrate
on studies of longer duration for chronic painful conditions. Poor,
inconsistent reporting, together with low event rates, meant that
evidence for adverse events was of very low quality.
Potential biases in the review process
One potential bias is that clinical trials for topical NSAIDs may
not have been published. One previous review did find previously
unpublished trials (Moore 1998a), but a subsequent attempt that
included extensive contacts with pharmaceutical companies re-
vealed no additional data (Mason 2004a).While some old unpub-
lished studies of topical NSAIDs in chronic painful conditions
may exist, they constitute an unknown number of studies and
participants whose results are unknown, and are likely to remain
unknown. Furthermore, their relevance to current clinical practice
may be limited as better formulations are developed. New systems
of trial registration mean that we know what recent studies have
been done or are ongoing; the number of studies and participants
is known even if their results remain unknown. We identified a
number of completed and ongoing studies in Clinicaltrials.gov.
Although this review involved over 10,000 participants, we know
of additional studies with almost 7000 further participants, for
which we have no results. Perhaps not all would have been rel-
evant, but the fact that almost 6000 of these participants were
in studies concluded more than three years ago, and yet have no
results available, is something of a cause for concern. The reasons
might lie in the obvious difficulty in performing clinical trials in
chronic musculoskeletal pain, as well as in protecting proprietary
information.
Agreements and disagreements with other
studies or reviews
The results of this review are in substantial agreement with the pre-
vious version, and a number of previous systematic reviews of top-
ical NSAIDs in chronic painful conditions (Biswal 2006; Mason
2004b; Moore 1998a; Towheed 2006), but do not agree with oth-
ers (Bjordal 2007; Lin 2004). In 2004, Lin and colleagues had
available only a few studies, and those with the longest duration
(four weeks) used topical felbinac which showed no effect at any
time; they were able to conclude only that the evidence supported
topical NSAID effectiveness for two weeks (Lin 2004). Bjordal
and colleagues also concluded, using very similar study informa-
tion, that topical NSAIDs had efficacy over 1 to 3 weeks (Bjordal
2007). The results presented here show clearly that high quality
large studies demonstrate efficacy of topical NSAIDs in 12-week
studies, with NNTs probably similar to those of oral NSAIDs.
A review of topical NSAIDs for osteoarthritis provides some ex-
perimental evidence on the mechanism of action and the concen-
trations of drug found in different tissues following a period of
administration (Barthel 2010). Efficacy and safety are reviewed
in the most recent studies using diclofenac formulations that are
licensed in the USA, in studies lasting 12 weeks, all of which are
included in this review. There was no quantitative analysis.
Another review looks at all topical treatments for osteoarthritis,
again providing information on mechanisms of action and phar-
macology (Altman 2011). There is a narrative review of trials using
various topical NSAIDs, all of whichwere considered for inclusion
in this review; there is no quantitative analysis.
Other systematic reviews of safety of topical NSAIDs in acute
and chronic conditions agree that topical NSAIDs tend to be well
tolerated (Taylor 2011), as do longer-term open studies (Peniston
2011; Shainhouse 2010). Results on adverse events in this review
were similar to those in a pooled analysis of topical diclofenac
studies (Roth 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
For people with chronic musculoskeletal pain
Topical diclofenac and topical ketoprofen can provide good levels
of pain relief in knee osteoarthritis in people aged over 40 years,
but only in about 10% more people than with carrier. Adverse
events are minimal with topical nonsteroidal anti-inflammatory
drugs (NSAIDs).
For clinicians
Topical diclofenac and topical ketoprofen can provide good levels
of pain relief in knee osteoarthritis, but only in about 10% more
people than with carrier. Adverse events are minimal with topi-
cal NSAIDs. For this reason guidelines often suggest the use of
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topical NSAIDs before oral NSAIDs, particularly in older people.
There is little good evidence for topical NSAIDs in other chronic
musculoskeletal pain.
For policy makers
Topical NSAIDs are not associated with an increased incidence of
local skin reactions compared with the inert carrier, and while the
carriermay causemild, transient irritation, it is rarely troublesome.
Topical NSAIDs do not cause systemic (mainly gastrointestinal)
problems commonly seen with oral NSAIDs, making them par-
ticularly useful for individuals with osteoarthritis who are unable
to tolerate oral administration, or for whom it is contraindicated.
The efficacy results we have are only applicable to knee osteoarthri-
tis.
For funders
Topical diclofenac and topical ketoprofen preparations should be
considered for treatment of chronic musculoskeletal painful con-
ditions like knee osteoarthritis where there are no contraindica-
tions, such as damaged skin.
Formulations of topical NSAIDs are likely to change over time,
therefore the relevant trials performed and reported over 25 years
ago must be limited and may be questionable. Funders might wish
to consider asking pharmaceutical companies without recent trial
evidence for their products to produce it.
Implications for research
General
The general thrust of these findings is that gel formulations of
topical diclofenac and topical ketoprofen can provide good levels
of pain relief in patients with knee osteoarthritis, but only about 1
in 10 more will benefit with the topical NSAID than with topical
placebo, or carrier. Response rates to topical placebo in relevant
longer duration studies appear to be substantially higher than with
oral placebo. The reason for this is not known, but the fact that
50% of osteoarthritis patients can report very high levels of pain
relief without NSAID is not without importance.
There is little good evidence about other topicalNSAIDs or topical
NSAIDs in other chronic conditions, and research in other forms
of chronic pain might be appropriate.
Design
The design of the trials is generally good, and the knee osteoarthri-
tis model appears to be reliable and reproducible. Modern stud-
ies have ensured that participants entering the trials have at least
moderate pain, and this helps sensitivity to detect an analgesic
response. Major changes to the design of these trials would not
appear to be needed, other than ensuring an adequate duration
because shorter studies consistently report higher efficacy.
Measurement (endpoints)
A major issue is not in the measurement of pain, as most studies,
especially modern ones, have used standard pain intensity and
pain relief scales. However, reporting of average pain changes is
inadequate, and the use of responder analyses (at least 50% pain
intensity reduction, or patients experiencing mild or no pain) is
preferred.
Comparison between active treatments
Indirect comparisons with carrier are probably as informative as
use of an active comparator, for which there are few. However,
comparisons between oral placebo and topical placebo (carrier
only without NSAID) are an obvious target for future studies.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
102-93-1
Methods R, DB, PC, parallel group
Assessment at baseline, 2, 4, 6 weeks
Participants OA knee (diagnosed by standard radiological criteria and interview) with ≥ moderate
pain within previous 2 weeks
N = 122
No further demographic details provided
Interventions (1) Diclofenac solution (with 45.5% DMSO)
(2) Control (with 45.5% DMSO)
(3) Placebo (with 4.55% DMSO)
Measured dose (4 x 40 drops, about 1 mL) applied 4 times daily using applicator pad,
for 6 weeks
Number of participants in each group not reported
2-week washout if confounding medication had been used
Outcomes Daily global comparison (better, same, worse) for pain at rest, pain on motion, nocturnal
pain
Adverse events: local, systemic
Notes Oxford Quality Score: R2, DB1, W0. Total = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Imputation: N/A - no useable efficacy data.
Total attrition < 10%
Study duration Low risk 6 weeks
Size High risk < 50 participants per treatment arm
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108-97
Methods R, DB, PC, parallel group
Assessment at baseline, 2, 4, 6 weeks
Participants OA hand (diagnosed by standard radiological criteria and interview) with ≥ moderate
(but not extreme) pain
N = 203 (195 for ITT)
No further demographic details provided
Interventions (1) Diclofenac solution (with 45.5% DMSO), n = 48
(2) Control (with 45.5% DMSO), n = 47
(3) Diclofenac solution (with 2.3% DMSO), n = 50
(4) Placebo (with 2.3% DMSO), n = 50
Measured dose (to maximum 40 drops/hand) applied 4 times daily for 6 weeks
Rescue medication: paracetamol (500 mg to maximum 3 g daily) except in 24 h before
assessments
Outcomes AUSCAN LK3 pain dimension
PGE: 5-point scale
Withdrawals
Notes Oxford Quality Score: R1, DB1, W1. Total = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Imputation: N/A - no useable efficacy data.
Total attrition < 10%
Study duration Low risk 6 weeks
Size High risk < 50 participants in 2 treatment arms, 50
in other 2
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Altman 2009
Methods R, DB, PC, parallel group
Assessment at baseline, 1, 2, 4, 6, 8 weeks
Participants OA hand (ACR criteria) for ≥ 12 months, use of NSAID for ≥ 1 episode of pain. Flare
required following NSAID washout (≥ 7 days) if applicable
N = 385
M 89, F 296
Mean age 64 years (range 40 to 92)
Baseline pain ≥ 40 mm
Interventions (1) Diclofenac sodium gel 1% (Voltaren) with vehicle, n = 198
(2) Placebo gel (vehicle carrier) n = 187
Measured dose (2 g) of gel applied with gentle massage 4 times daily for 8 weeks
Rescue medication: paracetamol 500 mg (to maximum 4 g daily) but not for 36 h before
assessment
Outcomes OARSI response in dominant hand at 8 weeks
AUSCAN score for the dominant hand
PGE: 5-point scale (responder = “very good” or “excellent”)
Adverse events
Withdrawals
Notes Oxford Quality Score: R1, DB2, W1. Total = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “identical in appearance, smell, and tex-
ture”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Worst observation carried forward, adverse
event withdrawal low, “other” attrition <
10%
Study duration Low risk 8 weeks
Size Unclear risk 50 to 200 participants per treatment arm
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Baer 2005
Methods R, DB, PC, parallel groups
Assessed at baseline, 6 weeks
Participants Primary OA of at least 1 knee
A flare of pain after withdrawal of prior therapy with either NSAID or paracetamol
N = 216 (212 for efficacy)
M 94, F 122
Mean age 65 years
Mean baseline pain 13/20
Interventions (1) Diclofenac sodium 1.5% (with DMSO, Pennsaid®), n = 107
(2) Placebo (vehicle carrier), n = 109
Medication (40 drops) applied around affected knee (front, back, and sides) without
massage, 4 times daily for 6 weeks
Rescue medication: paracetamol (maximum 1500 mg daily) except during washout and
week before final assessment
Outcomes ≥ 50% PR (provided by author)
PGE: 5-point scale (responder = “good” or “very good”)
OMERACT-OARSI responder
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated”
Allocation concealment (selection bias) Low risk “randomisation schedule was concealed
from the investigators, their support staff,
study participants and the sponsor’s clinical
research personnel”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “two study solutions were identical clear,
colourless liquids packaged in opaque bot-
tles”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Primary outcome using BOCF imputa-
tion supplied by author. “Other” attrition
greater in placebo arm (11%)
Study duration Low risk 6 weeks
Size Unclear risk 50 to 200 participants per treatment arm
35Topical NSAIDs for chronic musculoskeletal pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Balthazar-Letawe 1987
Methods R, DB, AC, parallel groups
Assessed at baseline, 7, 14 days
Participants Finger or knee arthritis, or shoulder tendinitis
N = 50
M/F not reported
Age not reported
Baseline pain not reported
Interventions (1) Diclofenac (Voltaren Emulgel), n = 25
(2) Indomethacin (Indocid) gel, n = 25
Gel applied twice daily with gently rubbing, for 2 weeks
Outcomes No dichotomous efficacy outcomes
Improvement in composite of 4 scales (mean)
Adverse events
Withdrawals
Notes Oxford Quality Score: R1, DB2, W1. Total = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “tubes were presented in the same outer
packaging, bearing a serial number so as to
randomize the allocation of treatments”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk N/A - no useable efficacy data
Study duration High risk 2 weeks
Size High risk < 50 participants per treatment arm
Baraf 2011
Methods 3 separate studies, combined for analysis. R, DB, PC, parallel groups
Assessment at baseline, 1, 4, 8, 12 weeks
Participants OA knee, with radiographic confirmation, according to ACR criteria, and ≥ 6 months
after symptom onset. Daily pain requiring treatment for ≥ 2 weeks in previous month
N = 1426 (ITT = 1424)
M/F not reported
36Topical NSAIDs for chronic musculoskeletal pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Baraf 2011 (Continued)
Mean age not reported: 25 to 64 years, N = 888, ≥ 65 years, N = 538
Baseline pain on movement ≥ 50/100 mm
Subpopulation who had no change or increase in baseline pain during washout (similar
to ”flare“ population), N = 976
Interventions (1) Diclofenac sodium gel 1%, n = 721
(2) Placebo gel (vehicle only), n = 705
Measured dose (4 g) of gel applied around knee 4 times daily for 12 weeks. Participants
instructed towait≥ 10minutes before dressing and to avoid vigorous exercise or bathing/
showering within 1 h
Rescue: paracetamol (maximum 4 g daily) but not within 24 h of assessments
Outcomes OARSI response in treated knee (using pain on movement) at 12 weeks
OARSI response in treated knee (using WOMAC pain index) at 12 weeks
WOMAC subscales: pain (0 to 20) and physical function (0 to 68) (mean data)
Pain on movement: 100 mm VAS (mean data)
PGE: 5-point scale (mean data)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ”central randomization list generated by
manufacturer
Allocation concealment (selection bias) Low risk Remote allocation; “all site and sponsor
personnel, and patients, were blinded as to
treatment allocationuntil after the database
was locked and the statistical analysis plan
was finalized”
Blinding (performance bias and detection
bias)
All outcomes
Low risk Gels were “identical in appearance, feel,
and smell”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Imputation: BOCF for early discontinua-
tion. “Other” attrition higher in placebo
group (12%)
Study duration Low risk 12 weeks
Size Low risk > 200 participants per treatment group
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Bolten 1991
Methods R, DB, PC, parallel group
Assessed at baseline, 7, 14 days
Participants Extra-articular rheumatic disorders
N = 281
M 98, F 183
Mean age 53 years (18 to 79 years)
Baseline pain moderate or severe at rest or with movement
Interventions (1) Felbinac gel 3%, n = 142
(2) Placebo gel, n = 139
Gel (1 g) applied 3 times daily without massage, for up to 2 weeks
Rescue medication: paracetamol
Physiotherapy could be continued without change
Outcomes Any improvement: (responder = improved)
Adverse events
Notes Oxford Quality Score: R1, DB2, W0. Total = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “identical appearance”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Study duration High risk 2 weeks
Size Unclear risk 50 to 200 participants per treatment arm
Bookman 2004
Methods R, DB, PC, parallel groups
Assessed at baseline, 1, 2, 3, 4 weeks, with patients daily assessment of pain, function,
stiffness, and weekly PGE
Participants OA knee (no flare required), radiographically confirmed and with ≥ moderate pain for
2 weeks. Worst affected knee designated as study knee
N = 248
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Bookman 2004 (Continued)
M 91, F 157
Mean age 62 years
At least moderate pain, mean baseline pain > 9/20
Interventions (1) Diclofenac solution 1.5% in DMSO 45.5% (Pennsaid®), n = 84
(2) Carrier with DMSO 45.5%, n = 80
(2) Carrier with DMSO 4.55%, n = 84
Medication (40 drops) applied around affected knee (front, back, and sides), without
massage, 4 times daily for 4 weeks
Rescue medication: paracetamol (maximum 3 g daily) except during 24 h before baseline
and final assessments
Outcomes ≥ 50% PR (provided by authors)
WOMAC sub scales: pain (0 to 20), pain on walking (0 to 4), and physical function (0
to 68) (mean data)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated”
Allocation concealment (selection bias) Low risk “sequence concealed from anyone directly
involved in conducting the study until fi-
nal data lock”. Study kits labelled indepen-
dently
Blinding (performance bias and detection
bias)
All outcomes
Low risk “study solutions were identical, clear
colourless liquids in opaque bottles”. Small
amount of DMSO in placebo solution pro-
vided characteristic smell
Incomplete outcome data (attrition bias)
All outcomes
Low risk Imputation:
primary outcome using BOCF imputation
supplied by author. “Other” attrition low
and equal between groups
Study duration Unclear risk 4 weeks
Size Unclear risk 50 to 200 participants per treatment arm
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Bruhlmann 2003
Methods R, DB, PC, parallel groups
Assessed at baseline, 4, 7, 14 days
Participants Symptomatic knee osteoarthritis
N = 103
M 43, F 60
Mean age 64 years
Baseline pain ≥ 40 mm
Interventions (1) Diclofenac (DHEP 1.3%) patch, n = 51
(2) Placebo patch, n = 52
Patch applied topically twice daily for 2 weeks
Rescue medication: paracetamol 500 mg (maximum 2 g daily)
Outcomes Patient overall assessment of efficacy: 5-point scale (responder = “excellent”)
Reduction in pain at rest: VAS (mean)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated randomisation sys-
tem”
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Placebo patchwas identical in appearance,
colour and odour”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Study duration High risk 2 weeks
Size Unclear risk 50 to 200 participants per treatment arm
Burgos 2001
Methods R, DD, AC, parallel groups
Assessed at baseline, 7, 14 days
Participants Soft tissue rheumatism (tendinitis, bursitis, adhesive capsulitis), mean duration of symp-
toms 3 to 4 months
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Burgos 2001 (Continued)
N = 129
M 31, F 87
Mean age 55 years
Baseline pain ≥ 50 mm
Interventions (1) Flurbiprofen LAT, 2 x patch (= 40 mg) daily + placebo cream 3 x daily, n = 64
(2) Piketoprofen cream 1.8%, 3 x 4 cm (~ 36 mg) daily + placebo patch 2 x daily, n = 65
Cream applied 3 times daily, followed by patch after 15 minutes twice daily for 14 days
Rescue medication: paracetamol 500 mg (maximum 4 g daily)
Outcomes Relief from treatment
Pain at rest: VAS (mean)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated randomisation list”
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double dummy technique
Incomplete outcome data (attrition bias)
All outcomes
High risk Imputation: LOCF. “Other” attrition >
10%
Study duration High risk 2 weeks
Size Unclear risk 50 to 200 participants per treatment arm
Conaghan 2013
Methods Topical: R, DB, VC; oral: R, DB, PC
Participants blinded to treatment or control, but not to topical or oral
Assessed at baseline, 2, 6, 9, 12, weeks at clinic
Participants OA knee (function class I-III and ACR criteria) with flare, PI (index knee) on walking
≥4/10
N = 1395
Mean age 61 years (range 24 to 90)
M 475, F 920
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Conaghan 2013 (Continued)
Mean baseline PI 4.8/10
Interventions (1) Ketoprofen (IDEA-033) gel 2 x 50 mg daily, n = 233
(2) Ketoprofen (IDEA-033) gel 2 x 100 mg daily, n = 230
(3) Vehicle 2 x 2.2 g daily, n = 238
(4) Vehicle 2 x 4.4 g daily, n = 235
(5) Oral celecoxib 2 x 100 mg daily. N = 235
(6) Oral placebo, n = 228
(vehicle = TDT-064)
Gel applied twice daily for 12 weeks to intact skin on sides and back of knee, avoiding
patella and any wounds. Spread evenly with fingers then left to dry ≥ 15 mins before
covering
Washout: ≥ 5 days or 5 x half life of analgesic
Rescue medication: paracetamol up to 4 x 500 mg daily, but not within 24 h of any
study visit. Participants needing ≥ 2 g daily or other analgesic for > 3 successive days
were considered treatment failures
Outcomes Pain, function, stiffness: 11-point NRS WOMAC subscales
Responder: ≥ 50% improvement in PI at week 12 (also for ≥ 30% and ≥ 80%)
PGE: 5-point scale (responder = “good” or “excellent”)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Sponsor: IDEA AG, Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “list generated by a random permuted
block scheme”
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “matching gels”; “same primary packaging
for active and placebo treatments”; “dosing
aids virtually identical”
Incomplete outcome data (attrition bias)
All outcomes
Low risk BOCF imputation for missing data and
lack of efficacy
Study duration Low risk 12 weeks
Size Low risk > 200 participants per treatment group
42Topical NSAIDs for chronic musculoskeletal pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dickson 1991
Methods R, DD, AC parallel groups
Assessed at baseline, 2, 4 weeks
Participants Knee osteoarthritis (“well documented, mild”)
N = 235
M 80, F 155
Mean age 63 years
Baseline pain moderate (median 3-4/9)
Interventions (1) Piroxicam gel 0.5%, 3 x 1 g (= 5 mg piroxicam) + placebo tablet daily, n = 117
(2) Ibuprofen tablet 3 x 400 mg + placebo cream daily, n = 118
Cream (3 cm ribbon) rubbed in to affected knee joint + 1 tablet taken orally 3 times
daily for up to 4 weeks
Washout: 7 days
Rescue medication: paracetamol (maximum 4 g daily)
Outcomes PGE: 4-point scale (responder = “good” or “excellent”)
Adverse events
Withdrawals
Notes Oxford Quality Score: R1, DB2, W1. Total = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double dummy technique
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. “Other” attrition ~ 8%
Study duration Unclear risk 4 weeks
Size Unclear risk 50 to 200 participants per treatment arm
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Dreiser 1993
Methods R, DB, PC, parallel groups
Assessed at baseline, 4, 7, 15 days
Participants Knee osteoarthritis, diagnosed radiographically, with at least moderate spontaneous pain
N = 155
M 35, F 120
Mean age 67 years
Baseline pain ≥ 57/100
Interventions (1) Diclofenac (DHEP) patch (= 180 mg), n = 78
(2) Placebo patch, n = 77
Patch applied twice daily (held by slightly elastic net) for 15 days
Washout: 7 days if NSAIDs had been used
Rescue medication: paracetamol 500 mg after 4 days
Outcomes PGE: 5-point scale (responder = “good” or “excellent”)
Pain intensity: VAS (mean)
Adverse events
Withdrawals
Notes Oxford Quality Score: R1, DB2, W1. Total = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “matched placebo plaster”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Study duration High risk 2 weeks
Size Unclear risk 50 to 200 participants per treatment arm
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Ergun 2007
Methods R, DB, PC, parallel group
Assessed at baseline, 30 days
Participants OA knee diagnosed using ACR criteria (no flare required)
N = 74
M 4, F 70
Mean age 54 years
Mean baseline pain > 5/10
Interventions (1) Nimesulide gel 1% (Sulidin) 0.4 mg/10 cm2, n = 51
Placebo gel, n = 23
(2) Medication applied x 3 daily
Gel rubbed in for < 1 minute, 3 times daily for 30 days
Rescue medication: paracetamol (maximum 2 g daily), but not on day of evaluation
Outcomes PGE: 5-point scale (responder = “effective” and “very effective”)
WOMAC scores for individual components and overall: mean data
Adverse events
Withdrawals
Notes Oxford Quality Score: R1, DB2, W1. Total = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “identical (color and odor) gel preparation
containing only vehicle”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. Total withdrawals low
Study duration Unclear risk 4 weeks
Size High risk < 50 participants in placebo arm, 51 in ac-
tive arm
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Galeazzi 1993
Methods R, DB, PC, parallel groups
Assessed at baseline, 3, 5, 7, 14 days
Participants Inflammatory peri- and extra-articular rheumatological diseases
N = 60
M 10, F 50
Mean age 57 years
Baseline pain on pressure severe
Interventions (1) Diclofenac (DHEP), 2 x plaster (= 180 mg) daily, n = 30
(2) Placebo, 2 x plaster daily, n = 30
Patch applied to affected area twice daily for 14 days
Stable (> 2 months) systemic treatment continued unchanged, more recent treatment
suspended. Rescue medication: paracetamol when strictly necessary
Outcomes No dichotomous data
Pain on pressure: 4-point scale (mean)
Adverse events
Withdrawals
Notes Oxford Quality Score: R1, DB2, W1. Total = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “matched placebo plaster”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. No withdrawals reported
Study duration High risk 2 weeks
Size High risk < 50 participants per treatment arm
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Grace 1999
Methods R, DB, PC, parallel groups
Assessment at baseline, 7, 21 days
Participants Osteoarthritis of the knee (in flare condition at baseline), diagnosed radiographically and
by symptoms, of ≥ 3 months’ duration, requiring drug therapy
N = 74
M 29, F 45
Mean age 62 years
Mean baseline pain ≥ 40 (WOMAC pain subscale)
Interventions (1) Diclofenac with lecithin gel, 2%, 3 x 2.5 g daily, n = 38
(2) Placebo gel, n = 36
Level scoop of gel (2.5 g) applied to target knee, 3 times daily for 3 weeks, with rubbing
for 2 to 20 seconds and no occlusion. Strenuous activity and bathing to be avoided ± 1
h
Rescue medication: paracetamol. No other concomitant medication for OA allowed
Outcomes PGE: 4-point scale (responder = “none” or “mild”)
PI: WOMAC pain subscale (mean)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB1, W1. Total = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer generated randomization
scheme”
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. Total withdrawals low
Study duration High risk 3 weeks
Size High risk < 50 participants per treatment arm
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Gui 1982
Methods R, DB, PC, parallel groups
Assessed at baseline and end of study
Participants Mixed conditions: osteoarthritis, periarthritis and degenerative diseases of the tendons
N = 40
M 16, F 24
Mean age 48 years
Mean baseline pain 2.2 (scale 0 to 3)
Interventions (1) Ibuprofen cream, n = 20 (strength, dose, quantity not reported)
(2) Placebo cream, n = 20
Cream applied twice daily for 3 weeks
Outcomes Pain on movement: responder = “improved”
Spontaneous pain: responder = “improved”
Adverse events
Withdrawals
Notes Oxford Quality Score: R, DB2, W1. Total = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “identical preparations guaranteed blind-
ing” [translated]
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. Total withdrawals low
Study duration High risk 3 weeks
Size High risk < 50 participants per treatment arm
Hohmeister 1983
Methods R, DB, PC, parallel group
Assessed at baseline, 7, 14, 21 days
Participants Cervical and lumbar back pain
N = 100
M 55, F 43
Age 17 to 72 years
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Hohmeister 1983 (Continued)
Baseline pain not reported
Interventions (1) Flufenamate 3% plus salicylate 2% gel (Mobilisin), n = 49 (quantity not reported)
(2) Placebo gel, n = 51
Gel applied 3 times daily for 3 weeks
Outcomes Patient-rated improvement: (responder = “substantial” or “moderate”)
Adverse events
Withdrawals
Notes Oxford Quality Score: R1, DB2, W1. Total = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Tubes indistinguishable
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. No withdrawals reported
Study duration High risk 3 weeks
Size High risk < 50 participants in active treatment arm,
51 in placebo arm
Kneer 2013
Methods R, DB, VC, parallel group
Assessed at baseline, 2, 6, 12 weeks at clinic, and daily diary for first 2 weeks
Participants OA knee > 6 months (function class I-III and ACR criteria) with flare
N = 866 (ITT 828)
Mean age 62 years (range 19 to 78)
M 235, F 593
Mean baseline pain 65/100
Interventions (1) Ketoprofen (IDEA-033) gel 2 x 25 mg daily, n = 223
(2) Ketoprofen (IDEA-033) gel 2 x 50 mg daily, n = 223
(3) Ketoprofen (IDEA-033) gel 2 x 100 mg daily, n = 221
(4) Vehicle, n = 199
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Kneer 2013 (Continued)
Gel applied twice daily for 12 weeks to intact skin on sides and back of knee, avoiding
patella. Spread evenly with fingers then left to dry≥ 15 mins before covering. Specifically
no rubbing, kneading, massaging
Washout: 5 x half life of analgesic + 2 days
Rescue medication: paracetamol up to 2 g daily for ≥ 5 days in any 7-day period, but
not within 48 h of any study visit
Outcomes Pain, function, stiffness: 11-point NRS WOMAC subscales
OMERACT-OARSI responder at final visit
PGE: 5-point scale (responder = “good” or “excellent”)
Adverse events
Withdrawals
Notes Oxford Quality Score: R1, DB2, W1. Total = 4
Sponsor: IDEA AG, Germany
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “matching amount”; “identical in terms of
appearance and constituents (with the ex-
ception of ketoprofen)”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Imputation not mentioned
Study duration Low risk 12 weeks
Size Unclear risk 50 to 200 participants per treatment group
as analysed
Link 1996
Methods R, DB, PC, parallel group
Assessed at baseline 3, 7, 14, days
Participants Non-articular rheumatism
N = 115
M/F not reported
Age not reported
Baseline pain not reported
50Topical NSAIDs for chronic musculoskeletal pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Link 1996 (Continued)
Interventions (1) Ketoprofen gel 2.5%, n = 56
(2) Placebo gel, n = 59
Gel applied as 4 to 10 cm strip 3 to 4 times daily for 2 weeks
No antirheumatic medication during trial
Outcomes No patient-rated outcomes
Withdrawals
Notes Oxford Quality Score: R2, DB1, W0. Total = 3
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “zufallsgenerator” [random numbers gen-
erator]
Allocation concealment (selection bias) Low risk Randomisation number corresponded to
number on medication
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Study duration High risk 2 weeks
Size Unclear risk 50 to 200 participants per treatment arm
McCleane 2000
Methods R, DB, PC, and AC, parallel group
Assessed at baseline, 1, 2, 3, 4 weeks
Participants Localised musculoskeletal pain ≥ 3 months
N = 100
M/F inconsistent data
Mean age 46 years
Mean pain score in week before treatment: 62.3/100 mm
Interventions (1) Piroxicam gel 2.5%, n = 50
(2) Glyceryl trinitrate 1%, n = 50
(3) Piroxicam 2.5% + glyceryl trinitrate 1% gel, n = 50
(4) Placebo gel, n = 50
Gel applied as “small volume” to painful area 3 times daily for 4 weeks
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McCleane 2000 (Continued)
Outcomes PR: responder = 50% PR
PI: VAS (mean)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated random number list”
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Creamswere “all off-white/yellow in colour
andput in identical brownglass containers”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. “Other”withdrawals > 10%
Study duration Unclear risk 4 weeks
Size High risk 50 participants per treatment arm, not all
contributed data
NCT01980940
Methods Randomised, double-blind, cross-over study
Assessed at 2, 4, 7, 11, 14 days
Participants OA knee for > 6 months (clinical and radiological criteria), ARA functional Class I, II,
or III, age 40 years or older
N = 70
Men and women
Interventions (1) Etoricoxib 50 mg (1.31 mL, 4% DMSO gel)
(2) Placebo gel
(Unclear if placebo gel contained DMSO)
Gel applied twice daily to the affected knee
Outcomes Change in pain (group mean) over 14 days
PGE: 5-point scale (responder = “well” and “very well”) at 14 days
Adverse events
Withdrawals
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NCT01980940 (Continued)
Notes Oxford Quality Score: R1, DB2, W1. Total = 4
Completed November 2014
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of sequence generation not de-
scribed
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “matching placebo”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Imputation not mentioned, but no with-
drawals
Study duration Unclear risk 2 weeks
Size High risk < 50 participants per treatment arm (24)
Niethard 2005
Methods R, DB, PC, parallel groups
Assessed weekly at study centre and daily with patient diaries
Participants OA knee, clinically diagnosed, symptomatic, with pain > 50/100 mm and > “moderate”
on 4-point scale
N = 238
M 87, F 151
Mean age 66 years
Mean baseline pain 67/100 mm
Interventions (1) Diclofenac 1.16% gel (Voltaren Emulgel), n = 117
(2) Placebo gel, n = 121
Gel (4 g) applied to front of knee and rubbed in for≥ 1 minute 4 times daily for 3 weeks
Rescue medication: paracetamol (maximum 2 g daily)
Outcomes PGE: 5-point scale (responder = “very good” and “excellent”)
OMERACT-OARSI responder at end of trial
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
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Niethard 2005 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated”
Allocation concealment (selection bias) Low risk Remote allocation. Each site assigned a se-
ries of numbers and kits. Patients assigned
lowest number available
Blinding (performance bias and detection
bias)
All outcomes
Low risk Gels were “identical in colour, feel, and ap-
pearance”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. “Other”withdrawals > 10%
Study duration High risk 3 weeks
Size Unclear risk 50 to 200 participants per treatment arm
Ottillinger 2001
Methods R, DB, PC, parallel group
Assessment at baseline, 1, 2, 3, 4 weeks
Participants Knee osteoarthritis, diagnosis according to ACR criteria, symptomatic. Age > 50 years
N = 234
M 53, F 181
Mean age 67 years
Baseline pain > 50 mm
Interventions (1) Eltenac gel 0.1%, n = 57
(2) Eltenac gel 0.3%, n = 59
(3) Eltenac gel 1.0%, n = 59
(4) Placebo gel, 3 x 3 g daily, n = 59
Gel applied to affected knee joint, with rubbing, as 4 inch string (approximately 3 g gel)
3 times daily for 4 weeks; to give 9 mg, 27 mg, 90 mg daily doses
Washout: 7 days
Rescue medication: paracetamol (maximum 2 g daily) if strictly necessary
Outcomes PGE: verbal rating scale (no details)
PI: 10 cm VAS (mean)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
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Ottillinger 2001 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “random plan”, generated a priori using
method of permuted blocks
Allocation concealment (selection bias) Low risk Remote randomisation. Labelling included
no identification of the actual treatment
group
Blinding (performance bias and detection
bias)
All outcomes
Low risk Active and placebo gels were “indistin-
guishable in appearance, handling and la-
belling”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk N/A - no useable efficacy data. “Other”
withdrawals > 10%
Study duration Unclear risk 4 weeks
Size Unclear risk 50 to 200 participants per treatment arm
Poul 1993
Methods R, DB, PC, parallel groups
Assessed at baseline, 7, 14 days
Participants Local, non-articular form of rheumatism, with moderate to severe pain, requiring treat-
ment
N = 104
M 55, F 49
Mean age 47 years
Baseline pain moderate or severe
Interventions (1) Flurbiprofen patch, n = 53
(2) Placebo patch, n = 51
Patch (= 40 mg flurbiprofen) applied to affected area twice daily for 14 days. Bathing
allowed only at times of patch changes
Rescue medication: paracetamol (maximum 4 g daily). Other analgesia and physiother-
apy not allowed
Outcomes No dichotomous efficacy data
Adverse events
Withdrawals
Notes Oxford Quality Score: R1, DB2, W1. Total = 4
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Poul 1993 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Placebo patch “non-medicated, but other-
wise identical”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. “Other”withdrawals < 10%
Study duration High risk 2 weeks
Size Unclear risk 50 to 200 participants per treatment arm
Rose 1991
Methods R, DB, PC, parallel group
Assessed at baseline, 3, 7, 10, 14 days
Participants Gonarthrosis, symptomatic
N = 30
M/F not reported
Age 42 to 83 years
Baseline pain not reported (but all inpatients)
Interventions (1) Piroxicam gel 5%, n = 15
(2) Placebo gel, n = 15
Gel (1 mg = 5 mg piroxicam) applied 4 times daily for up to 14 days
Outcomes PGE: 4-point scale (responder = “good” or “excellent”)
PI: VAS (mean data)
Adverse events
Notes Oxford Quality Score: R1, D1, W0. Total = 2
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
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Rose 1991 (Continued)
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described
Study duration High risk 2 weeks
Size High risk < 50 participants per treatment arm
Roth 1995
Methods R, DB, PC, parallel group
Assessed at baseline, 7, 14 days
Participants Osteoarthritis requiring NSAID treatment ≥ 1 month
N = 119
M 16, F 103
Mean age 67 years
Baseline pain 3.3 (scale 1 to 5)
Interventions (1) Diclofenac 3% + hyaluron 2.5% gel, n = 59
(2) Placebo + hyaluron 2.5% gel, n = 60
Gel (2 g) applied 4 times daily for 2 weeks
Stable doses of NSAID continued unchanged. No other analgesics allowed
Outcomes No dichotomous data
PI: 5-point scale (mean change)
Adverse events
Withdrawals
Notes Oxford Quality Score: R1, DB2, W1. Total = 4
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “identical placebo gel”
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Roth 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. Total withdrawals low
Study duration High risk 2 weeks
Size Unclear risk 50 to 200 participants per treatment arm
Roth 2004
Methods R, DD, PC, and AC, parallel group
Assessed at baseline, 2, 4, 6 weeks at clinic and daily patient diaries
Participants OA knee with flare, and duration ≥ 6 months
N = 397
M 160, F 237
Mean age 63 years
Mean baseline pain > 66/100
Interventions (1) Ketoprofen gel (IDEA-33) 2 x 110 mg daily, n = 138
(2) Celecoxib tabs 2 x 100 mg daily, n = 132
(3) Placebo gel and tabs, n = 127
Gel (measured) applied to knee twice daily for 6 weeks
Rescue med: paracetamol
Outcomes PGE: 5-point scale (responder = “good” or “excellent”)
OMERACT-OARSI responder at final visit
Pain on movement: 100 mm VAS (mean data)
WOMAC subscales: pain, stiffness, and physical function (mean data)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer-generated randomization
schedule by outside consultant”
Allocation concealment (selection bias) Low risk Remote allocation. Each site assigned a se-
ries of numbers and kits. Participants as-
signed sequentially
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The two study solutions were identical
clear, colourless liquids in opaque bottles
with labels identical except for patient iden-
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Roth 2004 (Continued)
tification number”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Imputation using BOCF where necessary.
“Other” withdrawals < 10%
Study duration Low risk 6 weeks
Size Unclear risk 50 to 200 participants per treatment arm
Rother 2007
Methods R, DB, PC, parallel group
Assessed at baseline, 1, 6, and 12 weeks
Participants Primary OA in at least 1 knee, defined by radiological findings and flare of pain after
washout of stable therapy
N = 326
M 105, F 221
Mean age 64 years
Mean baseline pain 13/20
Interventions (1) Diclofenac 1.5% in DMSO (45.5%), n = 164
(2) Vehicle with DMSO, n = 162
Medication (40 drops) applied 4 times daily for 12 weeks
Rescue medication: paracetamol, maximum 3 g daily, not during washout period and 3
days before final assessment at week 12
Outcomes ≥ 50% PR (provided by author)
Change from baseline to final assessment in pain and physical function (WOMAC score)
Global clinical assessment (5-point Likert scale)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Study kits were prepared and numbered
according to a computer-generated ran-
domisation schedule”
Allocation concealment (selection bias) Low risk “The randomisation schedule was con-
cealed from the investigators and their sup-
port staff, study patients, and the sponsor’s
clinical research personnel until final data
lock and transfer to the statistician”
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Rother 2007 (Continued)
Blinding (performance bias and detection
bias)
All outcomes
Low risk “The two study solutions were identical
clear, colourless liquids in opaque bottles
with labels identical apart from the indi-
vidual patient identification number.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Imputation:
primary outcome using BOCF imputation
supplied by author. “Other” withdrawals <
10%
Study duration Low risk 12 weeks
Size Unclear risk 50 to 200 participants per treatment arm
Rother 2013
Methods R, DB, VC, parallel group
Assessment at baseline, 2, 6, 9, 12 weeks at clinic and daily diary for first 14 days
Participants OA knee (function class I-III and ACR criteria), PI (index knee) on walking ≥ 4/10. No
flare required for inclusion
N = 555
Mean age 62 years (SD 11)
M 209, F 346
Mean baseline pain 5.2 (SD 1.0)
Interventions (1) Ketoprofen (IDEA-033) gel 2 x 100 mg daily, n = 274
(2) Vehicle 2 x 4.4 g daily, n = 281
Gel applied to knee twice daily for 12 weeks
Washout: ≥ 5 days
Rescue medication: paracetamol up to 4 x 500 mg daily, but not within 24 h of any
study visit. Participants needing ≥ 2 g daily or other analgesic for > 3 successive days
were considered treatment failures
Outcomes Pain, function, stiffness: 11-point NRS WOMAC subscales
Responder: ≥ 50% improvement in PI at week 12
PGE: 5-point scale (responder = “good” or “excellent”)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB1, W1. Total = 4
Sponsor: IDEA AG, Germany
Risk of bias
Bias Authors’ judgement Support for judgement
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Rother 2013 (Continued)
Random sequence generation (selection
bias)
Low risk “list generated by a random permuted
block scheme”
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not described
(Likely to be adequate)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Imputation for dichotomous outcomes not
reported
Study duration Low risk 12 weeks
Size Low risk > 200 participants per treatment group
Sandelin 1997
Methods R, DD, PC, and AC, parallel group
Participants Osteoarthritis of the knee, radiologically confirmed, pain symptoms for most days in
last month, requiring treatment. Patients with severe OA or pain excluded
N = 290
M 101, F 189
Mean age 61 years
Baseline pain ≥ 48/100
Interventions (1) Eltenac 1% gel + placebo tablets, n = 126
(2) Diclofenac 50 mg tablets + placebo gel, n = 82
(3) Placebo gel and tablets, n = 82
Tablets (50 mg or placebo) taken morning and evening with food, and gel (3 g = 30 mg
eltenac or placebo, measured with spoon) applied 3 times daily, with gentle rubbing, for
4 weeks. In bilateral cases, both knees were treated with the same regimen
Rescue medication: not reported. No new physical therapies allowed, but physiotherapy
or orthotic devices started ≥ 7 days before study to be continued
Outcomes PGE: 4-point scale - only physician evaluation reported
Overall pain in preceding week (10 cm VAS) - mean data reported
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB 2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
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Sandelin 1997 (Continued)
Random sequence generation (selection
bias)
Low risk “randomplan generated usingPROCPLANSAS
version 6.07”
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double dummy technique
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk N/A - no useable efficacy data. Total withdrawals
< 10%
Study duration Unclear risk 4 weeks
Size Unclear risk 50 to 200 participants per treatment group
Simon 2009
Methods R, DB (DD), PC, VC, and AC study
Assessments at baseline, 4, 8, and 12 weeks or at dropout
Participants Primary OA, confirmed radiographically, with pain requiring regular analgesic, and flare
following washout
N = 755
M 490, F 292
Mean age 64 years
Mean baseline pain 288/500
Interventions (1) Diclofenac solution 1.5% (with DMSO 45.5%, Pennsaid®) + oral placebo, n = 154
(2) DMSO (45.5%) vehicle solution + oral placebo, n = 155
(3) Placebo solution (with 2.3% DMSO) + oral placebo, n = 161
(4) Placebo solution (with 2.3% DMSO) + 100 mg slow-release oral diclofenac, n = 151
Treatment with 40 drops solution, 4 times a day around entire circumference of the
knee, plus 1 capsule daily, taken orally, for 12 weeks
Rescue medication: paracetamol (maximum 1300 mg daily) permitted except during 3
days before each efficacy assessment
Outcomes ≥ 50% PR (provided by authors)
WOMAC pain and physical function measured on 5-point Likert scale
Patient overall health assessment
WOMAC stiffness
Patient global assessment of knee OA
Adverse effects
Withdrawals
Notes Oxford Quality Score: R2, DB 2, W1. Total = 5
Risk of bias
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Simon 2009 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Each study kit was assembled accord-
ing to a computer-generated randomisa-
tion schedule created by an external statis-
tician”
Allocation concealment (selection bias) Low risk “The randomisation sequence was con-
cealed from investigators, subjects and the
sponsor’s clinical research personnel until
after data lock”
Blinding (performance bias and detection
bias)
All outcomes
Low risk “All study solutions were identical clear,
colourless liquids” “it was expected that
some subjects applying topical diclofenac
or DMSO vehicle solution would report
a garlic taste or odour from exhaling
dimethyl sulphide... [therefore] a token
amount of DMSO (2.3%) was included in
the placebo solution”
Incomplete outcome data (attrition bias)
All outcomes
Low risk Imputation:
primary outcome using BOCF imputation
supplied by author. “Other”withdrawals≥
10%, equally distributed between groups
Study duration Low risk 12 weeks
Size Unclear risk 50 to 200 participants per treatment group
Tugwell 2004
Methods R, DD, AC, parallel group
Assessed at baseline, 12 weeks, or at dropout
Participants OA knee, symptomatic, radiologically confirmed (no flare required)
N = 622 (604 analysed)
M 266, F 356
Mean age 64 years
Mean baseline pain 288/500
Interventions (1) Diclofenac solution 1.5% (with DMSO 45.5%, Pennsaid®) + placebo capsule, n =
311
(2) Diclofenac capsule + placebo solution, n = 311
Medication applied as 50 drops of solution applied around affected knee (front, back,
and sides) without massage, plus oral capsule (50 mg diclofenac or placebo), 3 times
daily for 12 weeks (daily total 4.6 mL = 75 mg diclofenac or placebo)
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Tugwell 2004 (Continued)
Outcomes OMERACT-OARSI responder
Patient global assessment on a 100 mm VAS - mean data reported
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer generated”
Allocation concealment (selection bias) Low risk Sequence generated by external statistician
and concealed until final data lock and
transfer of data to external statistician
Blinding (performance bias and detection
bias)
All outcomes
Low risk Active and placebo solutions were both
clear and colourless and in identical bottles.
Placebo solution included small amount
of DMSO to give characteristic odour on
application. Capsules for diclofenac and
placebo were identical
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. “Other” withdrawals >
10%, distributed between groups
Study duration Low risk 12 weeks
Size Low risk > 200 participants per treatment group
van Haselen 2000
Methods R, DB, AC, parallel group
Assessed at baseline, 28 days
Participants Osteoarthritis of the knee, radiographically confirmed
N = 184
M 48, F 136
Mean age 64 years
Mean baseline pain on walking ≥ 50 mm
Interventions (1) Piroxicam gel 0.5% (Feldene), n = 92
(2) Homeopathic gel (SRL*), n = 92
Gel (1 g, measured with spatula) applied to worst affected knee 3 times daily for 4 weeks
Rescue medication: paracetamol (maximum 3 g daily). Stable oral NSAIDs and other
medication continued during trial
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van Haselen 2000 (Continued)
* SRL contains comfrey, poison ivy and marsh tea
Outcomes PGE: 6-point scale (responder = “good” or “excellent”)
PI: 100 mm VAS (mean)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated
Allocation concealment (selection bias) Low risk Third party allocation, sealed boxes
Blinding (performance bias and detection
bias)
All outcomes
Low risk Tubes made to look identical and patients
did not open medication boxes until they
returned home. In 5 cases masking of tube
identity was compromised
Incomplete outcome data (attrition bias)
All outcomes
Low risk Imputation: missing values assume the
worst possible outcome. Total withdrawals
< 10%
Study duration Unclear risk 4 weeks
Size Unclear risk 50 to 200 participants per treatment arm
Varadi 2013
Methods R, DB, PC, parallel group
Assessment at baseline, 1 and 2 weeks
Participants Primary OA knee in single joint (grade II or III), radiologically confirmed and symp-
tomatically active, PI at rest ≥ 40/100. Treatment naive and requiring treatment or dis-
satisfied with treatment
N = 75
Mean age 61 years (SD 11)
M 27, F 48
Interventions (1) VALE-ibuprofen cream 2 x 2 g daily, n = 39
(2) Placebo cream, n = 36
Medication applied twice daily for 2 weeks using ribbon method and dosing card (2 g
dose)
Rescue medication: paracetamol up to 4 x 500 mg daily, but not within 24 h of any
65Topical NSAIDs for chronic musculoskeletal pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Varadi 2013 (Continued)
study visit. No more than 2 g daily for 3 successive days
Outcomes Pain, function, stiffness: 11-point NRS WOMAC subscales
PGE: 7-point scale (mean data reported)
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W0. Total = 4
Sponsor: BioChemics, Inc
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “A randomization list (in blocks of 4 sub-
jects) was produced by the Biometric De-
partment of PFC”
Allocation concealment (selection bias) Low risk Remote allocation, packed and labelled for
each patient
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Investigators were randomly provided
with blinded samples of either ibuprofen or
placebo in 100 g tubes”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Imputation not mentioned
Study duration High risk 2 weeks
Size High risk < 50 participants per treatment arm
Widrig 2007
Methods R, DB, AC, parallel group
Assessment at baseline and 21 days
Participants OA of hand (ACR criteria). Pain intensity of at least 40/100 mm (VAS)
N = 198
M 51, F 147
Mean age 64 years
Mean baseline pain 67 mm
Interventions (1) Ibuprofen gel 5% (Optifen), n = 98
(2) Arnica gel 50%, n = 100
Medication applied as 4 cm strip of gel gently rubbed into affected joints 3 times daily
for 3 weeks
Rescue medication: paracetamol 500 mg, except 24 h before final evaluation
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Widrig 2007 (Continued)
Outcomes PGE: 4-point scale
Reduction in pain, measured by 100 mm VAS
Functional capacity of the hand using HAI assessment
Adverse events
Withdrawals
Notes Oxford Quality Score: R2, DB2, W1. Total = 5
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “Randomisation codes were computer-
generated in blocks of four”
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk “Double-blindness was assured by identi-
cal packing, as well as gel appearance and
consistency” “there was a slight difference
in odour for the first 30 seconds after ap-
plication, after which both were odourless”
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not described. “Other” withdrawals ±
10%, distributed between groups
Study duration High risk 3 weeks
Size Unclear risk 50 to 200 participants per treatment arm
Zacher 2001
Methods R, DD, AC, PC
Assessed at baseline, 3, 7, 14, 21 days
Participants Osteoarthritis of the finger joints, “activated”
N = 321
M 38, F 283
Mean age 62 years (35 to 95 years)
Baseline pain ≥ 40 mm
Interventions (1) Diclofenac Emulgel + placebo tablets, n = 165
(2) Ibuprofen tablets + placebo gel, n = 156
Gel (10 cm diclofenac diethylammonium 1.16% or placebo) applied 4 times daily, with
massage, plus 2 tablets (400 mg ibuprofen or placebo) taken 3 times daily, for 3 weeks
Rescue medication: paracetamol
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Zacher 2001 (Continued)
Outcomes PI: 100 mm VAS for ’general pain’, ’pain at rest’ (responder = ≥ 40% reduction in
general pain)
Disease activity: 100 mm VAS
Adverse events
Withdrawals
Notes Oxford Quality Score: R1, DB2, W1
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Not described
Allocation concealment (selection bias) Unclear risk Not described
Blinding (performance bias and detection
bias)
All outcomes
Low risk Double dummy technique
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Not true ITT analysis, but missing data
evenly distributed between groups. Use of
unauthorised medication = non-responder
Study duration High risk 3 weeks
Size Unclear risk 50 to 200 participants per treatment arm
AC: active controlled; ACR: American College of Rheumatology; ARA: American Rheumatology Association; AUSCAN: Australian/
Canadian Osteoarthritis Hand Index; BOCF: baseline observation carried forward; DB: double blind; DD: double dummy; DHEP:
diclofenac hydroxyethylpyrrolidine; DMSO: dimethyl sulphoxide; F: female; HAI: Hand Algofunctional Index; ITT: intention-
to-treat; M: male; N: number of participants in study; n: number of participants in the treatment arm; N/A: not applicable;
NRS: numerical rating scale; NSAID: nonsteroidal anti-inflammatory drug; OA: osteoarthritis; OARSI: Osteoarthritis Research
Society International; OMERACT: Outcome Measures in Rheumatology Clinical Trials; PC: placebo-controlled; PGE: patient
global evaluation; PI: pain intensity; PR: pain relief; R: randomised; VAS: visual analogue scale; VC: vehicle-controlled; WOMAC:
Western Ontario and McMaster Universities Arthritis Index
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Allegrini 2009 8-day study (too short)
Di Rienzo Businco 2004 Not double-blinded
Doi 2010 Open-labelled study
Fotiades 1976 Duration of symptoms unclear; treatment duration 6 to 20 days only
Galer 2010 Healthy volunteers; no baseline pain
Geller 1980 No appropriate control (etofenamate versus diethylamine salicylate)
Ginsberg 1991 Duration of symptoms up to 30 days only (too short)
Mattara 1994 Mean duration of condition 26 days (too short)
Peniston 2011 Open-label extension of NCT00171691
Rovensky 2001 Trial duration only 8 days
Tiso 2010 Open-labelled study; only 9 participants in the placebo group
Trnavský 2004 Trial duration only 8 days
Underwood 2008 Open-labelled study
Verkleij 2015 Open-labelled study
Vitali 1980 Mixed acute and chronic conditions, including surgery
Characteristics of studies awaiting assessment [ordered by study ID]
Bohlooli 2012
Methods Randomised, double-blind, controlled study. Duration 4 weeks
Participants Primary OA knee with flare after withdrawal of previous therapy
N = 60
Age 40 to 85 years
Interventions Olive oil
Piroxicam gel
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Bohlooli 2012 (Continued)
Outcomes WOMAC and PGs standard questionnaires
Notes Completed
Request for full paper sent to lead author 24 February 2015
Interventions repackaged in 60 g anonymous tubes - unclear if this is effective blinding for participants
Niempoog 2012
Methods Randomised, double-blind, controlled study. Duration 6 weeks
Participants OA knee
N = 100
Interventions Plygersic gel (4% ginger and plai extract)
Diclofenac 1% solution
Outcomes Knee Injury and Osteoarthritis Outcome Score
Notes Completed
Request for full paper sent to lead author 24 February 2015
Abstract reports: Plygersic gel relieves joint pain and improves problematic symptoms and improves the quality of
life in osteoarthritis knees during a 6-week treatment regimen with no differences to the 1% diclofenac gel group
OA: osteoarthritis; WOMAC: Western Ontario and McMaster Universities Arthritis Index
Characteristics of ongoing studies [ordered by study ID]
NCT01377038
Trial name or title Central pain mechanisms in osteoarthritis: a randomized, double-blind, crossover study to evaluate the effec-
tiveness of topical diclofenac versus duloxetine for chronic osteoarthritis pain
Methods Randomised, double-blind, cross-over study. Duration ?8 weeks
Participants OA knee (ACR criteria), age 50 years or older
N = 70
Men and women
Interventions Topical diclofenac, 4 times daily
Oral duloxetine 20 to 30 mg daily
Outcomes Pain
Starting date September 2011
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NCT01377038 (Continued)
Contact information PI: Kristine Phillips, MD, PhD, University of Michigan
Notes Estimated primary completion: November 2015
NCT02068859
Trial name or title Treatment of knee pain with topical diclofenac cream 8% or diclofenac gel 1%
Methods Randomised, double-blind, parallel-group study. Duration 6 weeks
Participants Acute and chronic knee pain, along with postoperative knee pain lasting at least two months, age 18 years
and older
Estimated N = 106
Men and women
Interventions Diclofenac cream 8% applied 3 - 4 times daily for 6 weeks
Diclofenac gel 1% applied 3 - 4 times daily for 6 weeks
Outcomes Pain scores
Starting date January 2014
Contact information FPR Specialty Pharmacy
Notes Estimated completion date January 2015
NCT02121002
Trial name or title
Methods Randomised, double-blind, parallel-group study. Duration 4 weeks
Participants OA knee, clinical diagnosis and Kellgren-Lawrence grade 1 - 3 disease, ≥ moderate pain on movement after
discontinuing pain medication for ≥ 7 days, age 35 years or older
N = 1176
Men and women
Interventions Diclofenac Sodium Topical Gel, 1%. 4 g, 4 times a day for 4 weeks
Voltaren Topical Gel, 1%. 4 g, 4 times a day for 4 weeks
Vehicle Diclofenac Sodium Topical Gel. 4 g, 4 times a day for 4 weeks (placebo)
Outcomes Pain score and change in pain (group mean) over 4 weeks
Starting date
Contact information
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NCT02121002 (Continued)
Notes Completed October 2014
ACR: American College of Rheumatology; N: number of participants in study; OA: osteoarthritis
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D A T A A N D A N A L Y S E S
Comparison 1. Topical diclofenac versus carrier
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical success 9 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Duration 6 to 12 weeks 4 2343 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [1.12, 1.29]
1.2 2 to ≤ 6 weeks 5 732 Risk Ratio (M-H, Fixed, 95% CI) 1.86 [1.50, 2.31]
2 Local adverse events 13 3658 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [1.54, 2.21]
3 Systemic adverse events 7 1266 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.59, 1.34]
4 Gastrointestinal adverse events 10 3240 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.76, 1.58]
5 Withdrawals due to adverse
events
12 3552 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [1.14, 2.11]
6 Withdrawals due to lack of
efficacy
11 3455 Risk Ratio (M-H, Fixed, 95% CI) 0.59 [0.47, 0.75]
Comparison 2. Topical ketoprofen versus carrier
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical success 4 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Duration 6 to 12 weeks 4 2573 Odds Ratio (M-H, Fixed, 95% CI) 1.22 [1.03, 1.45]
2 Local adverse events 4 2621 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.85, 1.27]
3 Gastrointestinal adverse events 4 2621 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.69, 1.32]
4 Withdrawals due to adverse
events
4 2621 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.92, 1.78]
5 Withdrawals due to lack of
efficacy
4 2885 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.80, 1.55]
Comparison 3. Topical NSAID versus oral NSAID
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical success 5 1735 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.95, 1.12]
2 Local adverse events 5 1651 Risk Ratio (M-H, Fixed, 95% CI) 3.74 [2.76, 5.06]
3 Gastrointestinal adverse events 6 1961 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.56, 0.77]
4 Withdrawals due to adverse
events
6 1961 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.68, 1.06]
5 Withdrawals due to lack of
efficacy
3 1197 Risk Ratio (M-H, Fixed, 95% CI) 2.47 [1.45, 4.22]
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Analysis 1.1. Comparison 1 Topical diclofenac versus carrier, Outcome 1 Clinical success.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 1 Topical diclofenac versus carrier
Outcome: 1 Clinical success
Study or subgroup Diclofenac Carrier Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Duration 6 to 12 weeks
Altman 2009 130/198 106/187 18.5 % 1.16 [ 0.99, 1.36 ]
Baer 2005 46/105 27/107 4.5 % 1.74 [ 1.17, 2.57 ]
Baraf 2011 461/719 394/705 67.5 % 1.15 [ 1.05, 1.25 ]
Roth 2004 79/163 55/159 9.4 % 1.40 [ 1.07, 1.83 ]
Subtotal (95% CI) 1185 1158 100.0 % 1.20 [ 1.12, 1.29 ]
Total events: 716 (Diclofenac), 582 (Carrier)
Heterogeneity: Chi2 = 5.97, df = 3 (P = 0.11); I2 =50%
Test for overall effect: Z = 4.94 (P < 0.00001)
2 2 to ≤ 6 weeks
Bookman 2004 44/84 26/79 31.6 % 1.59 [ 1.09, 2.32 ]
Bruhlmann 2003 12/51 4/52 4.7 % 3.06 [ 1.06, 8.86 ]
Dreiser 1993 55/78 21/77 24.9 % 2.59 [ 1.75, 3.83 ]
Grace 1999 12/38 9/36 10.9 % 1.26 [ 0.61, 2.63 ]
Niethard 2005 36/117 24/120 27.9 % 1.54 [ 0.98, 2.41 ]
Subtotal (95% CI) 368 364 100.0 % 1.86 [ 1.50, 2.31 ]
Total events: 159 (Diclofenac), 84 (Carrier)
Heterogeneity: Chi2 = 5.97, df = 4 (P = 0.20); I2 =33%
Test for overall effect: Z = 5.61 (P < 0.00001)
Test for subgroup differences: Chi2 = 14.09, df = 1 (P = 0.00), I2 =93%
0.5 0.7 1 1.5 2
Favours carrier Favours diclofenac
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Analysis 1.2. Comparison 1 Topical diclofenac versus carrier, Outcome 2 Local adverse events.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 1 Topical diclofenac versus carrier
Outcome: 2 Local adverse events
Study or subgroup Diclofenac Carrier Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
102-93-1 21/41 6/42 4.2 % 3.59 [ 1.61, 7.97 ]
Altman 2009 9/198 4/187 2.9 % 2.13 [ 0.67, 6.78 ]
Baer 2005 42/107 23/109 16.1 % 1.86 [ 1.21, 2.87 ]
Baraf 2011 34/721 4/704 2.9 % 8.30 [ 2.96, 23.27 ]
Bookman 2004 30/84 11/80 8.0 % 2.60 [ 1.40, 4.82 ]
Bruhlmann 2003 3/51 2/52 1.4 % 1.53 [ 0.27, 8.77 ]
Dreiser 1993 1/78 2/77 1.4 % 0.49 [ 0.05, 5.33 ]
Galeazzi 1993 0/30 0/30 Not estimable
Grace 1999 4/38 7/36 5.1 % 0.54 [ 0.17, 1.69 ]
Niethard 2005 4/117 3/120 2.1 % 1.37 [ 0.31, 5.98 ]
Roth 1995 12/59 26/60 18.3 % 0.47 [ 0.26, 0.84 ]
Roth 2004 60/164 41/162 29.2 % 1.45 [ 1.04, 2.02 ]
Simon 2009 41/154 12/157 8.4 % 3.48 [ 1.90, 6.37 ]
Total (95% CI) 1842 1816 100.0 % 1.84 [ 1.54, 2.21 ]
Total events: 261 (Diclofenac), 141 (Carrier)
Heterogeneity: Chi2 = 45.44, df = 11 (P<0.00001); I2 =76%
Test for overall effect: Z = 6.56 (P < 0.00001)
Test for subgroup differences: Not applicable
0.05 0.2 1 5 20
Favours diclofenac Favours carrier
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Analysis 1.3. Comparison 1 Topical diclofenac versus carrier, Outcome 3 Systemic adverse events.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 1 Topical diclofenac versus carrier
Outcome: 3 Systemic adverse events
Study or subgroup Diclofenac Carrier Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bruhlmann 2003 1/51 1/52 2.2 % 1.02 [ 0.07, 15.87 ]
Dreiser 1993 0/78 2/77 5.7 % 0.20 [ 0.01, 4.05 ]
Galeazzi 1993 0/30 0/30 Not estimable
Grace 1999 2/38 2/36 4.6 % 0.95 [ 0.14, 6.37 ]
Niethard 2005 7/117 8/120 17.8 % 0.90 [ 0.34, 2.40 ]
Roth 2004 19/164 16/162 36.2 % 1.17 [ 0.63, 2.20 ]
Simon 2009 10/154 15/157 33.4 % 0.68 [ 0.32, 1.47 ]
Total (95% CI) 632 634 100.0 % 0.89 [ 0.59, 1.34 ]
Total events: 39 (Diclofenac), 44 (Carrier)
Heterogeneity: Chi2 = 2.18, df = 5 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.58)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diclofenac Favours carrier
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Analysis 1.4. Comparison 1 Topical diclofenac versus carrier, Outcome 4 Gastrointestinal adverse events.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 1 Topical diclofenac versus carrier
Outcome: 4 Gastrointestinal adverse events
Study or subgroup Diclofenac Carrier Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Altman 2009 15/198 7/187 13.9 % 2.02 [ 0.84, 4.85 ]
Baraf 2011 3/721 3/704 5.9 % 0.98 [ 0.20, 4.82 ]
Bookman 2004 6/84 4/80 7.9 % 1.43 [ 0.42, 4.88 ]
Bruhlmann 2003 1/51 0/52 1.0 % 3.06 [ 0.13, 73.36 ]
Dreiser 1993 0/78 2/77 4.9 % 0.20 [ 0.01, 4.05 ]
Galeazzi 1993 0/30 0/30 Not estimable
Grace 1999 2/38 2/36 4.0 % 0.95 [ 0.14, 6.37 ]
Niethard 2005 0/117 2/120 4.8 % 0.21 [ 0.01, 4.23 ]
Roth 2004 19/164 15/162 29.1 % 1.25 [ 0.66, 2.38 ]
Simon 2009 10/154 15/157 28.7 % 0.68 [ 0.32, 1.47 ]
Total (95% CI) 1635 1605 100.0 % 1.10 [ 0.76, 1.58 ]
Total events: 56 (Diclofenac), 50 (Carrier)
Heterogeneity: Chi2 = 6.57, df = 8 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 0.50 (P = 0.62)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diclofenac Favours carrier
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Analysis 1.5. Comparison 1 Topical diclofenac versus carrier, Outcome 5 Withdrawals due to adverse
events.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 1 Topical diclofenac versus carrier
Outcome: 5 Withdrawals due to adverse events
Study or subgroup Diclofenac Carrier Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
108-97 10/198 4/187 6.5 % 2.36 [ 0.75, 7.40 ]
Altman 2009 9/107 9/109 14.0 % 1.02 [ 0.42, 2.47 ]
Baer 2005 39/721 18/705 28.6 % 2.12 [ 1.22, 3.67 ]
Baraf 2011 5/84 3/80 4.8 % 1.59 [ 0.39, 6.43 ]
Bookman 2004 1/51 2/52 3.1 % 0.51 [ 0.05, 5.45 ]
Bruhlmann 2003 0/78 1/77 2.4 % 0.33 [ 0.01, 7.96 ]
Dreiser 1993 0/30 0/30 Not estimable
Galeazzi 1993 1/38 0/36 0.8 % 2.85 [ 0.12, 67.68 ]
Grace 1999 2/117 0/120 0.8 % 5.13 [ 0.25, 105.67 ]
Niethard 2005 8/164 4/162 6.3 % 1.98 [ 0.61, 6.43 ]
Roth 2004 16/154 18/157 28.0 % 0.91 [ 0.48, 1.71 ]
Simon 2009 7/48 3/47 4.8 % 2.28 [ 0.63, 8.31 ]
Total (95% CI) 1790 1762 100.0 % 1.55 [ 1.14, 2.11 ]
Total events: 98 (Diclofenac), 62 (Carrier)
Heterogeneity: Chi2 = 8.38, df = 10 (P = 0.59); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0050)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diclofenac Favours carrier
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Analysis 1.6. Comparison 1 Topical diclofenac versus carrier, Outcome 6Withdrawals due to lack of efficacy.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 1 Topical diclofenac versus carrier
Outcome: 6 Withdrawals due to lack of efficacy
Study or subgroup Diclofenac Carrier Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Altman 2009 8/198 13/187 8.2 % 0.58 [ 0.25, 1.37 ]
Baer 2005 8/107 18/109 10.9 % 0.45 [ 0.21, 1.00 ]
Baraf 2011 32/721 51/705 31.6 % 0.61 [ 0.40, 0.94 ]
Bookman 2004 2/84 8/80 5.0 % 0.24 [ 0.05, 1.09 ]
Bruhlmann 2003 1/51 2/52 1.2 % 0.51 [ 0.05, 5.45 ]
Dreiser 1993 0/78 9/77 5.9 % 0.05 [ 0.00, 0.88 ]
Galeazzi 1993 0/30 0/30 Not estimable
Grace 1999 0/38 0/36 Not estimable
Niethard 2005 1/117 0/120 0.3 % 3.08 [ 0.13, 74.76 ]
Roth 2004 28/164 42/162 25.9 % 0.66 [ 0.43, 1.01 ]
Simon 2009 16/154 18/155 11.0 % 0.89 [ 0.47, 1.69 ]
Total (95% CI) 1742 1713 100.0 % 0.59 [ 0.47, 0.75 ]
Total events: 96 (Diclofenac), 161 (Carrier)
Heterogeneity: Chi2 = 7.62, df = 8 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 4.34 (P = 0.000014)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours diclofenac Favours carrier
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Analysis 2.1. Comparison 2 Topical ketoprofen versus carrier, Outcome 1 Clinical success.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 2 Topical ketoprofen versus carrier
Outcome: 1 Clinical success
Study or subgroup Ketoprofen Carrier Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Duration 6 to 12 weeks
Conaghan 2013 (1) 205/453 192/472 44.4 % 1.21 [ 0.93, 1.56 ]
Kneer 2013 (2) 562/638 147/190 11.6 % 2.16 [ 1.43, 3.28 ]
Rother 2007 64/138 35/127 8.4 % 2.27 [ 1.36, 3.80 ]
Rother 2013 113/274 142/281 35.5 % 0.69 [ 0.49, 0.96 ]
Subtotal (95% CI) 1503 1070 100.0 % 1.22 [ 1.03, 1.45 ]
Total events: 944 (Ketoprofen), 516 (Carrier)
Heterogeneity: Chi2 = 24.19, df = 3 (P = 0.00002); I2 =88%
Test for overall effect: Z = 2.28 (P = 0.023)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours carrier Favours ketoprofen
(1) 100 mg and 200 mg daily doses combined
(2) 50 mg, 100 mg, and 200 mg daily doses combined
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Analysis 2.2. Comparison 2 Topical ketoprofen versus carrier, Outcome 2 Local adverse events.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 2 Topical ketoprofen versus carrier
Outcome: 2 Local adverse events
Study or subgroup Ketoprofen Carrier Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Conaghan 2013 41/463 40/472 24.7 % 1.04 [ 0.69, 1.58 ]
Kneer 2013 127/667 39/199 37.4 % 0.97 [ 0.70, 1.34 ]
Rother 2007 39/138 28/127 18.2 % 1.28 [ 0.84, 1.95 ]
Rother 2013 29/274 32/281 19.7 % 0.93 [ 0.58, 1.49 ]
Total (95% CI) 1542 1079 100.0 % 1.04 [ 0.85, 1.27 ]
Total events: 236 (Ketoprofen), 139 (Carrier)
Heterogeneity: Chi2 = 1.33, df = 3 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.37 (P = 0.71)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
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Analysis 2.3. Comparison 2 Topical ketoprofen versus carrier, Outcome 3 Gastrointestinal adverse events.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 2 Topical ketoprofen versus carrier
Outcome: 3 Gastrointestinal adverse events
Study or subgroup Ketoprofen Carrier Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Conaghan 2013 (1) 40/463 40/472 58.3 % 1.02 [ 0.67, 1.55 ]
Kneer 2013 (2) 22/667 9/199 20.4 % 0.73 [ 0.34, 1.56 ]
Rother 2007 13/138 12/127 18.4 % 1.00 [ 0.47, 2.10 ]
Rother 2013 2/274 2/281 2.9 % 1.03 [ 0.15, 7.23 ]
Total (95% CI) 1542 1079 100.0 % 0.96 [ 0.69, 1.32 ]
Total events: 77 (Ketoprofen), 63 (Carrier)
Heterogeneity: Chi2 = 0.60, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.27 (P = 0.79)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ketoprofen Favours carrier
(1) 100 mg and 200 mg daily doses combined
(2) 50 mg, 100 mg, and 200 mg daily doses combined
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Analysis 2.4. Comparison 2 Topical ketoprofen versus carrier, Outcome 4 Withdrawals due to adverse
events.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 2 Topical ketoprofen versus carrier
Outcome: 4 Withdrawals due to adverse events
Study or subgroup Ketoprofen Carrier Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Conaghan 2013 (1) 16/463 15/472 24.8 % 1.09 [ 0.54, 2.17 ]
Kneer 2013 (2) 40/667 8/199 20.6 % 1.49 [ 0.71, 3.13 ]
Rother 2007 23/138 20/127 34.8 % 1.06 [ 0.61, 1.83 ]
Rother 2013 20/274 12/281 19.8 % 1.71 [ 0.85, 3.43 ]
Total (95% CI) 1542 1079 100.0 % 1.28 [ 0.92, 1.78 ]
Total events: 99 (Ketoprofen), 55 (Carrier)
Heterogeneity: Chi2 = 1.50, df = 3 (P = 0.68); I2 =0.0%
Test for overall effect: Z = 1.49 (P = 0.14)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ketoprofen Favours carrier
(1) 100 mg and 200 mg daily doses combined
(2) 50 mg, 100 mg, and 200 mg daily doses combined
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Analysis 2.5. Comparison 2 Topical ketoprofen versus carrier, Outcome 5 Withdrawals due to lack of
efficacy.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 2 Topical ketoprofen versus carrier
Outcome: 5 Withdrawals due to lack of efficacy
Study or subgroup Ketoprofen Carrier Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Conaghan 2013 (1) 11/463 13/472 20.6 % 0.86 [ 0.39, 1.91 ]
Kneer 2013 (2) 35/463 35/667 45.9 % 1.44 [ 0.92, 2.27 ]
Rother 2007 1/138 3/127 5.0 % 0.31 [ 0.03, 2.91 ]
Rother 2013 16/274 18/281 28.5 % 0.91 [ 0.47, 1.75 ]
Total (95% CI) 1338 1547 100.0 % 1.11 [ 0.80, 1.55 ]
Total events: 63 (Ketoprofen), 69 (Carrier)
Heterogeneity: Chi2 = 3.26, df = 3 (P = 0.35); I2 =8%
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours ketoprofen Favours carrier
(1) 100 mg and 200 mg daily doses combined
(2) 50 mg, 100 mg, and 200 mg daily doses combined
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Analysis 3.1. Comparison 3 Topical NSAID versus oral NSAID, Outcome 1 Clinical success.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 3 Topical NSAID versus oral NSAID
Outcome: 1 Clinical success
Study or subgroup Topical NSAID Oral NSAID Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dickson 1991 75/117 71/118 15.2 % 1.07 [ 0.87, 1.30 ]
Rother 2007 68/138 51/132 11.2 % 1.28 [ 0.97, 1.68 ]
Simon 2009 73/154 77/151 16.7 % 0.93 [ 0.74, 1.17 ]
Tugwell 2004 201/303 210/301 45.2 % 0.95 [ 0.85, 1.06 ]
Zacher 2001 66/165 53/156 11.7 % 1.18 [ 0.88, 1.57 ]
Total (95% CI) 877 858 100.0 % 1.03 [ 0.95, 1.12 ]
Total events: 483 (Topical NSAID), 462 (Oral NSAID)
Heterogeneity: Chi2 = 6.05, df = 4 (P = 0.20); I2 =34%
Test for overall effect: Z = 0.64 (P = 0.53)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Favours oral NSAID Favours topical NSAID
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Analysis 3.2. Comparison 3 Topical NSAID versus oral NSAID, Outcome 2 Local adverse events.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 3 Topical NSAID versus oral NSAID
Outcome: 2 Local adverse events
Study or subgroup Topical NSAID Oral NSAID Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dickson 1991 3/117 4/118 8.3 % 0.76 [ 0.17, 3.31 ]
Rother 2007 39/138 27/132 57.7 % 1.38 [ 0.90, 2.12 ]
Sandelin 1997 16/126 1/82 2.5 % 10.41 [ 1.41, 77.02 ]
Simon 2009 41/154 11/151 23.2 % 3.65 [ 1.95, 6.84 ]
Tugwell 2004 83/311 4/322 8.2 % 21.48 [ 7.97, 57.88 ]
Total (95% CI) 846 805 100.0 % 3.74 [ 2.76, 5.06 ]
Total events: 182 (Topical NSAID), 47 (Oral NSAID)
Heterogeneity: Chi2 = 38.18, df = 4 (P<0.00001); I2 =90%
Test for overall effect: Z = 8.54 (P < 0.00001)
Test for subgroup differences: Not applicable
0.02 0.1 1 10 50
Favours topical NSAID Favours oral NSAID
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Analysis 3.3. Comparison 3 Topical NSAID versus oral NSAID, Outcome 3 Gastrointestinal adverse events.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 3 Topical NSAID versus oral NSAID
Outcome: 3 Gastrointestinal adverse events
Study or subgroup Topical NSAID Oral NSAID Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dickson 1991 15/117 11/118 4.4 % 1.38 [ 0.66, 2.87 ]
Rother 2007 13/138 18/132 7.3 % 0.69 [ 0.35, 1.35 ]
Sandelin 1997 6/126 11/82 5.3 % 0.35 [ 0.14, 0.92 ]
Simon 2009 10/154 36/151 14.4 % 0.27 [ 0.14, 0.53 ]
Tugwell 2004 108/311 150/311 59.6 % 0.72 [ 0.59, 0.87 ]
Zacher 2001 15/165 22/156 9.0 % 0.64 [ 0.35, 1.20 ]
Total (95% CI) 1011 950 100.0 % 0.66 [ 0.56, 0.77 ]
Total events: 167 (Topical NSAID), 248 (Oral NSAID)
Heterogeneity: Chi2 = 13.17, df = 5 (P = 0.02); I2 =62%
Test for overall effect: Z = 5.02 (P < 0.00001)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours topical NSAID Favours oral NSAID
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Analysis 3.4. Comparison 3 Topical NSAID versus oral NSAID, Outcome 4 Withdrawals due to adverse
events.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 3 Topical NSAID versus oral NSAID
Outcome: 4 Withdrawals due to adverse events
Study or subgroup Topical NSAID Oral NSAID Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Dickson 1991 9/117 7/118 4.9 % 1.30 [ 0.50, 3.37 ]
Rother 2007 23/138 18/132 13.0 % 1.22 [ 0.69, 2.16 ]
Sandelin 1997 4/126 1/82 0.9 % 2.60 [ 0.30, 22.88 ]
Simon 2009 16/154 19/151 13.6 % 0.83 [ 0.44, 1.54 ]
Tugwell 2004 64/311 79/311 55.9 % 0.81 [ 0.61, 1.08 ]
Zacher 2001 5/165 16/156 11.6 % 0.30 [ 0.11, 0.79 ]
Total (95% CI) 1011 950 100.0 % 0.85 [ 0.68, 1.06 ]
Total events: 121 (Topical NSAID), 140 (Oral NSAID)
Heterogeneity: Chi2 = 7.92, df = 5 (P = 0.16); I2 =37%
Test for overall effect: Z = 1.48 (P = 0.14)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours topical NSAD Favours oral NSAID
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Analysis 3.5. Comparison 3 Topical NSAID versus oral NSAID, Outcome 5 Withdrawals due to lack of
efficacy.
Review: Topical NSAIDs for chronic musculoskeletal pain in adults
Comparison: 3 Topical NSAID versus oral NSAID
Outcome: 5 Withdrawals due to lack of efficacy
Study or subgroup Topical NSAID Oral NSAID Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Rother 2007 1/138 3/132 16.9 % 0.32 [ 0.03, 3.03 ]
Simon 2009 16/154 5/151 27.9 % 3.14 [ 1.18, 8.35 ]
Tugwell 2004 28/311 10/311 55.2 % 2.80 [ 1.38, 5.67 ]
Total (95% CI) 603 594 100.0 % 2.47 [ 1.45, 4.22 ]
Total events: 45 (Topical NSAID), 18 (Oral NSAID)
Heterogeneity: Chi2 = 3.53, df = 2 (P = 0.17); I2 =43%
Test for overall effect: Z = 3.33 (P = 0.00087)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours topical NSAID Favours oral NSAID
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
1. MeSH descriptor Anti-inflammatory Agents, non-steroidal/ (13421)
2. (bufexamac OR bufexine OR calmaderm OR ekzemase OR dicoflenac OR solaraze OR pennsaid OR voltarol OR emulgel OR
voltarene OR optha OR voltaren OR etofenamate OR afrolate OR algesalona OR bayro OR deiron OR etofen OR flexium OR
flogoprofen OR rheuma-gel OR rheumon OR traumalix OR traumon OR zenavan OR felbinac OR dolinac OR flexfree OR
napageln OR target OR traxam OR fentiazac OR domureuma OR fentiazaco OR norvedan OR riscalon OR fepradinol OR dalgen
OR flexidol OR cocresol OR rangozona OR reuflodol OR pinazone OR zepelin OR flufenamic OR dignodolin OR rheuma OR
lindofluid OR sastridex OR lunoxaprofen OR priaxim OR flubiprofen OR fenomel OR ocufen OR ocuflur OR “Trans Act LAT”
OR tulip OR ibuprofen OR cuprofen OR “deep relief ” OR fenbid OR ibu-cream OR ibugel OR ibuleve OR ibumousse OR
ibuspray OR “nurofen gel” OR proflex OR motrin OR advil OR radian OR ralgex OR ibutop OR indomethacin OR indocin OR
indospray OR isonixin OR nixyn OR ketoprofen OR tiloket OR oruvail OR powergel OR solpaflex OR ketorolac OR acular OR
trometamol OR meclofenamic OR naproxen OR naprosyn OR niflumic OR actol OR flunir OR niflactol topico OR niflugel OR
nifluril OR oxyphenbutazone OR californit OR diflamil OR otone OR tanderil OR piketoprofen OR calmatel OR triparsean OR
piroxicam OR feldene OR pranoprofen OR oftalar OR pranox OR suxibuzone OR danilon OR flamilon OR ufenamate OR
fenazol):ti,ab,kw. (24140)
3. 1 OR 2 (32382)
4. MeSH descriptor Administration, Topical/ (12177)
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5. (topical* OR cutaneous OR dermal OR transcutaneous OR transdermal OR percutaneous OR skin OR massage OR
embrocation OR gel OR ointment OR aerosol OR cream OR creme OR lotion OR mousse OR foam OR liniment OR spray OR
rub OR balm OR salve OR emulsion OR oil OR patch OR plaster):ti,ab,kw. (69415)
6. 4 OR 5 (71972)
7. (pain OR painful OR analgesi*):ti,ab,kw. (76989)
8. MeSH DESCRIPTOR pain EXPLODE ALL TREES (29985)
9. 7 or 8 (82235)
10. 3 AND 6 AND 9 (1163)
11. 2012 TO 2015:YR (111751)
12. 10 AND 11 (179)
13. To update
Appendix 2. MEDLINE search strategy (via OVID)
1. exp Anti-inflammatory Agents, non-steroidal/ (19443)
2. (bufexamac OR bufexine OR calmaderm OR ekzemase OR dicoflenac OR solaraze OR pennsaid OR voltarol OR emulgel OR
voltarene OR optha OR voltaren OR etofenamate OR afrolate OR algesalona OR bayro OR deiron OR etofen OR flexium OR
flogoprofen OR rheuma-gel OR rheumon OR traumalix OR traumon OR zenavan OR felbinac OR dolinac OR flexfree OR
napageln OR target OR traxam OR fentiazac OR domureuma OR fentiazaco OR norvedan OR riscalon OR fepradinol OR dalgen
OR flexidol OR cocresol OR rangozona OR reuflodol OR pinazone OR zepelin OR flufenamic OR dignodolin OR rheuma OR
lindofluid OR sastridex OR lunoxaprofen OR priaxim OR flubiprofen OR fenomel OR ocufen OR ocuflur OR “Trans Act LAT” OR
tulip OR ibuprofen OR cuprofen OR “deep relief ” OR fenbid OR ibu-cream OR ibugel OR ibuleve OR ibumousse OR ibuspray
OR “nurofen gel” OR proflex OR motrin OR advil OR radian OR ralgex OR ibutop OR indomethacin OR indocin OR indospray
OR isonixin OR nixyn OR ketoprofen OR tiloket OR oruvail OR powergel OR solpaflex OR ketorolac OR acular OR trometamol
OR meclofenamic OR naproxen OR naprosyn OR niflumic OR actol OR flunir OR niflactol topico OR niflugel OR nifluril OR
oxyphenbutazone OR californit OR diflamil OR otone OR tanderil OR piketoprofen OR calmatel OR triparsean OR piroxicam OR
feldene OR pranoprofen OR oftalar OR pranox OR suxibuzone OR danilon OR flamilon OR ufenamate OR fenazol).mp. (135055)
3. 1 OR 2 (149887)
4. exp Administration, Topical/ (9882)
5. (topical* OR cutaneous OR dermal OR transcutaneous OR transdermal OR percutaneous OR skin OR massage OR
embrocation OR gel OR ointment OR aerosol OR cream OR creme OR lotion OR mousse OR foam OR liniment OR spray OR
rub OR balm OR salve OR emulsion OR oil OR patch OR plaster).mp. (183886)
6. 4 OR 5 (186650)
7. exp Musculoskeletal diseases/ (109780)
8. (arthrit* OR rhemat* or osteoarth* OR tend?nitis OR sciatica OR lumbago OR fibrositis*).mp. (32728)
9. 7 OR 8 (115939)
10. Chronic Pain/ (4060)
11. (pain OR painful OR analgesi*).mp. (97784)
12. 10 OR 11 (97784)
13. randomized controlled trial.pt. (79001)
14. controlled clinical trial.pt. (6294)
15. randomized.ab. (70728)
16. placebo.ab. (25005)
17. drug therapy.fs. (291957)
18. randomly.ab. (45688)
19. trial.ab. (71983)
20. groups.ab. (257513)
21. OR/13-20 (603334)
22. 3 AND 6 AND 9 AND 12 AND 21 (115)
23. Limit 22 to yr=“2012-Current” (90)
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Appendix 3. EMBASE search strategy
1. exp nonsteroid antiinflammatory agent/ (320629)
2. (bufexamac OR bufexine OR calmaderm OR ekzemase OR dicoflenac OR solaraze OR pennsaid OR voltarol OR emulgel OR
voltarene OR optha OR voltaren OR etofenamate OR afrolate OR algesalona OR bayro OR deiron OR etofen OR flexium OR
flogoprofen OR rheuma-gel OR rheumon OR traumalix OR traumon OR zenavan OR felbinac OR dolinac OR flexfree OR
napageln OR target OR traxam OR fentiazac OR domureuma OR fentiazaco OR norvedan OR riscalon OR fepradinol OR dalgen
OR flexidol OR cocresol OR rangozona OR reuflodol OR pinazone OR zepelin OR flufenamic OR dignodolin OR rheuma OR
lindofluid OR sastridex OR lunoxaprofen OR priaxim OR flubiprofen OR fenomel OR ocufen OR ocuflur OR “Trans Act LAT” OR
tulip OR ibuprofen OR cuprofen OR “deep relief ” OR fenbid OR ibu-cream OR ibugel OR ibuleve OR ibumousse OR ibuspray
OR “nurofen gel” OR proflex OR motrin OR advil OR radian OR ralgex OR ibutop OR indomethacin OR indocin OR indospray
OR isonixin OR nixyn OR ketoprofen OR tiloket OR oruvail OR powergel OR solpaflex OR ketorolac OR acular OR trometamol
OR meclofenamic OR naproxen OR naprosyn OR niflumic OR actol OR flunir OR niflactol topico OR niflugel OR nifluril OR
oxyphenbutazone OR californit OR diflamil OR otone OR tanderil OR piketoprofen OR calmatel OR triparsean OR piroxicam OR
feldene OR pranoprofen OR oftalar OR pranox OR suxibuzone OR danilon OR flamilon OR ufenamate OR fenazol).mp. (667855)
3. 1 OR 2 (911117)
4. exp topical drug administration/ (14839)
5. (topical* OR cutaneous OR dermal OR transcutaneous OR transdermal OR percutaneous OR skin OR massage OR
embrocation OR gel OR ointment OR aerosol OR cream OR creme OR lotion OR mousse OR foam OR liniment OR spray OR
rub OR balm OR salve OR emulsion OR oil OR patch OR plaster).mp. (1268303)
6. 4 OR 5 (1268303)
7. exp musculoskeletal disease/ (1087620)
8. (arthrit* OR rhemat* or osteoarth* OR tend?nitis OR sciatica OR lumbago OR fibrositis*).mp. (232138)
9. 7 OR 8 (1104767)
10. chronic pain/ (33061)
11. (pain OR painful OR analgesi*).mp. (742030)
12. 10 OR 11 (742030)
13. clinical trial.sh. (692438)
14. controlled clinical trial.sh. (344474)
15. randomized controlled trial.sh. (314236)
16. double-blind procedure.sh. (93716)
17. (clin* adj25 trial*).ab. (303361)
18. ((doubl* or trebl* or tripl*) adj25 (blind* or mask*)).ab. (102398)
19. placebo*.ab. (159368)
20. random*.ab. (791695)
21. OR/13-20 (1460942)
22. 3 AND 6 AND 9 AND 12 AND 21 (2317)
23. Limit 24 to yr=“2012-Current” (327)
Appendix 4. GRADE: criteria for assigning grade of evidence
The GRADE system uses the following criteria for assigning grade of evidence (GRADEpro GDT 2015).
• High = further research is very unlikely to change our confidence in the estimate of effect.
• Moderate = further research is likely to have an important impact on our confidence in the estimate of effect and may change
the estimate.
• Low = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to
change the estimate.
• Very low = any estimate of effect is very uncertain.
We decrease grade if we find:
• a serious (-1) or very serious (-2) limitation to study quality;
• important inconsistency (-1);
• some (-1) or major (-2) uncertainty about directness;
91Topical NSAIDs for chronic musculoskeletal pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• imprecise or sparse data (-1);
• a high probability of reporting bias (-1).
Appendix 5. Unpublished studies
NCT number
* identified in earlier
review
Preparation Date of completion Number of participants Sponsor
NCT00108992 Diclofenac, solution and
tablet (DD)
September 2005 OA knee (flare)
750
Nuvo Research Inc
NCT00171652 Diclofenac sodium gel
1%
October 2005
(included in Barthel
2010)
OA hand
360
Novartis
NCT00211549* Ketoprofen (IDEA-033) Verified complete in
March 2009
OA knee
875
IDEA AG
NCT00265304*
some patients from
NCT00211549
Ketoprofen (IDEA-033) July 2007 OA knee
550
IDEA AG
NCT00365586* Ketoprofen patch April 2007 OA knee (flare)
300
Endo Pharmaceuticals
NCT00484120* Diclofenac 3% nano-
emulsion cream
November 2008 OA knee
123
Pharmos
NCT00546507* Diclofenac sodium 4%
spray
October 2008 OA knee (flare)
650
Mika Pharma GmbH
NCT00546832* Diclofenac sodium 4%
spray
November 2008 OA knee (flare)
650
Mika Pharma GmbH
NCT00647231* Ketoprofen patch
(HKT-500)
August 2008 OA knee
300
Hisamitsu Pharmaceuti-
cal Co., Inc
NCT00792727* Ketoprofen patch
(HKT-500)
May 2008 OA knee
380
Hisamitsu Pharmaceuti-
cal Co., Inc
NCT01119898* Diclofenac sodium2.0%
(PENNSAID)
March 2011 OA knee (flare)
260
Mallinckrodt
NCT01456611* Diclofenac sodium 1%
gel (Anchen versus No-
vartis)
April 2012 OA knee
749
Anchen
Pharmaceuticals, Inc
92Topical NSAIDs for chronic musculoskeletal pain in adults (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Appendix 6. Summary of results in individual studies - efficacy
Summary of outcomes: successful treatment
Study ID Treatment Definition of clinical
response
Study duration
Number with success-
ful outcome
Secondary measures
102-93-1 (1) Diclofenac solution
(with 45.5% DMSO;
Pennsaid®)
(2) Control (with 45.5%
DMSO)
(3) Placebo (with 4.55%
DMSO)
Solution applied as 40
drops (about 1 mL) x 4
daily
Number of participants
in each group not re-
ported
6 weeks No dichotomous out-
comes reported
Mean pain-relief-level
days: (1) > (2) > (3)
108-97 (1) Diclofenac solution
(with 45.5% DMSO;
Pennsaid®), n = 48
(2) Control (with 45.5%
DMSO), n = 47
(3) Diclofenac solution
(with 2.3%DMSO), n =
50
(4) Placebo (with 2.3%
DMSO), n = 50
Solution applied 4 x
daily to maximum 40
drops per hand
6 weeks No dichotomous out-
comes reported
(1) had greatest im-
provement in pain score,
but differences between
groups were not statisti-
cally significant
Altman 2009 (1) Diclofenac sodium
gel 1% (Voltaren) with
vehicle 2 g, n = 198
(2) Placebo gel (vehicle
carrier) n = 187
Gels applied x 4 daily
OARSI response in
dominant hand
PGE 5-point scale
8 weeks
OARSI responder:
(1) 65.7% = 130/198
(2) 56.7% = 106/187
PGE: very good or excel-
lent
(1) 47.7% = 93/195
(2) 36.5% = 66/185
Baer 2005 (1)Diclofenac sodium1.
5% (with 45.
5%DMSO; Pennsaid®)
, n = 107
(2) Placebo (vehicle car-
rier), n = 109
Solution applied as 40
Participants with≥ 50%
PR (provided by author)
PGE 5-point scale
6 weeks
≥ 50% PR:
(1) 46/105
(2) 27/107
PGE: good or very good
(1) 46/105
(2) 18/107
OMERACT-OARSI re-
sponder (post hoc)
(1) 69/105
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(Continued)
drops x 4 daily (2) 53/107
Significant improve-
ment in score with top-
ical diclofenac for pain,
physical function, PGE,
and stiffness at 6 weeks
Balthazar-Letawe 1987 (1) Diclofenac (Voltaren
Emulgel), n = 25
(2) Indomethacin (Indo-
cid) gel, n = 25
Gels applied x 2 daily
2 weeks No dichotomous out-
comes reported
No data
Baraf 2011 (1) Diclofenac sodium
gel 1%, n = 721
(2) Placebo gel (vehicle
only), n = 705
Medication applied 4 x 4
g daily
OARSI response in
treated knee (using pain
on movement)
PGE 5-point scale
12 weeks
OARSI:
(1) 461/719
(2) 394/705
PGE: very good, excel-
lent
(1) 344/719
(2) 266/705
Bolten 1991 (1) Felbinac gel 3% 1 g,
n = 142
(2) Placebo gel, n = 139
Gel applied x 3 daily
Pain on rest: 5-point
scale (-1 to +3 where + =
improvement)
2 weeks
Spontaneous pain (+3 or
+2):
(1) 34/142
(2) 15/139
Mean change in pain at
rest or activity signifi-
cantly improved after 14
days in (1)
Bookman 2004 (1) Diclofenac solution
1.5% in DMSO (45.
5%: Pennsaid®), n = 84
(2) Carrier with DMSO
(45.5%), n = 80
(3) Carrier with 1/10th
DMSO (4.55%), n = 84
Solution applied as 40
drops (= 1.3 mL) x 4
daily
Participants with≥ 50%
PR (from author)
4 weeks
≥ 50% PR:
(1) 44/84
(2) 26/79
(3) no data
Pain on walking at 4
weeks (4-point scale):
(1) 1.0 (SD 1.0)
(2) 1.5 (SD 1.1)
Mean change in pain,
physical function, stiff-
ness, pain on walking,
and PGE score all statis-
tically better for (1) than
(2) or (3)
Mean paracetamol con-
sumption less in (1) than
(2) or (3)
Bruhlmann 2003 (1) Diclofenac sodium
patch 1% (180 mg; Flec-
tor-EP), n = 51
(2) Placebo patch, n = 52
Patch applied x 2 daily
PGE 5-point scale
2 weeks
PGE excellent:
(1) 12/51
(2) 4/52
Num-
ber of patients judging
the treatment group “no
efficacy”:
(1) 5/51
(2) 9/52
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(Continued)
Significantly greater re-
duction in mean sponta-
neous pain with (1) than
(2) on day 7 and 14
There was a significant
difference between treat-
ment group and baseline
at all 3 visits
Burgos 2001 (1) Flurbiprofen LAT (=
40 mg) + placebo cream,
n = 64
(2) Piketoprofen cream
1.8% (4 cm ~ 36 mg) +
placebo patch, n = 65
Patch applied x 2 daily,
cream x 3 daily
Undefined improve-
ment: “Do you think
that the treatment ap-
plied relieved the pain?”
2 weeks
Improved:
(1) 80% = 46/58
(2) 65% = 39/60
Patients showed a sig-
nificant mean improve-
ment in all clinical pa-
rameters assessed: sever-
ity of disease, sponta-
neous pain, tenderness,
and mobility of the in-
volved joints, although
no statistically signifi-
cant differences between
the 2 groups
Conaghan 2013 (1) Ketoprofen (IDEA-
033) gel 100 mg daily, n
= 233
(2) Ketoprofen (IDEA-
033) gel 200 mg daily, n
= 230
(3) 4.4 g vehicle daily, n
= 238
(4) 8.8 g vehicle daily, n
= 235
(5) Oral celecoxib 200
mg daily. N = 235
(6)Oral placebo, n = 228
All medication admin-
istered in divided daily
dose
(vehicle = TDT-064)
Participants with≥ 50%
PR
12 weeks
≥ 50% PR:
(1) 105/233
(2) 100/230
(3) 97/238
(4) 95/234
(5) 100/233
(6) 67/227
Mean PI reduction from
baseline 1.9 (SD 1.6),
~39%) in all groups ex-
cept oral placebo (1.4
(SD 1.6), 29%)
Mean change from base-
line in physical function
was similar for all treat-
ment groups except oral
placebo
Dickson 1991 (1) Piroxicam gel 0.5%
(1 g = 5 mg piroxicam) +
placebo tablet, n = 117
(2) Ibuprofen tablet 400
mg + placebo cream, n =
118
mg x 3 daily, n = 118
Gels applied x 3 daily,
tablet taken x 3 daily
PGE 4-point scale
4 weeks
PGE excellent or good:
(1) 64% = 75/117
(2) 60% = 71/118
Mean reduction in pain
and improvement
in ability to perform task
for all arthritic symp-
toms - difference not sig-
nificant between gel and
oral groups
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(Continued)
Dreiser 1993 (1) Diclofenac (DHEP)
patch (= 180 mg), n = 78
(2) Placebo patch, n = 77
Patch applied x 2 daily
PGE 5-point scale
4 weeks
PGE excellent or good:
(1) 55/78
(2) 21/77
(1) significantly better
than (2) for group mean
spontaneous pain from
4th day on
Ergun 2007 (1) Nimesulide gel 1%
(Sulidin) 0.4 mg/10 cm
2, n = 51
(2) Placebo gel, n = 23
Gels applied x 3 daily
PGE 5-point scale
4 weeks
PGE very effective or ef-
fective:
(1) 23/49
(2) 2/21
(1)
significantly better than
(2) for mean change in
overall WOMAC score
over 30 days, but indi-
vidual components did
not reach statistical sig-
nificance
Galeazzi 1993 (1) Diclofenac (DHEP)
plaster (= 180 mg di-
clofenac derivative), n =
30
(2) Placebo plaster, n =
30
Plasters applied x 2 daily
No patient-reported di-
chotomous outcomes
2 weeks
No data (1) better than (2) for
pain on pressure after 5
days
Grace 1999 (1) Diclofenac (with
lecithin) gel 2% (2.5 g),
n = 38
(2) Placebo gel, n = 36
Gels applied as one
scoop 3 x daily
PGE 4-point scale
2 weeks
PGE mild or none:
(1) 12/38
(2) 9/36
Non-
significant difference be-
tween 2 trial groups
at baseline and post
treatment on aggregated
WOMAC and pain sub-
scale scores (pain, stiff-
ness, physical function)
. (1) significantly bet-
ter than (2) for improve-
ment in WOMAC pain
subscale
Gui 1982 (1) Ibuprofen cream, n =
20 (strength, dose, quan-
tity not reported)
(2) Placebo cream, n=20
Creams applied x 2 daily
Undefined improvement
in pain
3 weeks
With movement:
(1) 14/18
(2) 7/19
With pressure:
(1) 15/20
(2) 7/20
(1)
significantly better than
(2) for mean improve-
ment in pain (sponta-
neous, movement, pres-
sure) and functional in-
capacity
Hohmeister 1983 (1) Flufenamate 3% plus
salicylate 2% gel (Mobil-
isin), n = 49 (quantity
not reported)
(2) Placebo gel, n = 51
Gels applied x 3 daily
PGE
3 weeks
PGE very good or good:
(1) 44/49
(2) 4/51
-
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Kneer 2013 (1) Ketoprofen (IDEA-
033) gel 50 mg daily, n =
223
(2) Ketoprofen (IDEA-
033) gel 100 mg daily, n
= 223
(3) Ketoprofen (IDEA-
033) gel 200 mg daily, n
= 221
(4) Vehicle, n = 199
All medication admin-
istered in divided daily
dose
OMERACT/OARSI re-
sponse
12 weeks
OMERACT/OARSI
(ITT)
(1) 88.6% = 190/214
(2) 86.8% = 185/213
(3) 88.6% = 187/211
(4) 77.5% = 147/190
PGE - group mean data
only. No clinically rele-
vant differences at week
12
Mean PI reduction from
baseline
(1) 34/100
(2) 37/100
(3) 37/100
(4) 33/100
Link 1996 (1) Ketoprofen gel 2.5%,
n = 56
(2) Placebo gel, n = 59
Gels applied as 4 to 10
cm strip x 3 or 4 daily
No patient-reported di-
chotomous outcomes
2 weeks
No data -
McCleane 2000 (1) Piroxicam gel 2.5%,
n = 40
(2) GTN 1%, n = 36
(3) Piroxicam gel 2.5%/
GTN 1%, n = 37
(4) Placebo gel, n = 46
Gels applied as “small
volume” x 3 daily
Participants with≥ 50%
relief of pain
4 weeks
≥ 50% PR:
(1) 1/40
(2) 4/36
(3) 7/37
(4) 4/46
Significant reduction in
mean pain scores in
group (4), with no fall in
the placebo and piroxi-
cam groups (this is prob-
ably relative to baseline
as opposed to head-to-
head comparison)
NCT01980940 (1) Etoricoxib gel 50mg,
4% DMSO, n = 24
(2) Placebo gel, n = 24
PGE 5-point scale
2 weeks
PGE of treatment, well
or very well:
(1) 13/24
(2) 14/24
No
significant difference be-
tween groups for change
in mean WOMAC pain
score, function, or stiff-
ness
Niethard 2005 (1)Diclofenac 1.16%gel
(Voltaren Emulgel), n =
117
(2) Placebo gel, n = 121
Gels applied 4 g x 4 daily
PGE 5-point scale
3 weeks
PGE excellent or very
good:
(1) 36/117
(2) 24/120
OMERACT-OARSI re-
sponder at end of trial
(1) 73/117
(2) 46/120
Ottillinger 2001 (1) Eltenac gel 1% 3 g, n
= 57
(2) Eltenac gel 0.3% 3 g,
n = 59
(3) Eltenac gel 0.1% 3 g,
n = 59
(4) Placebo gel, n = 59
PGE (no details of scale)
4 weeks
No useable data Patient-reported global
efficacy did not differ be-
tween treatments
Measurement of global
pain on VAS showed no
significant difference for
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Gels applied as 4 inch
string (approx 3 g) x 3
daily; to give 9 mg, 27
mg, 90 mg daily doses,
or placebo
eltenac versus placebo
Poul 1993 (1) Flurbiprofen LAT
patch, 40 mg, n = 53
(2) Placebo patch, n = 51
Medication applied as
patch x 2 daily
Participants’ overall effi-
cacy estimates.
2 weeks
No useable data There were statistically
significant differences in
favour of flurbiprofen
LAT at both days 7 +
14 for the investigators’
overall opinion of sever-
ity of condition
Participant-re-
ported night pain, qual-
ity of sleep, day pain
not significantly differ-
ent between 2 treatment
groups
Rose 1991 Piroxicam gel 5% (5 mg)
, n = 15
Placebo gel, n = 15
Gels applied 1 mg x 4
daily
PGE 4-point scale
2 weeks
PGE excellent:
(1) 8/15
(2) 8/15
-
Roth 1995 Diclofenac 3%
+ hyaluron 2.5% gel, n =
59
Placebo + hyaluron 2.
5% gel, n = 60
Gels applied 2 g x 4 daily
Participant
estimate of overall pain,
5-point scale
2 weeks
No useable data Analgesic effect of di-
clofenac gel was sig-
nificantly greater than
placebo at week 2
Roth 2004 (1) Diclofenac
1.5% with DMSO (45.
5%; Pennsaid®), n =
164
(2) Carrier with DMSO
(45.5%), n = 162
Solution applied as 40
drops x 4 daily
Participants with≥ 50%
PR (from author)
6 weeks
≥ 50% PR:
(1) 79/163
(2) 55/159
Mean change in pain,
physical function, stiff-
ness and PGE all statis-
tically better for (1) than
(2) and also for pain on
walking
Rother 2007 (1) Ketoprofen
gel (IDEA-33) 110 mg +
placebo tabs, n = 138
(2) Celecoxib tabs 100
mg+placebo gel, n =132
(3) Placebo gel and tabs,
PGE 5-point scale
6 weeks
PGE excellent or good:
(1) 64/138
(2) 51/132
(3) 35/127
Mean change in pain,
but not physical func-
tion statistically better
for (1) than (3) in ITT
analysis. Both signifi-
cantly better in PP anal-
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n = 127
Gel applied x 2 daily,
tablet taken x 2 daily
ysis
(2) better than (3) for
both
Rother 2013 (1) Ketoprofen (IDEA-
033) gel 200 mg daily, n
= 274
(2) 8.8 g vehicle daily, n
= 281
All medication admin-
istered in divided daily
dose
Participants with≥ 50%
PR
12 weeks
≥ 50% PR:
(1) 41.2% = 113/274
(2) 50.5% = 142/281
PGE good or excellent at
12 weeks:
(1) 54.7% = 150/274
(2) 60.5% = 170/281
Progressive improve-
ments in mean PI (37%
red) and function (about
40%) in both groups
throughout study. Com-
parable between groups
Sandelin 1997 (1) Eltenac 1% gel +
placebo tablets, n = 126
(2) Diclofenac tablet 50
mg + placebo gel, n = 82
(3) Placebo gel and
tablets, n = 82
Gel applied as 3 g (= 30
mg eltenac or placebo) x
3 daily, tablets x 2 daily
No patient-reported di-
chotomous outcome
4 weeks
No data No significant difference
inVAS score between the
3 groups
Simon 2009 (1) Diclofenac solution
1.5% (with DMSO 45.
5%, Pennsaid®) + oral
placebo, n = 154
(2) DMSO (45.5%) ve-
hicle solution + oral
placebo, n = 155
(3) Placebo solution
(with 2.3% DMSO) +
oral placebo, n = 161
(4) 100 mg slow-re-
lease oral diclofenac +
placebo solution (with 2.
3% DMSO), n = 151
Solution applied as 40
drops of solution x 4
daily, tablet taken x 1
daily
Participants with≥ 50%
PR (from author)
12 weeks
50% PR:
(1) 73/154
(2) 53/155
(4) 77/151
Topical diclofenac was
statistically superior to
placebo for all 3 primary
variables (pain, physical
function, patient overall
health assessment); supe-
riority was also observed
for PGE but not stiffness
A comparison of oral
versus topical diclofenac
found no statistically sig-
nificant difference for
any of the 5 efficacy vari-
ables above
Tugwell 2004 (1) Diclofenac solution
(with 45.5% DMSO;
Pennsaid®) placebo oral
capsule, n = 311
(2) Diclofenac capsule +
OMERACT-OARSI re-
sponder
12 weeks
ITT analyses:
(1) 201/303
(2) 210/301
PP analysis:
Mean changes in pain,
physical function, stiff-
ness, and patient assess-
ment not statistically dif-
ferent between groups
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placebo topical solution
(carrier with small quan-
tity DMSO), n = 311
Solution applied as 50
drops of solution x 3
daily (daily total 4.6
mL = 75 mg diclofenac
or placebo), oral cap-
sule (50mgdiclofenac or
placebo) taken x 3 daily
(1) 167/236
(2) 184/254
van Haselen 2000 (1) Piroxicam 0.5% gel,
n = 91
(2) SRL gel: Symphy-
tum officinale (comfrey)
, Rhus toxicodendron
(poison ivy), and Ledum
palustre (marsh-tea), n =
89
Gels applied 1 g x 3 daily
PGE 6-point scale
4 weeks
PGE excellent or good:
(1) 20/91
(2) 38/89
Mean pain reduction as
8.1/100 mm (SD 25) in
the piroxicam group and
16.5/100 mm (SD 24.6)
VAS in the SRL group,
an 8.4mmdifference be-
tween treatment groups
(95% CI 0.8 to 15.9)
Varadi 2013 (1) VALE-ibuprofen
cream 4 g daily, n = 39
(2) Placebo cream, n=36
All medication admin-
istered in divided daily
dose
No dichotomous data
2 weeks
No dichotomous data Mean decrease in PI on
walking from baseline to
week 2:
(1) 2.0/10 (SD 2.4)
(2) 1.6/10 (SD 1.9)
Mean improvement in
function greater with
ibuprofen than placebo
(32% versus 16%)
Widrig 2007 (1) Ibuprofen 5% gel
(Optifen), n = 98
(2) Arnica 50% gel, n =
100
Gel applied as 4 cm strip
x 3 daily
PGE 4-point scale
3 weeks
PGE very good or good:
(1) 56.5% = 50/85
(2) 64% = 57/89
Mean change in pain and
hand functionnot signif-
icantly different between
groups
Zacher 2001 (1) Diclofenac Emulgel
(verum) + placebo tabs,
n = 165
(2) Oral ibuprofen 300
mg+placebo gel, n =156
Gel applied x 4daily, tabs
taken x 3 daily
≥ 40% PR (unclear if
physician or patient as-
sessment reported)
3 weeks
≥ 40% PR
modified ITT:
(1) 66/165
(2) 53/156
-
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DMSO: dimethyl sulphoxide; ITT: intention-to-treat; n: number of participants in the treatment arm;OARSI:Osteoarthritis Research
Society International; OMERACT: Outcomes Measures in Rheumatology Clinical Trials; PGE: patient global evaluation; PR: pain
relief; SD: standard deviation; VAS: visual analogue scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index
Appendix 7. Summary of results in individual studies - adverse events and withdrawals
Summary of outcomes: adverse events and withdrawals
Study ID Treatment Local AEs Systemic AEs Serious AEs AE withdrawals Other
withdrawals
102-93-1 (1) Diclofenac
solution (with
45.5% DMSO;
Pennsaid®)
(2) Con-
trol (with 45.5%
DMSO)
(3) Placebo (with
4.55% DMSO)
Solution applied
as 40 drops
(about 1 mL) x 4
daily
Number of par-
ticipants in each
group not re-
ported
(1) 21/41
(2) 6/42
No useable data None reported No data No data
108-97 (1) Diclofenac
solution (with
45.5% DMSO;
Pennsaid®), n =
48
(2) Con-
trol (with 45.5%
DMSO), n = 47
(3) Diclofenac
solution (with 2.
3%DMSO), n =
50
(4) Placebo (with
2.3%DMSO), n
= 50
Solution applied
Com-
mon, almost ex-
clusively of dry-
ness and other
minor events at
the site of appli-
cation - of mini-
mal practical sig-
nif-
icance for com-
pliance or safety
No data None reported (1) 7/48
(2) 3/47
No data
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4 x daily to max-
imum 40 drops
per hand
Altman 2009 (1) Diclofenac
sodium gel 1%
(Voltaren) with
vehicle 2 g, n =
198
(2) Placebo gel
(vehicle carrier)
n = 187
Gels applied x 4
daily
“Application-site
reactions”
(1) 4.5% = 9/
198
(2) 2.1% = 4/
187
Most common:
paraesthesia
Any AE (sys-
temic or local)
(1) 52% = 103/
198
(2) 43.9% = 82/
187
Most common:
headache
GI AE:
(1) 7.6% = 15/
198
(2) 3.7% = 7/
187
Only 2 in (1)
judged related to
treatment
Most mild. Most
common: diar-
rhoea, no ulcers
or GI bleeds
None reported (1) 10/198
(2) 4/187
LoE:
(1) 8/198
(2) 13/187
Lost to follow-
up:
(1) 2/198
(2) 1/187
Withdrew con-
sent, protocol
deviation, admin
problem:
(1) 5/198
(2) 8/187
Baer 2005 (1) Di-
clofenac sodium
1.5% (with 45.
5% DMSO;
Pennsaid®), n =
107
(2) Placebo (ve-
hicle carrier), n =
109
Solution applied
as 40 drops x 4
daily
(1) 42/107
(2) 23/109
Most common:
dry skin
GI events more
frequent with (1)
. Most common,
abdominal pain
and dyspepsia
None reported (1) 9/107
(2) 9/109
(Skin-related):
(1) 5/107
(2) 0/109
LoE:
(1) 8/107
(2) 4/107
Other:
(1) 18/109
(2) 12/109
2 in each group
excluded due to
major violations
of entry criteria
Balthazar-
Letawe 1987
(1) Diclofenac
(Voltaren Emul-
gel), n = 25
(2) In-
domethacin (In-
docid) gel, n = 25
Gels applied x 2
daily
None observed None observed None None Lost to follow-
up:
(1) 8/25
(2) 6/25
Baraf 2011 (1) Di-
clofenac sodium
Dermatitis
(1) 34/721
Any AE (sys-
temic or local):
(1) 12/721
(2) 5/705
(1) 39/721
(2) 18/705
LoE:
(1) 32/721
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gel 1%, n = 721
(2) Placebo gel
(vehicle only), n
= 705
Medication ap-
plied 4 x 4 g daily
(2) 4/705 (1) 406/721
(2) 340/705
GI AEs infre-
quent
Most com-
mon: headache,
arthralgia, back
pain
One in (1) con-
sidered related to
treatment (DVT
and PE
in woman with
multiple risk fac-
tors)
1 death in (1)
judged unrelated
to treatment (AF
with mul-
tiple pre-existing
medical
problems)
(2) 51/705
Lost to follow-
up:
(1) 14/721
(2) 26/705
Withdrew con-
sent, protocol
deviation, admin
problem:
(1) 46/721
(2) 58/705
Bolten 1991 (1) Felbinac gel
3% 1 g, n = 142
(2) Placebo gel, n
= 139
Gel applied x 3
daily
(1) 2/142
(2) 4/139
All skin AEs
resolved without
treatment
(1) 1/142 (gen-
eralised itching)
No other AEs
mentioned
None reported None No data
Bookman 2004 (1) Diclofenac
solution 1.5% in
DMSO (45.5%:
Pennsaid®), n =
84
(2) Carrier with
DMSO (45.5%)
, n = 80
(3) Carrier with
1/10th DMSO
(4.55%), n = 84
Solution applied
as 40 drops (= 1.
3 mL) x 4 daily
(1) 30/84
(2) 11/80
(3) 1/84
Most common:
dry skin
Re-
versible on stop-
ping treatment
GI AEs did not
differ
between groups.
Most common:
dyspepsia
None reported (1) 5/84
(2) 3/80
(3) 0/84
LoE:
(1) 2/84
(2) 8/80
(3) 10/84
Other medical/
personal reason:
(1) 3/84
(2) 3/80
(3) 5/84
Bruhlmann
2003
(1) Di-
clofenac sodium
patch 1% (180
mg; Flector-EP),
n = 51
(2) Placebo
patch, n = 52
Patch applied x 2
daily
(1) 3/51 (2 rash,
1 pruritus)
(2) 2/52 (1 rash,
1 local heat)
(1) 1/51 (nausea)
(2) 1/52 (weak-
ness/dizziness)
None (1) 1/51
(2) 2/52
LoE:
(1) 1/51
(2) 3/52
Other (lost to
follow-up, pro-
tocol violation):
(1) 0/51
(2) 3/52
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Burgos 2001 (1) Flurbiprofen
LAT (= 40 mg) +
placebo cream, n
= 64
(2) Piketoprofen
cream 1.8% (4
cm ~ 36 mg) +
placebo patch, n
= 65
Patch applied x 2
daily, cream x 3
daily
(1) 2/61 (1 rash,
1 contact der-
matitis)
(2) 1/60 (1 rash/
pruritus)
Mild
intensity, disap-
peared on dis-
continuing treat-
ment
(1) 4/64
(2) 4/65
None reported (1) 1/64
(2) 1/65
LoE:
(1) 2/64
(2) 3/65
Other:
(1) 3/64
(2) 5/65
Conaghan 2013 (1) Ke-
toprofen (IDEA-
033) gel 100 mg
daily, n = 233
(2) Ketoprofen
(IDEA-033) gel
200 mg daily, n =
230
(3) 4.4 g vehicle
daily, n = 238
(4) 8.8 g vehicle
daily, n = 235
(5) Oral cele-
coxib 200 mg
daily. N = 235
(6) Oral placebo,
n = 228
All med-
ication adminis-
tered in divided
daily dose
(vehicle = TDT-
064)
(1) 13/233
(2) 28/230
(3) 14/238
(4) 26/234
(5) 5/233
(6) 2/227
GI disorders:
(1) 3/233
(2) 3/230
(3) 2/238
(4) 7/234
(5) 37/233
(6) 33/227
No numbers for
patients with any
systemic AE, but
numbers for AEs
other thanGI are
low
(1) 0/233
(2) 3/230
(3) 3/238
(4) 4/234
(5) 4/233
(6) 1/227
No SAEs consid-
ered treatment-
related
No deaths
(1) 3/233
(2) 13/230
(3) 6/238
(4) 9/234
(5) 13/233
(6) 13/227
LoE:
(1) 7/233
(2) 4/230
(3) 5/238
(4) 8/234
(5) 5/233
(6) 21/227
Other:
(1) 3/233
(2) 13/230
(3) 6/238
(4) 7/234
(5) 13/233
(6) 13/227
Dickson 1991 (1) Piroxicam gel
0.5% (1 g = 5
mg piroxicam) +
placebo tablet, n
= 117
(2) Ibuprofen
tablet 400 mg +
placebo cream, n
= 118
mg x 3 daily, n =
118
Gels applied x
(1)
3/117 (1 rash, 1
bruising, 1 ery-
thema of knee
(rubbing))
(2) 4/118
(1 rash, 2 depen-
dant oedema,
1 local heat/ery-
thema (rubbing)
)
(1) 30/117 (12
upper
GI, 3 other GI, 7
CNS, 8 other)
(2) 27/118 (10
upper
GI, 1 other GI, 8
CNS, 8 other)
None (1) 9/117
(2) 7/118
(1) 7/117
(2) 16/118
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3 daily, tablet
taken x 3 daily
Dreiser 1993 (1) Diclofenac
(DHEP) patch
(= 180 mg), n =
78
(2) Placebo
patch, n = 77
Patch applied x 2
daily
(1) 1/78
(2) 2/77
(in-
termittent itch,
resolved sponta-
neously)
(1) 0/78
(2) 2/77 (nau-
sea and vomit-
ing, oedema un-
der plaster)
None (1) 0/78
(2) 1/
77 (oedema be-
neath plaster)
LoE:
(1) 0/78
(2) 9/77
Other:
(1) 1/78
(2) 3/77
Ergun 2007 (1) Nimesulide
gel 1% (Sulidin)
0.4 mg/10 cm2,
n = 51
(2) Placebo gel, n
= 23
Gels applied x 3
daily
(1) 2/51
(2) 1/23
(itching - mild)
None reported None None 2
from each group
lost to follow-up
Galeazzi 1993 (1) Diclofenac
(DHEP) plaster
(= 180 mg di-
clofenac deriva-
tive), n = 30
(2) Placebo plas-
ter, n = 30
Plasters applied x
2 daily
None None None None None
Grace 1999 (1)
Diclofenac (with
lecithin) gel 2%
(2.5 g), n = 38
(2) Placebo gel, n
= 36
Gels applied as 1
scoop 3 x daily
(1) 4/38 (rash)
(2) 7/36 (5 rash,
1 numbness, 1
pruritis)
All mild
(1) 2/38 (1 nau-
sea, 1 hirsutism)
(2) 2/36 (2 nau-
sea)
None (1) 1/38 (rash)
(2) 0/36
(1) 0/38
(2) 3/36 (lost to
follow-up/pro-
tocol violation)
Gui 1982 (1) Ibupro-
fen cream, n = 20
(strength, dose,
quantity not re-
ported)
(2) Placebo
cream, n = 20
Creams applied x
2 daily
None None None None No data
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Hohmeister
1983
(1) Flufenamate
3% plus salicy-
late 2% gel (Mo-
bilisin), n = 49
(quantity not re-
ported)
(2) Placebo gel, n
= 51
Gels applied x 3
daily
(1) 8/49
(2) 0/51
No data None reported None None
Kneer 2013 (1) Ke-
toprofen (IDEA-
033) gel 50 mg
daily, n = 223
(2) Ketoprofen
(IDEA-033) gel
100 mg daily, n =
223
(3) Ketoprofen
(IDEA-033) gel
200 mg daily, n =
221
(4) Vehicle, n =
199
All med-
ication adminis-
tered in divided
daily dose
(1) 31223
(2) 43/223
(3) 53/221
(4) 39/199
Most of mild or
moderate inten-
sity and resolved
without action
No photoallergic
contact dermati-
tis
GI disorders:
(1) 6223
(2) 6/223
(3) 10/221
(4) 9/199
No numbers for
participants with
any systemic AE.
Num-
bers with mus-
culoskeletal and
connective tissue
dis-
orders, and ner-
vous system dis-
orders > 10%
None reported (1) 9/223
(2) 15/223
(3) 16/221
(4) 8/199
LoE:
(1) 15/223
(2) 14/223
(3) 6/221
(4) 12/199
Other:
(1) 15/223
(2) 9/223
(3) 13/221
(4) 16/199
Link 1996 (1) Ketoprofen
gel 2.5%, n = 56
(2) Placebo gel, n
= 59
Gels applied as 4
to 10 cm strip x
3 or 4 daily
No data No data No data No data All withdrawals
(1) 5/56
(2) 8/59
McCleane 2000 (1) Piroxicam gel
2.5%, n = 40
(2) GTN 1%, n
= 36
(3) Piroxicam gel
2.5%/GTN 1%,
n = 37
(4) Placebo gel, n
= 46
Gels applied as
“small volume” x
None reported (1) 1/50 (nausea)
(2) 0/50 +*
(3) 1/50 (dys-
pepsia)
(4) 1/50 (nausea)
+*
*17/100 partici-
pants who had
GTN developed
None reported (1) 1/50
(4) 0/50
Other:
(1) 10/50
(4) 4/50
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3 daily headaches asso-
ciated with the
cream
NCT01980940 (1)
Etoricoxib gel 50
mg, 4% DMSO,
n = 24
(2) Placebo gel, n
= 24
Not separately
reported
Any AE (sys-
temic or local):
(1) 6/24
(2) 5/24
None None None
Niethard 2005 (1) Diclofenac 1.
16% gel
(Voltaren
Emugel), n =
117
(2) Placebo gel, n
= 121
Gels applied 4 g
x 4 daily
(1) 4/117
(2) 3/120
Reversible when
treatment
stopped
Any AE (sys-
temic or local):
(1) 11/117
(2) 11/120
(1) 0/117
(2) 1/120 (brain
tumour)
(1) 2/117
(2) 0/120
LoE:
(1) 1/117
(2) 2/120
Other:
(1) 2/117
(2) 5/120
Excluded due to
protocol
violations:
(1) 10/117
(2) 16/120
Ottillinger 2001 (1) Eltenac gel
1% 3 g, n = 57
(2) Eltenac gel 0.
3% 3 g, n = 59
(3) Eltenac gel 0.
1% 3 g, n = 59
(4) Placebo gel, n
= 59
Gels applied as 4
inch string (ap-
prox 3 g) x 3
daily; to give 9
mg, 27 mg, 90
mg daily doses,
or placebo
No useable data 17 AEs in 16/
237 participants
(did not report
which group/na-
ture of reaction)
None reported (1) 0/57
(2) 0/59
(3) 0/59
(4) 1/59
LoE:
(1) 0/57
(2) 0/59
(3) 1/59
(4) 0/59
Other “non
medical” reason:
(1) 0/57
(2) 0/59
(3) 4/59
(4) 1/59
Poul 1993 (1) Flurbiprofen
LAT patch, 40
mg, n = 53
(2) Placebo
patch, n = 51
Medication ap-
plied as patch x 2
daily
(1) 3/53 (1 skin
bruising, 2 mild
skin redness)
(2) 0/51
Any AE:
(1) 8/53
(2) 3/51
None reported (1) 2/53 (1
skin irritation, 1
UTI)
(2) 2/51 (sore-
ness at treatment
site and nausea
from odour of
patch)
LoE:
(1) 2/53
(2) 1/51
Other:
(1) 10/53
(2) 8/51
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Rose 1991 Piroxicam
gel 5% (5 mg), n
= 15
Placebo gel, n =
15
Gels applied 1
mg x 4 daily
(1) 1/15
(2) 1/15
None reported None reported No data No data
Roth 1995 Diclofenac 3% +
hyaluron 2.5%
gel, n = 59
Placebo
+ hyaluron 2.5%
gel, n = 60
Gels applied 2 g
x 4 daily
(1) 12/59 (7 pru-
ritis, 5 rash)
(2) 26/60 (15
pruritis, 11 rash)
No data None reported Not reported All withdrawals:
(1) 3/59
(2) 4/60
Roth 2004 (1) Diclofenac 1.
5% with DMSO
(45.5%;
Pennsaid®), n =
164
(2) Carrier with
DMSO (45.5%)
, n = 162
Solution applied
as 40 drops x 4
daily
Most common -
dry skin:
(1) 60/164
(2) 41/162
Rash:
(1) 18/164
(2) 8/162
Reversible on
withdrawal
GI AE:
(1) 19/164
(2) 15/162
Other:
(1) 21/164
(2) 17/162
None reported (1) 8/164
(2) 4/162
LoE:
(1) 28/164
(2) 42/162
Lost to follow-
up:
(1) 3/164
(2) 0/162
Other:
(1) 6/164
(2) 7/162
Rother 2007 (1) Ketopro-
fen gel (IDEA-
33) 110 mg +
placebo tabs, n =
138
(2) Celecoxib
tabs 100 mg +
placebo gel, n =
132
(3) Placebo gel
and tabs, n = 127
Gel applied x
2 daily, tablet
taken x 2 daily
Any skin/subcu-
taneous tissue:
(1) 39/138
(2) 27/132
(3) 28/127
Generally mild,
reversible
GI AE:
(1) 13/138
(2) 18/132
(3) 12/127
No GI bleeding
(1) 0/138
(2) 1/132 (MI)
(3) 1/127
(angina)
(1) 23/138
(2) 18/132
(3) 20/127
LoE:
(1) 1/138
(2) 3/132
(3) 3/127
Lost to follow-
up:
(1) 1/138
Other:
(1) 0/138
(2) 2/132
(3) 2/127
Rother 2013 (1) Ke-
toprofen (IDEA-
033) gel 200 mg
daily, n = 274
(2) 8.8 g vehicle
(1) 29/274
(2) 32/281
More than 50%
GI disorders:
(1) 2/274
(2) 2.281
(1) 3/274
(2) 4/281
1 event in (1)
(1) 20/274
(2) 12/281 (11/
281 in flow
chart)
LoE:
(1) 16/274
(2) 18/281
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daily, n = 281
All med-
ication adminis-
tered in divided
daily dose
were mild No “treatment-
related” cardiac
or vascular AE
reported
possibly related
to study medica-
tion - headache
Other:
(1) 28/274
(2) 29/281
Sandelin 1997 (1) Eltenac
1% gel + placebo
tablets, n = 126
(2)
Diclofenac tablet
50 mg + placebo
gel, n = 82
(3) Placebo gel
and tablets, n =
82
Gel applied as 3 g
(= 30 mg eltenac
or placebo) x 3
daily, tablets x 2
daily
(1) 16/126 (ery-
thema, eczema,
itching,rash, dry
skin)
(2) 1/82
(3) 5/82
(1) 25/126 (6
GI, 12 CNS, 7
other)
(2) 21/82 (11
GI, 6 CNS, 4
other)
(3) 13/82 (6 GI,
4 CNS, 13
other)
None reported (1) 4/126 (local
reaction)
(2) 1/82
(abdominal pain
+ diarrhoea)
(3) 1/82 (local
reaction)
3 for non med-
ical reasons, 6
had disease other
than OA
Simon 2009 (1)
Diclofenac solu-
tion 1.5% (with
DMSO 45.
5%, Pennsaid®)
+ oral placebo, n
= 154
(2) DMSO (45.
5%) vehicle solu-
tion + oral
placebo, n = 155
(3) Placebo solu-
tion (with 2.3%
DMSO) + oral
placebo, n = 161
(4) 100 mg slow-
release
oral diclofenac +
placebo
solution (with 2.
3%DMSO), n =
151
Solution applied
as 40 drops of so-
lution x 4 daily,
tablet taken x 1
(1) 41/154
(2) 12/157
(3) 27/161
(4) 11/151
(5) 47/152
Most common:
dry skin at the
application site,
contact dermati-
tis at the appli-
cation site, and
rash
GI AE (most
common):
(1) 10/154
(2) 15/157
(3) 18/161
(4) 36/151
(5) 39/152
Other system
events:
(1) 27/154
(2) 18/157
(3) 21/161
(4) 26/151
(5) 21/152
Includ-
ing such things
as headache,
back pain, and
arthralgia
(1) 0/154
(2) 4/157
(3) 1/161
(4) 1/151
(5) 3/152
(1) 16/154
(2) 18/157
(3) 12/161
(4) 19/151
(5) 23/152
LoE:
(1) 16/154
(2) 18/155
(3) 17/161
(4) 5/151
(5) 9/151
Consent
withdrawn:
(1) 6/154
(2) 6/155
(3) 10/161
(4) 8/151
(5) 8/151
Lost to follow-
up:
(1) 2/154
(2) 4/155
(3) 3/161
(4) 2/151
(5) 2/151
“Other”:
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daily (1) 11/154
(2) 8/155
(3) 6/161
(4) 10/151
(5) 9/151
Tugwell 2004 (1) Diclofenac
solution (with
45.5% DMSO;
Pennsaid®)
placebo oral cap-
sule, n = 311
(2) Di-
clofenac capsule
+ placebo topical
solution (carrier
with small quan-
tity DMSO), n =
311
Solution applied
as 50 drops of so-
lution x
3 daily (daily to-
tal 4.6 mL = 75
mg diclofenac or
placebo)
, oral capsule (50
mg diclofenac or
placebo) taken x
3 daily
Most common -
dry skin:
(1) 83/311
(2) 4/322
Rash:
(1) 36/311
(2) 5/322
Mostly mild and
reversible
GI AE:
(1) 108/311
(2) 150/311
More partic-
ipants had severe
GI AEs with oral
than topical
More partici-
pants had lab ab-
normalities with
oral than topical
None reported (1) 64/311
(2) 79/311
LoE:
(1) 28/311
(2) 10/311
Lost to follow-
up:
(1) 5/311
(2) 5/311
“Other”:
(1) 32/311
(2) 22/311
van Haselen
2000
(1) Piroxicam 0.
5% gel, n = 91
(2) SRLgel: Sym-
phytum officinale
(comfrey), Rhus
toxico-
dendron (poison
ivy), and Ledum
palustre (marsh-
tea), n = 89
Gels applied 1 g
x 3 daily
(1) 7/89
(2) 11/91
(1) 5/89
(2) 5/91
Not reported (1) 1/89
(2) 1/91
Did not start
treatment/lost to
follow-up:
(1) 5/89
(2) 2/91
Varadi 2013 (1) VALE-
ibuprofen cream
4 g daily, n = 39
(2) Placebo
(1) 1/30
(2) 1/31
Note - not ITT
Mild rash
None None Not reported (1) 3participants
terminated early,
2 excluded from
analysis for pro-
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cream, n = 36
All med-
ication adminis-
tered in divided
daily dose
tocol violations
(2) 1 participant
terminated early,
4 excluded from
analysis for pro-
tocol violations
Widrig 2007 (1) Ibuprofen
5% gel (Optifen)
, n = 98
(2) Arnica 50%
gel, n = 100
Gel applied as 4
cm strip x 3 daily
No useable data
Mostly skin reac-
tions
Any AE:
(1) 8/98
(2) 14/100
(1) 0/98
(2) 1/100 (back
trauma due to
fall)
(1) 1/98
(2) 3/100 (back
pain)
1 in (1) and 2 in
(2) had “early in-
tolerance of gel”
Exclu-
sions due to pro-
tocol violations:
(1) 12/98
(2) 9/100
Zacher 2001 (1) Diclofenac
Emulgel (verum)
+ placebo tabs, n
= 165
(2) Oral ibupro-
fen 300 mg +
placebo gel, n =
156
Gel applied x 4
daily, tabs taken
x 3 daily
No useable data Any AE:
(1) 36/165
(2) 42/156
GI AE:
(1) 15/165
(2) 22/156
(1) 0/165
(2) 1/156 (ileus,
judged unrelated
to medication)
(1) 5/167
(2) 16/160
No data or miss-
ing data
(1) 6/165
(2) 4/156
(added back in to
analyses)
Excluded
from PP analysis
due to protocol
violations:
(1) 9/165
(2) 6/156
AE: adverse event; AF: atrial fibrillation; CNS: central nervous system; DMSO: dimethyl sulfoxide; DVT: deep vein thrombosis; GI:
gastrointestinal; GTN: glycerine trinitrate; LoE: lack of efficacy; n: number of participants in the treatment arm; OA: osteoarthritis;
PE: pulmonary embolism; PP: per protocol
WH A T ’ S N E W
Last assessed as up-to-date: 3 February 2016.
Date Event Description
11 February 2016 New citation required and conclusions have changed Five new included studies, principally with topical ke-
toprofen (almost 3000 additional participants, a 38%
increase)
Two studies awaiting classification (additional details
sought). Three ongoing studies identified in clinical trial
registries. Twelve studies that are completed, but for
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which no results are available, identified in clinical trial
registries
Conclusions not changed for diclofenac.
New data for topical ketoprofen in this update.
New interpretation of possible beneficial effects of car-
rier, as well as NSAID
3 February 2015 New search has been performed New searches run and new studies identified.
H I S T O R Y
Protocol first published: Issue 4, 2008
Review first published: Issue 9, 2012
Date Event Description
30 June 2009 Amended Spelling of title corrected.
12 November 2008 Amended Contact details updated.
C O N T R I B U T I O N S O F A U T H O R S
For the original review Roy Rabbie and SD identified studies, and carried out data extraction, analysis and drafting. RAM was involved
in planning, acted as adjudicator, and was involved with writing.
For this update SD and RAM identified studies, and carried out data extraction, ’Risk of bias’ assessment, and analysis. PC and JdaS
provided much insight into the clinical contexts of the use of topical NSAIDs. All authors contributed to writing the full review.
SD will be responsible for updating the review.
D E C L A R A T I O N S O F I N T E R E S T
SD: none known.
PC is a specialist rheumatologist and manages patients with chronic musculoskeletal pain. He was an author of two studies included in
this review. He was not involved in data coding or data extraction for these studies. He has received speaking fees from Abbvie, BMS,
and Roche (2013).
JdS is a specialist rheumatologist and manages patients with chronic musculoskeletal pain.
PW: none known.
RAM: has received institutional grant support from Reckitt Benckiser (RB) relating to individual patient level analyses of trial data on
ibuprofen in acute pain and the effects of food on drug absorption of analgesics (2013), and from Grünenthal relating to individual
patient level analyses of trial data regarding tapentadol in osteoarthritis and back pain (2015). He has received honoraria for attended
boards with Menarini concerning methods of analgesic trial design (2014), with Novartis (2014) about the design of network meta-
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analyses, and RB on understanding pharmacokinetics of drug uptake (2015). None of these activities was related to topical NSAIDs.
Novartis and/or its subsidiaries may market a diclofenac gel product; Menarini or its subsidiaries markets a ketoprofen gel product;
and RB or its subsidiaries markets an ibuprofen gel product. As far as is known, only diclofenac gel product is licensed for use in
osteoarthritis.
S O U R C E S O F S U P P O R T
Internal sources
• Oxford Pain Relief Trust, UK.
General institutional support
External sources
• The National Institute for Health Research (NIHR), UK.
NIHR Cochrane Programme Grant: 13/89/29 - Addressing the unmet need of chronic pain: providing the evidence for treatments of
pain
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Since the protocol for this review was published the ’Risk of bias’ tool has been introduced to RevMan. We have used this tool and
removed the Oxford Validity Score because it assesses similar criteria. We have also used the GRADE system to assign grade of evidence
(GRADEpro GDT 2015) and included a ’Summary of findings’ table.
The original protocol planned to use four weeks as the cut-off point for analysis by study duration. Recent advances in our understanding
of potential biases in studies suggest slightly different cut-off points (PaPaS 2012). For this update we have analysed data according to
study duration of ≥ 2 to < 6 weeks, and of 6 to 12 weeks.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal [∗administration & dosage; adverse effects]; Chronic Pain [∗drug
therapy]; Diclofenac [administration & dosage; adverse effects]; Musculoskeletal Pain [∗drug therapy]; Randomized Controlled Trials
as Topic
MeSH check words
Adult; Humans
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